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Abstract 
The work presented in this thesis focuses on the synthesis, analysis and cyclisations of 
a series of N-halobenzylcycloalkenamides. Chapter 1 provides an introduction to 
atropisomerism, radical cyclisation and Heck cyclisation, including developments in 
the reaction conditions for radical and Heck cyclisations. The use of atropisomers in 
synthesis, and particularly in cyclisation reactions, is also discussed. 
Chapter 2 reports investigations into the effects of aryl, acyl and alkene substitution 
on the barrier to rotation about the N-alkenyl bond in a series of enamides. A range of 
enamides were synthesised and their barriers to rotation were investigated by 1H VT 
NMR, and where desirable, by racemisation of an enriched atropisomer. The highest 
barriers to rotation were obtained with tetrasubstituted enamides, although additional 
bulk adjacent to the double bond (such as in tetralone-based compounds) was found to 
increase the barrier to rotation to a lesser degree. A precursor analogue to the natural 
product norchelidonine was also synthesised and was found to have a barrier to 
rotation between 20 and 24 kcal/mol. 
Chapter 3 describes the results of Bu3SnH-mediated radical cyclisation of the 
enamides synthesised in Chapter 2. A range of cyclised products was obtained in most 
cases, resulting from either the 5-exo pathway or the 6-endo pathway, although the 6-
endo pathway was found to predominate in almost all cases. Cyclisations of enamides 
with higher barriers to rotation proved more difficult, and indeed it was not possible 
to cyclise some of them, such as the precursor to the natural product norchelidonine. 
Chiral transfer should be possible with at least one α,α’,α’-substituted enamide, under 
the conditions used in this chapter.  
viii 
 
Chapter 4 describes attempts to find a viable alternative method for the cyclisation of 
the enamides synthesised in Chapter 2, to combat the many disadvantages of the tin 
method. Samarium diiodide radical cyclisation and palladium Heck cyclisation of the 
simplest substrate were both successful. Samarium cyclisation generated the same 
products as tin cyclisation, in a slightly different ratio due to the difference in reaction 
conditions. Palladium Heck cyclisation gave only 5-exo cyclisation products: the direct 
product and the isomerised product, in varying ratios depending on the conditions 
used. The palladium Heck reaction conditions were then optimised for these 
compounds, and the optimised conditions were used to cyclise a selection of the 
compounds from Chapter 2. 
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Chapter 1: Introduction 
1.1 Atropisomerism 
Atropisomerism is a phenomenon where chirality is exhibited due to restricted rotation 
around a chemical bond. Atropisomers need not contain a stereogenic centre: the 
spatial arrangement of the two groups on either end of the chemical bond in question 
provides the two necessary enantiomers. These are designated by P and M descriptors 
rather than R and S.  
 
Figure 1.1: First isolated atropisomers. 
By definition, atropisomers must be fully resolvable at room temperature for 1000 
seconds, which corresponds to an energy barrier of 23.3 kcal.mol-1.1 This differentiates 
them from rotamers, which have no such requirement. Several factors can influence 
the configurational stability of a compound about a specific axis: the size of 
substituents in proximity to the axis, the presence, length and rigidity of bridging 
elements, and the involvement of other chemically- or photochemically-induced 
processes.  
Although the term was not coined until 1933, the first stable atropisomers 1.1 were 
identified in 1922 by Christie and Kenner.2 The chirality exhibited around the aryl-
aryl bond resulted in two separate and separable atropisomers, as shown in Fig. 1.1,. 
The atropisomers could be separated by co-crystallisation with the chiral amino 
alkaloid brucine. Following this discovery, little attention was paid to the possibilities 
represented by atropisomerism, until it was realised that many natural products contain 
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a chiral biaryl unit,3,4 and that 2,2’-bis(diphenylphosphino)-1,1’-binaphthyl 
(BINAP),5–7 QUINAP8–10 and other biaryl ligands were extremely useful for 
asymmetric synthesis. Biaryl systems therefore provided the majority of the inspiration 
for the first wave of investigations into atropisomerism.  
 
1.1.1 Atropisomerism in biaryl systems 
Atropisomerism in biaryl systems can, by virtue of their asymmetry, have interesting 
effects in asymmetric synthesis, and can be a decisive factor in determining the 
pharmacological properties of a compound. Many natural products exhibit this type of 
chirality, for example vancomycin 1.211, viriditoxin 1.312,13 and (-)-N-
acetylallocolchinol 1.414, a structural analogue of colchicine.  
 
Figure 1.2: Natural products exhibiting atropisomerism 
Vancomycin 1.2, one of the “last defence” antibiotics11,15,16, contains many points of 
chirality and two atropisomeric chiral planes formed from the bisaryl ethers with a 
chiral axis about the aryl-aryl bond, as shown. This is an example of an atropisomeric 
axis which works in conjunction with other points of chirality to ensure the correct 
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functioning of a molecule. The key biaryl linkage in vancomycin was first synthesised 
by Evans, using VOF3
17, and subsequently by Nicolaou, using a Suzuki coupling.18 
The latter went on to report the total synthesis of vancomycin,19 which has yet to be 
improved upon. Viriditoxin 1.3 was first extracted from Aspergillus veridinutans in 
1971,20 but was subsequently found to be present in many fungal extracts, including 
one derived from jellyfish.12 It has been shown to cause apoptosis and autophagy in 
human prostate cancer cells.13 The key 6,6’-binaphthopyranone atropisomeric linkage 
has been prepared by a vanadium-catalysed cross-coupling.13 Interestingly, good 
remote diastereocontrol was induced by the lactone chiral centre. The use of chiral 
catalysts could enhance or reverse this selectivity. (-)-N-Acetylallocolchinol 1.4, under 
the form of the pro-drug N-acetylallocolchinol-O-phosphate, has been seen to cause 
damage to tumour vasculature without damaging normal tissue,14 provoking a 
resurgence of interest in colchicine derivatives as cancer chemotherapy drug 
possibilities. A range of analogues have been prepared with the asymmetric linkage 
synthesised via a double elimination at the oxa bridge on the 7-membered ring,21 
previously synthesised by oxidative rearrangement using mCPBA.22 
Atropisomerism around an aryl-aryl bond, as exhibited by these natural products, has 
been extensively studied and synthetically exploited. The rate of racemisation in biaryl 
systems, according to a review by Adams23 and a study of steric interference values by 
Bott and Sternhell,24 depends on the size of the four ortho-substituents around the 
biaryl bond (see Fig. 1.3). If three of the four ortho substituents are larger than 
hydrogen, the molecule is usually separable as two atropisomers at room temperature. 
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Figure 1.3: Rotation in biaryl systems. 
A wide range of biaryl systems have been shown to exhibit atropisomeric behaviour, 
and their synthesis and uses are detailed in the following sections.  
 
1.1.1.1 Simple isocyclic biaryls 
This category contains those biaryls that contain a single atropisomeric axis between 
two carbon atoms in identical aryl systems. Commonly seen examples of biaryl 
systems of this variety exhibiting atropisomerism are 2,2'-bis(diphenylphosphino)-
1,1'-binaphthyl (BINAP)25 and its diol analogue 2,2’-dihydroxy-1,1’-binaphthyl 
(BINOL) (Fig. 1.4).26  
 
Figure 1.4: Isocyclic biaryl ligands BINAP and BINOL. 
BINAP is an organophosphorous compound which is commonly used in asymmetric 
synthesis, when complexed to a metal such as rhodium, ruthenium and palladium. 
BINAP was first synthesised and resolved in 1980 by Noyori, using an optically active 
amine-Pd(II) complex.5 However, a more convenient synthesis was reported in 1986, 
also by Noyori, using camphorsulfonic acid or 2,3-O-dibenzoyltartaric acid to resolve 
the racemic diphosphine dioxide, which was then reduced with trichorosilane.27 This 
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practical synthesis allowed for the scale-up and variation of the reaction, resulting in 
the synthesis of analogues of BINAP.28 These analogues included variations and 
substitutions at both the phenyl and naphthyl sites, the former to increase specificity 
and activity of the catalyst, the latter to facilitate removal and recycling of the 
catalysts.28 The 3-, 4-, 5-, and 6-positions on BINAP have been the subject of most 
research thus far: substitution in the 3,3’positions has the most effect on the chiral 
outcome of many processes, by forming a “chiral pocket” through restriction of the 
rotation of the phosphine groups.28  
 
Figure 1.5: Substitution positions on BINAP. 
This ligand has been immensely useful ever since its discovery: in the paper which 
detailed the first synthesis of the molecule, Noyori also used BINAP complexed to 
rhodium to asymmetrically hydrogenate α-(acylamino)acrylic acids.5 The metal to 
which BINAP is complexed has a strong effect on the utility of the resultant catalyst. 
When complexed to rhodium, the catalyst has a narrow range of use, and is mainly 
employed to asymmetrically isomerise allylic amines, while the BINAP-Ru catalyst 
has a broader chemical utility.29 Importantly, Rh-BINAP is used on an industrial scale 
in order to synthesise (-)-menthol from myrcene, thus confirming the utility of 
atropisomeric ligands in chiral catalysts.30 
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Scheme 1.1: Takasago menthol synthesis 
BINOL (Fig. 1.4, pg 4) is a precursor to BINAP which can itself be complexed to 
various metals to form catalysts, most notably the lanthanide Shibasaki catalysts (Fig 
1.6). These can be used as asymmetric catalysts in nitroaldol, Michael, Diels-Alder 
and hydrophosphonylation reactions.26 
 
Figure 1.6: General structure of a Shibasaki catalyst (Ln=lanthanide, M=metal). 
A similar ligand, (R,S)-1-(2-diphenylphosphino-1-naphthyl)isoquinoline or QUINAP, 
was synthesised in 1993.31 Rhodium and palladium complexes of this ligand were 
subsequently used to perform asymmetric catalytic hydroborations of olefins32 and 
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catalytic allylic alkylation33 respectively. A series of APN (atropos P,N) compounds 
based on QUINAP have since been synthesised and used in asymmetric catalysis, 
notably for the hydroboration and diboration of alkenes, 1,3-dipolar cycloadditions, 
alkynylation of iminium salts, and conjugate additions of copper acetylides.8   
 
Figure 1.7: QUINAP 
Isocyclic biaryl atropisomerism can also be found in natural products: for example, 
mastigophorene A has been isolated alongside mastigophorene B from the liverwort 
Mastigophora diclados, and shown to stimulate nerve growth.34 The first 
atroposelective synthesis of mastigophorenes A and B was reported by Degnan and 
Meyers in 1999,35 where the key biaryl bond was formed via an asymmetric Ullman 
coupling.  
 
Figure 1.8: Mastigophorene A 
This is a representative of a relatively small set of naturally occurring biphenyls: due 
to the small size of the phenyl ring, most biphenyl systems in naturally occurring 
molecules do not have a sufficiently high barrier to rotation to be considered 
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atropisomers. Most examples of atropisomerism in synthetically or medically 
significant natural products are provided by compounds containing dinaphthyls, as 
these are inherently more restricted in rotation, such as (-)-gossypol (1.8), which has 
anti-cancer and anti-spermatogenic properties, and selectively inhibits HIV-1 
replication. Gossypol was first isolated as a racemic mixture from the seeds of the 
cotton plant Gossypium hirsutum by Lonmore in 1886, but the first atroposelective 
synthesis was not reported until 1997,36 where the biaryl bond was formed by the same 
Ullman coupling that was used for the synthesis of mastigophorene A. 
 
Figure 1.9: (-)-Gossypol 
 
1.1.1.2 Biaryls containing fused heterocycles and heterobiaryls 
Biaryl systems containing fused heterocycles have also been shown to exhibit 
atropisomeric behaviour in certain natural products, such as viriditoxin (1.3, Fig. 1.2, 
pg 2), but also (+)-kotanin (1.9)37 and dioncophylline C (1.10).38 Kotanin is a naturally 
occurring bicoumarin, isolated from Aspergillus glaucus cultures. A racemic mixture 
was synthesised by metalation with BuLi, followed by oxidation with CuCl2 to form 
the key aryl-aryl bond. Dioncophylline C, an antimalarial lead compound, was 
synthesised by ring-formation and subsequent LiAlH4-mediated ring-opening. 
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Figure 1.10: Naturally occurring (+)-kotanin and dioncophylline C 
Streptonigrin is a highly functionalised aminoquinone heterobiaryl that exhibits broad-
spectrum anti-cancer activity and as such was the subject of investigations by both 
synthetic organic chemists and biochemists. Unfortunately, after reaching phase II 
clinical trials in the 1970s, medical trials were abandoned due to the side effects caused 
by the high level of toxicity. The total synthesis of this compound was reported by 
Donohoe, Jones and Barbosa in 201139 and involved the ring-closing metathesis of the 
pentasubstituted pyridine, as well as cross-coupling reactions to form the biaryl bonds.  
 
Figure 1.11: Streptonigrin 
Heterobiaryls and biaryls containing fused heterocycles have attracted increasing 
attention, due to their potential both as chiral catalysts and as chiral substrates.40,41 
Natural products containing N-heterocycles are an attractive scaffold for use in 
medicinal and pharmaceutical chemistry, as the wide range of pharmacological 
properties displayed by such compounds is highly favourable to their investigation.42  
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1.1.2 Atropisomerism in non-biaryl systems 
1.1.2.1 Arylamides and anilides 
Biaryl systems may have provided the first wave of inspiration for investigations into 
atropisomerism, but an increased interest in non-biaryl systems was sparked by 
Clayden43–50 and Curran46,51–55, both of whom published studies of non-biaryl 
atropisomers in the 1990s and 2000s. This work sprang from the discovery by Fuji in 
1991 that chiral ketone 1.11 could be stereospecifically alkylated using potassium 
hydride and methyl iodide, despite the intermediacy of a supposedly achiral enolate.56 
 
Scheme 1.2: Selective alkylation reported by Fuji 
Clayden later proved that the “chiral memory” shown in this reaction resulted from 
restricted rotation in the enolate intermediate.55 The term “atroposelective” was coined 
by Curran in order to describe reactions with stereocontrolling atropisomers. Non-
biaryl atropisomerism is less common in natural products, and has traditionally been 
less exploited by synthetic chemists. However, over the course of the subsequent two 
decades, investigations into non-biaryl atropisomers, their synthesis and their uses has 
become more prevalent.40,50,57,58 While former work had focussed on the isolation, 
structure and rotation barriers of such compounds40,45,47,50,51,57–62, the emphasis in 
recent years has shifted towards what can be accomplished with such molecules.40,50,63–
69 Asymmetric reactions of amides and imides have proven to be of particular interest, 
given that N-Ar bond rotation can be slowed when the aryl group is appropriately 
substituted. Radical reactions can thus be accomplished much faster than the rotation 
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of the N-Ar bond, and chiral transfer can often ensue. Atropisomerism has been 
observed in many such systems, including arylamides45,62 1.13, anilides62,70 1.14 and 
enamides 1.15.69,71,72 
 
Figure 1.12: Atropisomerism in amide systems. 
In the mid-1990s, Clayden published work on non-biaryl atropisomerism, focussed in 
the first instance on arylamides such as 1.16 and 1.17.44 
 
Figure 1.13: Arylamides originally studied by Clayden 
Atropisomerism in arylamides 1.16 had been proven to be contingent on the amide 
group being flanked by ortho-substituents on either side of the phenyl ring.73 
Mannschreck73 and Pirkle74 both isolated enantiomers of 1.16a (R1=R2=R3=Me) by 
chiral HPLC. Compounds 1.16 proved useful even when non-atropisomeric (if R1=H 
and R2=R3=alkyl, the half-life for racemisation at room temperature ranges from 0.01-
2 seconds) due to their ready functionalisation by lithiation in the 2-position, which 
produced a series of atropisomers43,44,49,55 1.16 and 1.17 where R2 and R3 are alkyl 
groups and R1 can be any group larger than hydrogen. Clayden subsequently 
synthesised and investigated many such systems, their rates of racemisation and the 
stereoselectivity of their reactions.67 Complete stereochemical stability could only be 
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attained with the most hindered of naphthamides (2,8-disubstitution of a naphthamide 
yields a half-life measurable in years) and benzamides (any fully-substituted carbon at 
one ortho position and any non-hydrogen substituent at the other yields a similar half-
life) (Figure 1.14). Both 1.16b and 1.17a have estimated half-lives of 100 years at 
25oC, and ΔG values of approximately 31 kcal.mol-1. Clayden also established that 
such atropisomers could exert conformational control over reactions occurring near to 
the bond about which rotation was restricted, and even, under certain circumstances, 
remotely.46 
 
Figure 1.14: Atropisomers isolated by Clayden.  
Curran75also published work on atropisomeric non-biaryls in the 1990s, although his 
focus was on the atropisomeric properties of anilides 1.18. 
 
Figure 1.15: Non-biaryl atropisomeric anilides discussed by Curran 
Curran observed that if R1 and R2 in compound 1.18 were hydrogens, the barrier to 
rotation around the C-N bond was low and the torsion angle between the amide and 
the phenyl moiety was around 30°. While encouraging, as the molecule was not planar 
and therefore the aryl group did not rotate freely through the plane of the amide, the 
small size of the ortho-substituents meant that the barrier to rotation was insufficient 
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to envisage atropisomeric possibilities. However, if both ortho-substituents were 
replaced with medium-sized alkyl or heteroatom groups, the N-Ar torsion angle and 
the barrier to rotation around the N-Ar bond were substantially increased. Curran 
hypothesised75 and subsequently showed76 that if one ortho-substituent was a large 
group such as a tertiary alkyl, and the other a hydrogen, then the system would be 
“stable to racemisation” (non-freely-rotating) at room temperature and also would 
possess a shape conducive to applications in stereoselective synthesis. In proof of this, 
he synthesised compound 1.18a-b: these compounds and analogues thereof were 
found to have barriers to rotation of 28-30 kcal.mol-1.75 This barrier to rotation is 
sufficiently high to envisage the possibility of stereoselective cyclisation reactions at 
room temperature and below. 
 
Figure 1.16: Atropisomeric compounds synthesised by Curran 
As depicted in Scheme 1.3, enantioenriched N-allyl-o-iodoanilides of type 1.18b can 
undergo radical cyclisation to oxindole 1.19 with faithful chirality transfer 
(enantiomeric ratio > 90:10), thus proving the feasibility and utility of atropisomeric 
molecules as pro-chiral compounds.53 
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Scheme 1.3: Radical cyclisation of anilide 1.18b. 
Soon after Curran’s initial report, other groups began investigating anilide derivatives 
for atropisomeric activity: Simpkins77 and Taguchi78 both synthesised derivatives of 
compound 1.18 where the R2 and R3 groups (i.e. those not on the phenyl ring) were 
altered. Simpkins found that good stereocontrol was obtained with alkylation and aldol 
reactions of anilides 1.18c (R1=tBu, R2=Et, R3=Me/MEM), providing further proof of 
the utility of atropisomeric anilides, while Taguchi used anilide 1.18d (R1=tBu, 
R2=CHCH2, R
3=CH2CHCH2) in a Diels-Alder reaction with cyclopentadiene, which 
proceeded with high diastereoselectivity.  Koide62also developed an asymmetric 
synthesis of atropisomeric benzanilides such as 1.20 using planar chiral 
(arene)chromium complexes. 
 
Figure 1.17: Atropisomeric anilides 1.18 and benzamides 1.20. 
 
1.1.2.2 Enamides 
Similar to anilides are enamides 1.21, which are remarkably versatile building blocks 
in organic synthesis, if the enamide is secondary (R2=H).79,80 The chemistry of tertiary 
enamides has only recently started to receive attention.81 The reason for this is that 
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tertiary enamides have complicated rotation dynamics due to rotation around both the 
amide N-CO bond and the N-alkenyl bond (Figure 1.18).  
 
Figure 1.18: General enamide configurational possibilities. 
The amide bond rotation barrier in enamides 1.21a (R1=R2=Me, R3=R4=R5=H) was 
calculated to be 14.0 kcal.mol-1, lower than the general value for amides (15-
20kcal.mol-1).82,83 Clark reported in 2009 on the bond rotation dynamics of a series of 
enamides 1.22, with a view to determining which substitution patterns would yield 
resolvable atropisomers.71 Cycloalkenyl-N-alkylacetamides of this variety exhibit a 
clear preference for the E-rotamer of the amide, as shown (Figure 1.19), and exhibit 
axial chirality on an NMR timescale,71 which can be exploited in NMR studies to 
calculate the barrier to rotation around the N-cycloalkenyl bond. 
 
Figure 1.19: Enamides investigated by Clark 
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Substitution at the alkene was found to increase the barrier to rotation about the N-
cycloalkenyl bond, when a dihydronaphthyl moiety replaced the simple cycloalkenyl. 
The tetrasubstituted enamide 1.23 exhibits rotation so slow that individual 
enantiomeric atropisomers can be separated by preparative chiral HPLC.69,84 
 
Figure 1.20: Atropisomeric tetrasubstituted enamide 1.23. 
The rotation barrier associated with the N-cycloalkenyl bond in compound 1.23 has 
been estimated to be approximately 29.3kcal.mol-1, corresponding to a half-life of 5.6 
years at 298K. It is possible that analogues of this structure would allow the tailoring 
of molecules which exhibit correct rotation dynamic requirements necessary for 
stereoselective cyclisation reactions. 
 
1.1.3 Measurement of the barrier to rotation in atropisomers 
Atropisomers have a half-life which can be measured using the barrier to rotation 
around the atropisomeric bond. The investigation into this barrier to rotation in 
benzamides and naphthamides 1.24 and 1.25 has been done by Clayden using three 
different analytical methods: variable temperature NMR spectroscopy, resolution by 
HPLC on chiral stationary phase, followed by analysis of subsequent racemisation, 
and chromatographic separation on silica, followed by analysis of subsequent 
epimerisation.45 Clayden found that VT NMR analysis was of most use when 
considering singly ortho-substituted benzamides (R2=H), as chromatography methods 
could not achieve separation of atropisomers when the barrier to rotation was lower. 
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However, when dealing with disubstituted benzamides 1.24 or with naphthamides 
1.25, chromatographic methods could achieve separation of the atropisomers and thus 
these were preferred.  
 
Figure 1.21: Benzamides and naphthamides studied by Clayden. 
The VT NMR method was also used by Clark69,71 to calculate the barriers to rotation 
in a series of N-benzylated enamides (for example 1.26, Figure 1.22). 
 
Figure 1.22: Expansion of the 1H NMR spectra of 1.26 at 215−297 K.71 
Low temperature NMR analysis of 1.26 showed the benzyl protons to be diastereotopic 
under these conditions, appearing as mutually coupled doublets due to slow rotation 
about the N-alkenyl bond. When heated to room temperature these doublets coalesce 
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into a singlet, as the rate of rotation increases. The rotational rate constant, krot, was 
calculated for each temperature using line-fitting software, and an Eyring plot of these 
values allowed rate of rotation at 298 K, k298, to be calculated. This was then factored 
into the Arrhenius equation to give the barrier to rotation about the N-alkenyl bond. 
Compounds which had N-alkenyl barriers to rotation too high to be calculated by this 
method, such as 1.23, were analysed using chiral HPLC (Figure 1.23).69 
 
Figure 1.23: Chiral HPLC trace for compound 1.23.69 
 
1.2 Radical Cyclisations 
1.2.1 Traditional radical cyclisations 
Radical cyclisation reactions are perhaps the simplest way of forming a carbocycle or 
heterocycle. As shown in Scheme 1.4, the generally accepted mechanism consists of 
generation of the radical by abstraction of a leaving group, commonly a halide85–87, 
followed by cyclisation of the radical onto an available multiple bond, and finally 
termination of the radical, which can be done in a variety of ways depending on the 
reaction conditions.  
 
Scheme 1.4: Overall mechanism of a radical cyclisation 
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Radical termination can occur by being trapped by a radical scavenger, undergoing a 
fragmentation reaction, or being converted in an electron transfer reaction to a cation 
or anion. Traditional radical cyclisations used organostannane or organosilane 
reagents, such as Bu3SnH
85,86 or (SiMe3)3SiH
88, to mediate the reactions, accompanied 
by a radical initiator such as AIBN or ABCN (Scheme 1.5).  
 
Scheme 1.5: Radical generation using Bu3SnH and AIBN. 
These conditions have broad utility and were thus widely used for many years. They 
have been used to synthesise heterocycles containing nitrogen, oxygen, sulfur, and 
silicon, amongst others,89 as well as carbocycles. A review by Curran in 1993 detailed 
some uses for these conditions in the synthesis of natural products, including a tandem 
radical cyclisation as a key step in the synthesis of cyclopentanoid (±)-hirsutene 
(Scheme 1.6).90,91 
 
Scheme 1.6: Key step in the synthesis of hirsutene. 
These conditions were also useful for mediating aryl radical cyclisation reactions 
(Scheme 1.7), and are now widely used for the synthesis of fused aromatic compounds. 
Work by Beckwith92 showed that aryl radicals will cyclise primarily in a 5-exo fashion 
in compounds such as 1.27. The 6-endo product does not arise in this case by direct 
cyclisation, but via a neophyl rearrangement from the 5-exo product.  
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Scheme 1.7: Aryl radical cyclisation. 
These conditions, while exceptionally useful in the arena of carbon-carbon bond 
formation, have several non-trivial drawbacks: for organostannanes the reagents are 
extremely toxic, the residues of the reagents are difficult to remove from the product, 
rendering purification more complicated, and the reductive nature of the reaction is 
also an issue.89 The termination of the reaction by hydrogen abstraction means that 
there is a loss of two functional groups during the transformation. The purification 
issue is of particular concern when considering pharmaceutical applications: 
acceptable impurity levels are very low, and as such tributyltin hydride reactions in 
particular are undesirable. Equally, the need for comparatively large amounts of 
mediating species (stoichiometric quantities of organostannane reagent are required) 
and the cost of the reagents contribute to the undesirability of these conditions. Despite 
all this, tributyltin hydride and AIBN are used to this day in radical cyclisation 
reactions, as they have an unparalleled range of utility and are often used to investigate 
the scope of cyclisation of a starting material.  
 
1.2.2 Modern radical cyclisation alternatives 
Attempts were therefore made to find alternative radical cyclisation conditions to 
remove some of the disadvantages of the organostannane and organosilane methods. 
In 1981, Kagan reported the use of samarium diiodide in water to mediate the reductive 
cyclisation of 6-bromo-1-hexene, where the cyclised intermediate was coupled with 2-
octanone (Scheme 1.8).93 
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Scheme 1.8: SmI2/H2O-mediated cyclisation of 6-bromo-1-hexene. 
The radical is generated by radical abstraction from the R-X species by Sm2+, 
generating Sm3+ and the radical anion, which then loses X- to generate the R. radical. 
Termination occurs by proton abstraction from the solvent. This work was later 
expanded on by Molander, who introduced HMPA as an additive and co-solvent to 
facilitate cyclisation,94 given the insolubility of many starting materials in water. These 
conditions maintain many of the disadvantages of the organostannane cyclisations, but 
the residues are easier to remove from reaction mixtures, simplifying product 
purification, and the reaction conditions are also milder, as a common reaction 
temperature is 25oC instead of 80oC for the tin methods.94 Ease of purification was 
also the rationale behind solid-supported tributyltin hydride cyclisation: when a series 
of bromoethylacetals were attached to a polymer resin and reacted under standard 
tributyltin hydride radical cyclisation conditions, the corresponding set of γ-
butyrolactones were generated in good yield and released from the resin by Jones 
oxidation, once all organostannane residues had been removed.95 The purification 
issue can therefore be avoided by judicious substitution of the organostannane 
conditions for alternative radical generation options, or by solid-supported starting 
materials, but that does not change the reductive nature of the reaction, nor is it 
rendered cost-effective or non-toxic. Alternative radical cyclisation methods were 
therefore required to combat these issues.  
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1.2.3 Atom Transfer Radical Cyclisation 
The atom transfer radical cyclisation process, derived from the similar atom transfer 
radical polymerisation reaction, was reported by several groups in the mid-to-late 
nineties as an efficient radical cyclisation process of haloacetates and haloacetamides 
onto alkenes95–100 and alkynes.101 This method has a number of advantages over 
traditional radical cyclisation methods: it is cost-effective, easy to work up and 
required catalytic amounts of copper, rather than the stoichiometric amounts used in 
tin cyclisations.86 
 
Scheme 1.9: CuCl-catalysed ATRC of haloacetamides 1.30 and 1.32. 
The reaction proceeds via a catalytic redox mechanism. For 1.30 the radical is 
generated by abstraction of a chlorine radical by CuCl. This radical then cyclises onto 
the double bond in a 5-exo fashion, and the primary radical thus created removes a 
chlorine radical from CuCl2, regenerating the CuCl catalyst. In both cases shown in 
scheme 1.9, the ATRC reactions are selective for the product shown,86,100 for 1.32 and 
despite the usual preference of 5-exo radical cyclisation the endo pathway 
predominates. For compounds 1.32 this selectivity was at first not fully understood 
and the observed regioselectivity was rationalised by the steric disfavouring of the 4-
membered ring systems due to ring strain.  However, it became clear that structures 
1.32 are not planar around the enamide functionality and as a consequence exhibit 
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atropisomerism around the N-alkenyl bond (see section 1.1.2.2).  This places the 
carbon at the 5-position with the correct orbital overlap for efficient cyclisation. 
Various attempts were made to improve the process by altering the solvent, 
temperature and adding a ligand for the copper. A comprehensive review by Clark86 
covered all the work done in the area up until early 2002 and more recently in 2016 
this has been updated.102 In particular, certain copper ligands have been proven to 
accelerate the reaction rate, allowing the cyclisation of less reactive substrates. The 
addition of 2,2’-bipyridine (bipy) in a 1:1 ratio with CuCl to the reaction of 
haloacetetate 1.34 was found to accelerate the rate of reaction fourfold.86 
 
Scheme 1.10: ATRC reaction of haloacetate 1.34. 
N,N,N’,N’-Tetramethylethylenediamine (TMEDA) also proved useful in the 
optimisation of the ATRC reaction, and made the catalyst system (Cu(TMEDA)2Cl) 
more reactive than the bipy ligands, improving yields as well as allowing for lower 
catalyst loadings.86 Further work introduced additives such as AIBN to accelerate the 
reaction further103 and reported the success of the ATRC-AGET (Activators Generated 
by Electron Transfer) method, which altered the copper source to the cheap and 
oxidatively stable CuSO4, in extremely low loading (0.05%) and used it in conjunction 
with borohydride salts to cyclise haloacetamides 1.36 in good to excellent yield within 
ten minutes (Scheme 1.11). 
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Scheme 1.11: ATRC-AGET reaction of haloacetamide 1.36. 
 
1.2.4 Radical cyclisation of atropisomers 
Control of absolute stereochemistry in radical cyclisation reactions has long been a 
synthetic challenge. Several strategies were attempted to achieve this, of which one of 
the most successful was chiral transfer from an atropisomeric anilide. Curran used the 
axial chirality occurring in iodoanilides such as 1.18 to show that efficient chiral 
transfer could be achieved. Enantiomerically enriched samples of 1.18b were cyclised 
to give chirality transfer in the oxindole product of 72-96%, as discussed in section 
1.1.2.1 (pg 14).53  
 
Scheme 1.12: Cyclisation of 1.18b. 
It is unsurprising that radical cyclisation was deemed an exciting possibility for 
application to atropisomers. The rapidity of cyclisation of aryl radicals (rate of radical 
cyclisation on the order of 1 x 10-8 s-1 for 5-exo cyclisation)104 compared to the rate of 
rotation around atropisomeric bonds implied the possibility of chiral transfer from a 
single atropisomer of the starting material to the product, which was seen to be the 
case for the above example of radical cyclisation under traditional conditions with no 
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chirality-inducing additive in the reaction. An excellent review by Sibi and Sivaguru 
details the work done on reactions using atropisomers (literature to 2015).40  
 
Scheme 1.13: Radical cyclisation of 1.18c. 
Clayden proposed that compounds such as 1.18c possess a “chiral memory” when 
being cyclised, as the abstraction of the iodine to form the aryl radical must necessarily 
diminish the barrier to rotation, and therefore lead to an overall lack of chiral 
transfer.46,48 That this did not occur (84% chiral transfer was observed when the 
resolved starting material was used) argued that the compound retained some memory 
of its previous chiral nature. This extra chiral element, however, proved unnecessary 
to obtain chirality transfer, as seen with cyclisation of 1.18b, which contains no chiral 
point and merely exhibits axial chirality. Axially chiral molecules can thus be cyclised 
in such a way as to achieve chiral transfer.  
Radical cyclisation of enamides has also been reported using conditions detailed in 
sections 1.2.1-1.2.3. Ishibashi used tributyltin hydride to cyclise enamide 1.38,105 
while Clark used both Bu3SnH and ATRC methods to cyclise 1.40 (generating in both 
cases the 5-endo product),100 providing examples of both exo- and endo-cyclisation 
pathways in enamides. Selectivity for each pathway is largely dependent on the sterics 
of the substrate being cyclised: 5-membered rings exhibit minimal ring strain 
compared to 4-membered rings, and in general the 5-position is closest to the reacting 
radical. Unfortunately, cyclisation of atropisomeric enamide 1.23 proved 
unsuccessful, yielding only reduction products. 
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Scheme 1.14: Radical cyclisations reported by Ishibashi and Clark. 
Radical generation and cyclisation on the acyl side of the enamide has therefore been 
reported,71,106 but aryl radical enamide cyclisations have been less investigated. 
Ishibashi107 has reported cyclisations of N-bromobenzylenamides such as 1.43, which 
were found to cyclise in a 6-endo-trig manner in relatively low yield (20-40%).  
 
Scheme 1.15: N-bromobenzylenamide radical cyclisation. 
The use of radical cyclisation methods to cyclise atropisomers is therefore sufficiently 
well-established in anilides, although there has been less research into the behaviour 
of N-halobenzylenamides under common radical cyclisation conditions.  
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1.3 The Heck reaction 
The Heck reaction is another powerful tool for carbon-carbon bond formation. First 
reported in 1968 by Heck108, it started gaining traction as a useful tool in organic 
synthesis in the late eighties. Several excellent reviews have covered the area: by De 
Meijere109 up until 1994,109 by Shibasaki110 until 2004, and by Muzart111 until 2011.  
 
1.3.1 Mechanism and conditions of the Heck reaction 
The Heck reaction proceeds via a catalytic cycle, as shown in Scheme 1.16. The 
catalytically active compound is the coordinatively unsaturated 14-electron 
[Pd(PPh3)2] complex, commonly generated in situ from [Pd(PPh3)4], to which R-X (R= 
aryl or alkenyl, X= halide or triflate) oxidatively adds, followed by syn-insertion of the 
alkene into the R-palladium bond. This is followed by β-hydride elimination of the 
alkene product and reductive elimination of HX from the palladium complex using 
base, regenerating the initial active catalyst [Pd(PPh3)2].
109–111 
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Scheme 1.16: General mechanism of a Heck reaction using Pd(PPh3)4. 
The reason for the initial lack of interest in the Heck reaction as a tool for organic 
synthesis can perhaps be supplied by the lack of regioselectivity observed when 
asymmetric alkenes were used, as well as isomerisation occurring after the fact. Thus, 
reaction of 1.45 with R-X will generate two regioisomers of the alkene product, 1.46 
and 1.47, depending on how the alkene inserted onto the palladium. This will in turn 
largely depend on the steric hindrance surrounding the alkene.109–111 
 
Scheme 1.17: Two possible regioisomeric products of the Heck reaction. 
Generally speaking, there are six variables to be considered in a Heck reaction 
protocol: the pre-catalyst, the ligand, the base, the solvent, the temperature and the 
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additive, although this last one is not always necessary.112 Common pre-catalysts 
include both Pd(II) and Pd(0) species, of which the most frequently used are Pd(OAc)2 
and Pd2(dba)3,
112 although palladacycles can also be used.113,114 Ligands must be weak 
electron donors such as tertiary phosphines (PPh3, P
tBu3, etc)
109, and in the case of 
asymmetric reactions chiral ligands such as BINAP112 can be used. The choice of base 
in the reaction is of lesser importance, as most inorganic bases (K2CO3, CaCO3 etc) 
can be used, or alternatively tertiary amine bases such as triethylamine.109,112 Polar 
aprotic solvents such as THF, acetonitrile and DMF are usually preferred for 
asymmetric Heck reactions, although benzene, toluene and DCE can also be 
used.109,112 Beletskaya reported in 1989 the successful Heck reaction of iodobenzoic 
acids and acrylic acid in aqueous media115, which introduced the possibility of running 
these reactions in water. The reaction temperature can range from room temperature 
to over 100oC, depending on the reactivity of the starting materials, and in particular 
of the organohalide, as the oxidative addition of this compound to the palladium 
complex is generally considered to be the rate-determining step of the Heck 
reaction.112 In certain cases additives can be used to accelerate the rate of reaction: 
silver salts are particularly popular due to their ability to act as halide scavengers, 
removing the halide or triflate from the palladium complex after oxidative addition of 
the R-X compound and thereby vacating a coordination site on the palladium so 
insertion into the alkene is easier.112  
 
1.3.2 The intramolecular Heck reaction  
The first case of an intramolecular Heck reaction was reported by Overman and co-
workers in 1989116, using palladium acetate to intramolecularly cyclise a set of trienyl 
triflates 1.48.  
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Scheme 1.18: Trienyl triflate cyclisation under Heck conditions 
The use of intramolecular Heck cyclisations in organic synthesis accordingly became 
widespread109,112 and gained a foothold in natural product synthesis: in 1993 Rawal 
synthesised (±)-dehydrotubifoline117 (Scheme 1.19), a member of the Strychnos 
alkaloid family, which combines an intricate structure with powerful physiological 
activity. 
 
Scheme 1.19: Synthesis of (±)-dehydrotubifoline 
The use of Heck reactions in natural product synthesis has not flagged over the past 
twenty years: earlier this year Hilton used a microwave-assisted intramolecular Heck 
reaction to form the key pentacyclic core of lycorane 1.51 from 1.50.118 
 
Scheme 1.20: Key step in the synthesis of lycorane. 
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1.3.3 Intramolecular Heck cyclisations of atropisomers 
The use of chiral ligands in Heck cyclisation to obtain chiral transfer to the product 
has been well documented,40,109,112,119,120 but the use of atropisomerism alone to ensure 
chiral transfer in such reactions has been less investigated. In 2011, Curran and co-
workers published a paper comparing the radical and Heck cyclisations of a series of 
diastereomeric ortho-haloanilide atropisomers, and found that the results of radical and 
Heck cyclisations of iodoanilides 1.52 depend on the configurations of the chiral axis 
and the stereocenter.66 If the precursor was in the syn-position, tin cyclisation resulted 
in a good yield of cyclised product 1.53, while Heck cyclisation did not take place. If 
the precursor was in the anti-position, radical cyclisation did not occur, and instead the 
reduced product 1.54 was obtained, but Heck cyclisation proceeded with acceptable 
yield to give 1.55. 
 
Scheme 1.21: Comparing tin and Heck cyclisations. 
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In the case of the organostannane cyclisation, anti-geometry resulted in the reduced 
product 1.54 due to the relative rates of rotation and reduction: the reduction pathway 
was in this case much faster than the cyclisation pathway (this would involve both a 
rotation of the aryl ring to bring it closer to the double bond, and the cyclisation itself); 
whereas in the syn-geometry, the generated radical is sufficiently close to the double 
bond to make the rate of cyclisation greater than the rate of reduction, as the molecule 
is already in the correct configuration for cyclisation. For the Heck reaction, Curran 
postulated that once oxidative addition of the palladium had occurred, concomitant 
rotation around the N-aryl and N-cyclohexenyl bonds from the anti-geometry would 
bring the reacting sites closer together and thus enable cyclisation to occur, whereas 
syn-geometry would sterically hinder the iodine to such an extent that oxidative 
addition did not take place. Axial chirality can therefore have a dramatic effect on the 
outcome of a reaction. 
 
 
1.4 Summary 
Atropisomerism is exhibited by a wide range of natural products, as well as a growing 
range of synthetic molecules, including ligands for chiral catalysts and precursors for 
asymmetric reactions. Clark reported the atropisomeric behaviour of a series of N-
benzylenamides, which could be separated at room temperature in order to allow 
reaction on isolated rotational isomers. Radical and Heck cyclisation methods are 
excellent tools for carbon-carbon bond formation, and can be used to cyclise 
atropisomeric compounds, in order to exploit the axial chirality exhibited to achieve 
chiral transfer to the product. Traditional Bu3SnH radical cyclisation methods have 
been found to result in the widest range of products, but display different reactivity 
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towards atropisomers than Heck conditions. Axial chirality can therefore dictate the 
reactivity of a molecule. Herein investigations into the barrier to rotation exhibited by 
enamides related to those previously studied by Clark are reported, and the results of 
their cyclisations using different methods studied.  
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Chapter 2: Axially Chiral N-o-Halobenzyl-N-acetylenamides: Substituent 
Effects, Rotation Barriers, Conformation Effects and Implications for 
their Cyclisation Reactions. 
2.1 Introduction 
As discussed in Chapter 1, 2,6-disubstituted anilides 2.1a (R3 and R4 ≠ H) exhibit axial 
chirality due to slow rotation around the N-aryl bond.51 Individual atropisomers of such 
anilides have been separated and shown to undergo a range of reactions,121–123  
including radical cyclisations with transfer of chirality.53  Tertiary enamides 2.1b also 
exhibit atropisomerism with barriers of rotation between 8-31 kcal mol-1 and half-lives 
for rotation up to 99 years at 298 K.69  
 
Figure 2.1: Structures of atropisomeric anilides and enamides. 
Two forms of restricted rotation complicate the rotation dynamics of tertiary enamides 
2.1c: around the amide N-CO bond and around the N-alkenyl bond. The N-CO bond 
in 2.1b (R1 = R2 = Me, R3 = R4 = R5 =H) has a measured barrier to rotation of 14.0 
kcal mol-1, lower82 than the general amide value of 15-20 kcal mol-1.83 N-Cycloalkenyl-
N-alkyl-acetamides such as 2.1c prefer the amide N-CO E-rotamer124 and exhibit 
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transient axial chirality on the NMR timescale. The rotational dynamics around the N-
alkenyl bond are therefore easy to study by VT 1H NMR.124 Trisubstituted alkene 
derivatives 2.1d have comparatively low barriers to rotation, unlike tetrasubstituted 
derivatives 2.1e-f, which have barriers high enough that individual atropisomers can 
be separated at room temperature.69 The X-ray structures of 2.1d-e have both been 
solved69 and confirm the N-CO E-rotamer geometry in the solid state.  Structures 2.1d-
e both have torsional angles of the key N-alkenyl bond C=C-NC(O) of 74°, similar to 
related anilides.125 The sum of the angles around the nitrogen atom in 2.1e is 359.9°, 
confirming the planarity of the nitrogen.  For relatively unsubstituted enamide 2.2, 
computational analysis using the TZVP basis set126 and the B3LYP-D3(BJ) 
functional127 has proven the (E)-anti geometry to be the major contributor. Related 
anilides125 show a similar effect at equilibrium, with a minor contribution from the (Z)-
anti isomer (2:1) which is corroborated by 1H NMR studies.69  
 
Scheme 2.1: Calculated relative energies and equilibrium contributions of 
conformers 
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Interestingly, two diastereomeric versions of the non-polar (E)-syn 2.2 exists, where 
the vinyl group is orientated either in front or behind the plane of the amide, suggesting 
that the nature of the aryl group may have some influence upon rotation. 
Figure 2.2: Correlation between R group cone angle (θR) and ln krot (ΔG 
(kcal/mol) in parentheses for each compound) 
The acyl group in tertiary enamides exerts a solely steric effect on the N-alkenyl 
rotation barrier, according to a study of enamides128 containing electron-poor and 
electron-rich substituents which demonstrated the negligible effect of the electronic 
nature of the group, and the effect of the size of the acyl group R in 2.1c has been 
shown to be moderate.71,72 An increase in barrier to rotation of 4.1 kcal mol-1 was 
observed when replacing an acetyl group (2.1c(i) ΔG‡298 rot = 10.1 kcal mol-1) with a 
much larger trichloroacetyl group (2.1c(vii) ΔG‡298 rot = 14.2 kcal mol-1). In the case of 
small acyl groups (2.1c(i)), rotation around the N-alkenyl bond is likely to be faster 
than around the amide N-CO bond (the amide barrier to rotation is approximately 14.0 
kcal mol-1, as discussed earlier); however, if the acyl group is larger (2.1c(vii)), the 
barriers to rotation are likely to be similar.82 
Enantiomerisation (E,M → E,P) is therefore possible via a number of potential 
mechanisms, ranging from simple enamide rotation to a geared process such as a 
cooperative coupled rotation of the amide and enamide (E,M→ Z,M→ E,P).43 A plot 
of ln(krot) values for 2.1c against the cone angle θR of the acyl substituent produced a 
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linear correlation129 (R2 = 0.958), suggesting that the rotation mechanism is likely to 
be the same for all compounds in the series and that the cone angle of the acyl 
substituent could be used to predict rotation barriers for a given series of enamides.  
 
Scheme 2.2: Rotamers of radical 2.3 and Bu3SnH mediated cyclisation to give 
2.4 
The bromide substrate 2.1d is known to undergo reductive Bu3SnH-mediated 5-endo-
trig radical cyclisation to give heterocycle 2.4.130–132 Unfortunately, the rates of 
rotation around the N-cycloalkenyl bond of 2.1d and intermediate radical 2.3 have 
been estimated to be comparable or faster than the rate of 5-endo cyclisation (2.3 → 
2.4), precluding the possibility of chirality transfer during the cyclisation. Reaction of 
1.23 could potentially lead to chirality transfer during cyclisation, as the rate of 
enantiomerisation of the intermediate radical was estimated to be 5.6 years at 298 K. 
However, attempts to cyclise 1.23 under high dilution conditions or at elevated 
temperatures failed and a number of non-cyclised materials were isolated.69 
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Scheme 2.3: Attempted cyclisation of 1.23 with Bu3SnH 
It is known that the rate of 5-exo-trig cyclisation of aryl radicals is about 5 x 108 M-1 
s-1 at 50 °C, (5 x 104 times faster than the 5-endo cyclisation of 2.1c).104,133 Due to the 
inherently greater reactivity of aryl radicals compared to α-carbonyl radicals, it was 
desirable to investigate whether chirality transfer could occur during a 5-exo-trig or 6-
endo-trig cyclisation of enamide-derived substrates such as 2.7.  These substrates are 
closely related to compounds 2.1d but interestingly, their cyclisation reactions have 
not been reported in the literature. 
 
Scheme 2.4: Is chirality transfer possible from N-o-halobenzyl-N-acetyl-
enamides 2.7? 
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2.2 Aims of Chapter 
• To gain a better understanding of the rotation dynamics (and hence potential 
chirality transfer) of substituted halobenzyl-derived enamides 2.8.  
• To prepare a range of substrates 2.8, where the effect of halogen (X, Y), acyl 
(R4) and alkene (R1- R3) substitution on the barriers to rotation around the N-
C=C bond is assessed. 
• Compare substituent effects, rotation barriers and conformation effects in 2.8 
with those of anilides 2.1a and enamides 2.1b where R1 is a simple benzyl 
group. 
 
Figure 2.3: Substrates 2.8 used in this study and substrates 2.1a and 2.1b used 
for comparison. 
2.3 Initial choice of targets. 
Despite the remoteness of any ortho aryl substituents to the enamide bond in substrates 
2.8, there is evidence from modelling and X-ray structures (already highlighted) that 
the benzyl substituent has the potential to influence rotation around the N-alkenyl 
bond.  N-Cycloalkenyl-N-benzylacetamide derivatives 2.8a-u were prepared because 
they should be amenable to analysis using variable temperature (VT) NMR. However, 
if X ≠ Y and the substituents are both large, then a further complication of a second 
element of restricted rotation around bonds ‘a’ or ‘b’ may arise in 2.8.70  This would 
make any variable temperature 1H NMR spectra more difficult to analyse.  In order to 
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remove the possibility of diastereomers arising from differently substituted 2,6-
disubstituted aryl groups, those where X = Y, (e.g. 2.8f-h) were focussed on initially.  
For monosubstituted analogues (e.g. 2.8b-e, X =H, Y = halogen) it was expected that 
free rotation around bonds ‘a’ and ‘b’ would not be hindered significantly due to one 
of the ortho substituents being a hydrogen atom. A range of molecules with different 
ring (n = 1-3) and acyl group (R) sizes were prepared as these are known to effect 
barriers to rotation.69 
 
Figure 2.4: Substrates 2.8a-u and 2.9 used in this study 
 
2.4 Synthesis of targets. 
Compounds 2.8a-u and 2.9 were prepared in a two-step procedure from the 
corresponding oximes 2.10 by an initial copper iodide mediated reaction to give the 
secondary enamides 2.11. Deprotonation of the enamide 2.11 with NaH in dry THF 
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followed by addition of the appropriate benzyl bromide 2.12 furnished the desired 
precursors 2.8-2.9. 
Scheme 2.5: Synthesis of substrates 2.8-2.9 
Where the oxime 2.10 was not available commercially, it was prepared from the cyclic 
ketone by reaction with hydroxylamine hydrochloride and NaOAc in MeOH at reflux 
for 24 hrs. 
 
2.5 Method for measuring barriers to rotation (1H VT NMR). 
The barriers to rotation around C-N bonds in anilides,45 benzamides,45,62 and 
enamides69,71,72 have been measured using 1H VT NMR analysis.   The N-benzyl 
enamides 2.8-2.9 are particularly well suited for analysis using this approach as they 
are expected to have barriers within the range accessible by this technique (8-20 kcal 
mol-1).69 This is illustrated below using data for 2.8g. 
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Figure 2.5: 500 MHz 1H VT NMR of 2.8g between 228-288 K in d8-toluene 
The two benzyl methylene protons Ha and Hb appear as a singlet in the 1H NMR when 
the N-alkenyl bond is rotating freely (2.8g, br s, 5.15-4.95 ppm at 288 K), and as two 
mutually coupled doublets (5.50 and 4.55 ppm at 228 K) when the rotation about the 
N-C=C bond is slow: the protons become diastereotopic due to the orthogonal nature 
of the amide and alkene functional groups.  Note that the peak 5.05 ppm at 288 K 
which moves to 4.90 ppm at 228 K is assigned to the alkenyl proton Hc. Line shape 
analysis of the VT NMR spectra using the WINDNMR or TOPSPIN software allowed 
values for krot to be determined at each temperature, which, when factored into the 
Arrhenius equation (Eq 2.1), allowed determination of ΔG‡ at each temperature. 
Eyring plots of 1/T against ln(k/T) were then produced, providing values for krot 298, 
ΔG298‡, ΔS‡, and ΔH‡ for the bond rotation, using equations 2.2 - 2.4.  
∆𝐺 = 𝑅𝑇ln⁡(
⁡𝑘ℎ
𝑘𝐵𝑇
)……………………………………………………..….Equation 2.1 
𝑘𝑟𝑜𝑡⁡298⁡ = 298𝐾⁡ ∙ ⁡𝑒
𝑠𝑙𝑜𝑝𝑒
298𝐾
+𝑖𝑛𝑡𝑒𝑟𝑐𝑒𝑝𝑡
………………………………………Equation 2.2 
∆𝐻 = ⁡−𝑅⁡ ∙ 𝑠𝑙𝑜𝑝𝑒……………………………………………………..…Equation 2.3 
43 
 
∆𝑆 = 𝑅⁡ ∙ (𝑖𝑛𝑡𝑒𝑟𝑐𝑒𝑝𝑡 − 𝑙𝑛
𝑘𝐵
ℎ
)…………………...………………………Equation 2.4 
 
Figure 2.6: Eyring plot for 2.8g in d8-toluene 
2.6 Substitution effects 
2.6.1. Effect of the halogen group. 
 
a Estimated errors krot 298 K ± 13%, ΔH
‡
298 = ± 0.3 kcal mol
-1, ΔS
‡
298 = ± 1.0 cal mol
-
1, ΔG
‡
298 = ± 0.2 kcal mol
-1, these are in line with related work. b See reference.72  
Table 2.1: Rotation data for 2.8a-h 
Comp. X Y ΔG
‡a  
(kcal mol-1) 
krot 298Ka  
(s-1) 
ΔS
‡a   
(cal mol-1 K-1) 
ΔH
‡a  
(kcal mol-1) 
2.8ab H H 10.1 2.51 x 105 -2.9 9.2 
2.9 2-bromonaphthyl 10.8 7.40 x 104 -11.7 14.4 
2.8b H F 9.9 3.57 x 105 -7.1 7.7 
2.8c H Cl 9.8 4.15 x 105 -11.4 6.4 
2.8d H Br 10.5 1.12 x 105 -9.3 7.8 
2.8e H I 10.0 3.04 x 105 -1.7 9.5 
2.8f F F 10.9 6.30 x 104 -6.7 8.9 
2.8g Cl Cl 11.7 1.49 x 104 -0.4 11.9 
2.8h Br Br 13.1 1.63 x 103 -7.3 10.9 
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For the series 2.8a-e containing one halogen ortho substituent, the values of ΔG
‡
298 
and krot 298 K are similar within the error for the analysis.  It can therefore be 
concluded that variation of the type of halogen on the benzyl ring has very little bearing 
on the rotation barrier of the N-cycloalkenyl bond, suggesting that the halogen itself is 
positioned away from the rotating bond.  Evidence for this is provided by (a) the X-
ray structure of the related compound 2.21 (vide infra) which clearly shows the 
bromine atom positioned away from the rotating bond of interest and (b) the fact that 
the structure 2.8a (X = Y = H) has similar rotation rates and activation parameters.  
The 2-naphthyl derivative 2.9 has similar measurements to 2.8d indicating the extra 
ring is positioned away from the rotating bond. 
 
Figure 2.7: X-ray structure of compound 2.21 showing position of bromine 
substituent 
On the other hand, benzyl groups containing two ortho aryl substituents increase the 
barrier to rotation in line with their size (2.8f F = +1.0 kcal mol-1, 2.8g Cl = +1.9 kcal 
mol-1, 2.8h Br = +2.6 kcal mol-1), despite their distance from the key N-alkenyl bond 
rotation.  While it was not possible to solve the X-ray structure of any of the 2,6-
disubstituted substrates to provide information about the conformation of these 
molecules, examination of the ΔS
‡
298 parameters provided some tentative insight. The 
vast majority of entropy values for rotation around the N-alkenyl bond of tertiary 
enamides are relatively small and negative.71,72 This suggests an ordering in the 
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transition state for rotation relative to the ground state.  This can be readily explained, 
when one considers that in the transition state it is likely that a degree of co-operative 
gearing of rotation around key bonds (N-(CO), N-alkenyl, acyl substituent) is required 
in order for the molecule to achieve some level of planarity.  In the ground state the 
general molecular motions of these bonds will be more randomised. The ΔS
‡
298 values 
for di-substituted aryl substituents are slightly lower than for their mono-substituted 
analogues. This may indicate that while there is little movement required of the benzyl 
substituent during N-alkenyl bond rotation in mono-substituted molecules (as the 
ground state already has the large atom pointing away from the area of interest) but 
that there is more movement required (more disorder) for di-substituted ones.  While 
the differences in ΔS
‡
298 are small (and for 2.8b and 2.8f, within experimental error), 
they are more likely to be greater in molecules with higher barriers to rotation (e.g. 
when the acyl substituent is larger than methyl or when the cycloalkenyl ring is larger, 
or both). This is indeed observed (vide infra) and in some cases leads to a positive 
ΔS
‡
298 value (2.8k, 2.8n and 2.8s). 
 
2.6.2. Effect of the acyl group and ring size. 
Previous work has shown that varying the size of the cycloalkenyl group has a 
moderate effect on the barrier to rotation,69 with barriers lowering as the ring was 
pinned back by its decreasing size.  The exception was the cyclooctene derivative 
2.13d, where the puckered conformation effectively decreased its cone angle, (Table 
2.2).   
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a Estimated errors krot 298 K ± 13%, ΔH
‡
298 = ± 0.3 kcal mol
-1,ΔS
‡
298 = ± 1.0 cal mol
-
1, ΔG
‡
298 = ± 0.2 kcal mol
-1, these are in line with related work. b See reference.71  
Table 2.2: Rotation data for 2.13a-d 
A similar trend was observed in this work.  For the two acetamide series (R = Me) 
where (a) X = H, Y = Br, (series 1: 2.8d → 2.8o → 2.8t) and (b) X = Y = Br (series 
2: 2.8h → 2.8p → 2.8s) the cycloheptenyl derivatives 2.8o and 2.8p have the highest 
barriers, (series 1: ΔG
‡
298 = 10.5 → 12.0 → 11.3 kcal mol-1, series 2: ΔG
‡
298 = 13.1 → 
14.8 → 12.4 kcal mol-1) (Table 2.3). 
 
 
 
 
 
 
 
Comp. n ΔG
‡a  
(kcal mol-1) 
krot 298Ka  
(s-1) 
ΔS
‡a   
(cal mol-1K-1) 
ΔH
‡a  
(kcal mol-1) 
2.13ab 0 10.0 3.11 x 105 -6.6 8.0 
2.13bb 1 13.3 1.06 x 103 -6.6 11.3 
2.13cb 2 13.5 735 -5.7 11.8 
2.13db 3 12.7 3.09 x 103 -4.3 11.4 
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a Estimated errors krot 298 K ± 13%, ΔH
‡
298 = ± 0.3 kcal mol
-1, ΔS
‡
298 = ± 1.0 cal mol
-
1 ΔG
‡
298 = ± 0.2 kcal mol
-1, these are in line with related work. b See reference.72  
Table 2.3: Rotation data for 2.8i-u and 2.13a-d 
Increasing the size of the acyl substituent R from Me → Et → iPr generally increases 
the barrier to rotation by approximately 0.7-1.0 kcal mol-1 per carbon. This is 
corroborated by the benzyl derivatives, series a, n = 1, X = Y = H, (Me → Et: 2.8a → 
2.8i δΔG
‡
298 = +0.8 kcal mol
-1, Et → iPr: 2.8i → 2.8l δΔG
‡
298 = +0.8 kcal mol
-1), for 
the 2-bromobenzyl derivatives, series b, n=1, X=H, Y=Br, (Me → Et: 2.8d → 2.8j 
δΔG
‡
298 = +0.8 kcal mol
-1, Et → iPr: 2.8j → 2.8m δΔG
‡
298 = +0.9 kcal mol
-1), and for 
the 2,6-dibromobenzyl derivatives, series c, n = 1, X = Y = Br, (Me → Et: 2.8h → 
2.8k δΔG
‡
298 = +0.3 kcal mol
-1, Et → iPr: 2.8k → 2.8n δΔG
‡
298 = +1.0 kcal mol
-1).  
Similarly for the cycloheptenyl derivatives, n = 2, the increase for Me → iPr, series d, 
Comp R n X Y ΔG
‡a  
(kcal mol-1) 
krot 298Ka  
(s-1) 
ΔS
‡a   
(cal mol-1K-1) 
ΔH
‡a  
(kcal mol-1) 
2.8ab Me 1 H H 10.1 2.51 x 105 -2.9 9.2 
2.8d Me 1 H Br 10.5 1.12 x 105 -9.3 7.8 
2.8h Me 1 Br Br 13.1 1.63 x 103 -7.3 10.9 
2.8ib Et 1 H H 10.9 7.46 x 104 -14.7 6.4 
2.8j Et 1 H Br 11.3 3.04 x 104 -13.1 7.4 
2.8k Et 1 Br Br 13.4 9.46 x 102 17.1 18.5 
2.8lb iPr 1 H H 11.7 1.80 x 104 -10.6 8.5 
2.8m iPr 1 H Br 12.2 6.83 x 103  -11.4 8.8 
2.8n iPr 1 Br Br 14.4 158 2.14 15.1 
2.8o Me 2 H Br 12.0 1.04 x 104 -4.9 10.5 
2.8p Me 2 Br Br 14.8 83.0  -11.2 11.5 
2.8q Et 2 H Br 12.7 3.16 x 103 -3.3 11.7 
2.8r iPr 2 H Br 13.9 4.11 x 102 -9.02 11.2 
2.8s iPr 2 Br Br 16.5 5.24 3.6 17.5 
2.8t Me 3 H Br 11.3 3.07 x 104 -14.3 7.1 
2.8u Me 3 Br Br 12.4 5.03 x 103 1.4 12.8 
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is δΔG
‡
298 = 1.9 kcal mol
-1 (X = H, Y = Br, 2.8o → 2.8r) and 1.7 kcal mol-1 (X = Br, 
Y = Br, 2.8p → 2.8s, series d). 
 
Figure 2.8: Graph of logkrot verses cone angle of acyl substituent 
Comparing plots of logkrot against the cone angle of acyl substituents for series a-d, 
Figure 2.8, shows a similar linear trend to that previously reported (gradient -0.05), 
suggesting similar mechanisms for rotation (series: a = -0.05, b = -0.05, c = -0.06 and 
d = -0.04).  The ΔS
‡
298 values for the X = Y = Br derivatives 2.8k, 2.8n and 2.8s are 
positive, indicating a more disordered TS with respect to the ground state for these 
molecules, presumably for the reasons suggested in section 2.6.1. Increasing the size 
of the acyl group, in combination with other sterically bulky groups 2.8s, could only 
drive the barrier to rotation up to 16.5 kcal mol-1 (various attempts to synthesise t-
butylacetamides were unsuccessful). This is insufficiently high to envisage chiral 
transfer possibilities, and thus other methods of increasing the barrier to rotation must 
be investigated. 
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2.7 Increasing the barrier to rotation further 
Recent work has suggested that in order to isolate individual atropisomers the alkene 
must be tetra-substituted.69 However, for substrates containing relatively large acyl 
substituents, such as 2.14, the barrier for N-(CO) amide bond rotation was found to be 
lower than that of N-alkenyl bond rotation. Figure 2.9b. Analysis of the 400MHz 1H 
NMR of 2.14 at 298K showed a doubling of all peaks, indicative of both (E)- and (Z)-
amide rotamers at room temperature. Heating at 373K led to coalescence of the four 
sets of doublets to two broad singlets, indicative of a rapid interconversion on the NMR 
timescale between the (E)- and (Z)-amide rotamers with a slower rotation around the 
enamide N-C bond, Figure 2.9a. In addition, the X-ray crystal structure of 2.14 clearly 
shows the (Z)-amide rotamer in the solid state, Figure 2.9c.  On the other hand, 
molecules with a smaller acyl group (R = Me), 2.15, only showed one amide rotamer 
in solution.  Consequently, initial investigations compared the N-benzyl 2.16a, 2-
bromo 2.16b and 2,6-dibromobenzyl 2.16c derivatives. 
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Figure 2.9 a) 400 MHz 1H NMR spectra of 2.14 in d8 toluene at 298K and 373K, 
b) Co-operative rotation during N-alkenyl bond rotation, c) X-ray crystal 
structure of 2.14, d) structure of (E)-2.15 and e) structures of enamides 2.16a-c.  
The targets 2.16a-c were synthesised using the method reported in section 2.4.  Hence, 
reaction of 3-methylbutan-2-one with hydroxylamine hydrochloride and NaOAc at 
reflux provided oxime 2.17, after which copper mediated acetylation and 
rearrangement furnished the secondary enamide 2.18 in 15% yield as a 4:1 mixture of 
isomers. Alkylation with the appropriate benzyl bromide 2.12  gave the targets 2.16a-
c in yields of 80%, 28% and 20% respectively.  The 1H NMR of the enamides 2.16a-
c showed clearly resolved doublets for the benzyl protons at room temperature. 
Heating to 373K broadened the peaks but they did not reach the point of total 
coalescence. This meant the barrier to rotation was too high to be calculated accurately 
by VT NMR, however 2.16b was estimated to have a ΔG
‡
298 = 19.9 kcal mol
-1 (krot = 
1.66 x 10-2 s-1).  Instead the substrate 2.16c was sent to collaborators, Curran and co-
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workers, in Pittsburg, America for attempted separation on a Whelk-O column, the 
type used previously for the separation of enamide atropisomers.69 
 
Scheme 2.6: Synthesis of substrates 2.16a-c 
Isolation of the pure enantiomer of compound 2.16c on the Whelk-O was successful 
(10% iPrOH/90% hexanes), and remained pure while kept on ice. When left at room 
temperature, the compound began racemising. Figure 2.10 shows the analytical HPLC 
chromatogram after 80 mins. By studying the kinetics of racemisation, the barrier to 
rotation was measured at 23.6 kcal mol-1, with a half-life of 176 mins at 298K. While 
2.16c exhibited a relatively higher barrier to rotation than previous compounds 2.8a - 
2.8u, it was not sufficiently high enough to qualify as an atropisomer. 
 
Figure 2.10: HPLC chromatogram of enamide 2.16c after 80 minutes 
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In order to increase the barrier to rotation further it was deemed necessary to introduce 
a further branching point at the α’-position such as in 2.19.  In this way, the enamides 
2.19 resemble anilides 2.20 with substituents R3 = Me which have barriers to rotation 
> 26 kcalmol-1. Recent work in the Clark group has established that compound 2.21a 
has a barrier to rotation of 31.0 kcal mol-1 and a half-life t½ for rotation of 99 years at 
298 K.  Consequently, the aryl bromide derivative 2.21b was prepared. 
Scheme 2.7: Enamides and anilides with branching at the α’ position 
Compounds 2.21a-b could not be synthesised using the copper iodide method 
described in section 2.4 and instead the oxime 2.22 was reacted with iron powder, 
acetic anhydride and acetic acid in toluene, to give a 6% yield of 2.23. Benzylation 
was then accomplished using NaH at reflux as before. 
 
Scheme 2.8: Synthesis of substrates 2.21a-b 
The X-ray structure of 2.21b (Figure 2.11) was solved.  Interestingly, the nitrogen is 
shown to be slightly pyramidalized: the sum of the three bond angles around the amide 
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nitrogen N9 is 353.5°.  This is unusual, in that the published X-ray structures of 2.1d, 
2.1e, 2.14 and related molecules have completely planar nitrogen atoms as expected, 
but it has been observed before in hindered anilides.61  Presumably pyramidalization 
occurs to relieve the steric congestion around the gem-dimethyl substituent. 
 
Figure 2.11: X-ray structure of 2.21b showing non-planarity of N9. 
Once again, at room temperature the benzyl protons appeared as clearly resolved 
doublets on the NMR spectrum, and did not fully coalesce when heated either in 
chloroform or toluene. Therefore, compound 2.21b was also sent to collaborators in 
Pittsburgh for attempted separation on a Whelk-O column (enantiomers observed at 
12.2 and 16.3 mins, Figure 2.12). Isolation of the pure enantiomer (retention time 12.2 
mins) of compound 2.21b on the Whelk-O column (10% iPrOH/90% hexanes) was 
successful and found to be configurationally stable at room temperature. When heated 
to 115°C in n-BuOH for 1 hr rotation around the N-C=C bond started to occur, with 
the other enantiomer (retention time 16.3 mins) appearing in the analytical HPLC 
chromatogram. The barrier to rotation was measured at 30.6 kcal mol-1, which equates 
to a half-life of 47.9 years at 298 K. This result was highly satisfactory, as it proved 
the efficacy of the further branching point in increasing the barrier to rotation in N-
bromobenzyl enamides, to the point that individual atropisomers could be prepared 
and stored at room temperature.  
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Figure 2.12: HPLC chromatogram of compound 2.21b 
 
2.8 Towards the synthesis of a natural product 
Our thoughts turned next to applications of this chemistry.  Natural products 
sanguinarine (2.24) and (-)-norchelidonine (2.25) were found to possess similar base 
structures to the supposed products of 6-endo-trig radical cyclisation of the enamide 
substrates 2.8, 2.9, 2.16 and 2.21 (likely cyclised product frame in red). 
 
Figure 2.11: Sanguinarine and (-)-norchelidonine 
Sanguinarine is a toxic ammonium salt which can be extracted from several plants, 
including bloodroot, where it was synthesised from dihydrosanguinarine by 
dihydrobenzophenanthridine oxidase. Low doses have been shown to have apoptotic 
effects on human cancer cells while leaving healthy cells unharmed by preliminary 
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preclinical in vitro and in vivo experiments134, although higher doses can cause 
epidemic dropsy if ingested or scabs if applied to the skin (sanguinarine is an 
escharotic). The apoptotic effect of sanguinarine originates in its action on the sodium-
potassium adenosine triphosphatase (Na+-K+-ATPase) transmembrane protein.135 
Norchelidonine is a derivative of chelidonine, a potential anti-cancer drug which can 
cause mitotic slippage and apoptotic-like cell death.136 The total synthesis of both (+)-
chelidonine and (+)-norchelidonine reported in 2012 by Hsung137, involving in each 
case a benzyne-enamide-[2+2] cycloaddition cascade, identified benzophenanthridine 
2.26 as a useful intermediate. Hence the dihydronaphthyl substrate 2.27 and the 
benzodioxole substrate 2.28 were synthesised, as described in scheme 2.5, p41, in 
order to study the effect of these moieties on the barrier to rotation around the N-C=C 
bond, with a view to the incorporation of these substituents in a larger molecule. 
 
Figure 2.13: Structures of compounds 2.27 and 2.28 
a Estimated errors krot 298 K ± 13%, ΔH
‡
298 = ± 0.3 kcal mol
-1,ΔS
‡
298 = ± 1.0 cal mol
-
1, ΔG
‡
298 = ± 0.2 kcal mol
-1, these are in line with related work. 
Table 2.4: Rotation data for 2.27 and 2.28 
Increasing hindrance at one of the alkene groups by incorporating the dihydronaphthyl 
substituent, as in substrate 2.27, affords a significant increase in rotational energy 
(2.8d/2.27 δΔG‡ = +7.4 kcal/mol).  In all probability, this is due to the steric clash 
Comp. ΔG
‡a 
(kcal mol-1) 
krot 298Ka 
(s-1) 
ΔS
‡a 
(cal mol-1K-1) 
ΔH
‡a 
(kcal mol-1) 
2.27 17.9 4.95 x 10-1 -11.7 14.4 
2.28 10.4 1.46 x 105 -8.2 7.9 
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present between the acyl hydrogens and the hydrogen at C-8 of the dihydronaphthyl 
ring during the high energy planar conformation during rotation. This would suggest 
replacing the C-8 hydrogen substituent with a methyl group should increase the barrier 
significantly. However removing this in order to synthesise either norchelidonine or 
sanguinarine would complicate the synthesis, although placing a TMS group here 
might be useful in chirality control, and could be easily removed afterwards. 
It was predicted that due to the incorporation of the steric bulk away from the potential 
rotation site that the barrier to rotation in 2.28 should be similar to the parent compound 
2.8d and the bromonaphthyl compound 2.9.  This proved to be the case with the δΔG‡ 
values for 2.8d/2.28 = -0.1 kcal/mol and 2.9/2.28 = -0.4 kcal/mol, almost within the 
margin of error for the measurements (± 0.2 kcal/mol). It can be concluded that the 
benzodioxole moiety, like the naphthyl, is rotated out of the way of the cycloalkenyl 
group and therefore does not affect the barrier to rotation significantly. Given the 
success of the dihydroaphthalene moiety in driving up the barrier to rotation in 2.27, a 
possible precursor 2.29 to an analogue of norchelidonine was synthesised. 
 
Figure 2.14: Compound 2.29 
A slightly different benzodioxole moiety was used for this compound than in the 
synthesis of 2.28, due to both the positioning of the benzodioxole in norchelidonine 
and to the probable effect on the barrier to rotation of this changed regiochemistry. 
Rotation of the bromoaryl moiety can no longer remove its influence on the barrier to 
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rotation around the N-cycloalkenyl bond, as both sides of the aryl group are hindered 
(by the bromine and the methylenedioxy substituent). This, in combination with the 
steric clash between the dihydronaphthyl and the acyl groups, could therefore be 
reasonably expected to increase the barrier to rotation in 2.29 to the 25 kcal/mol needed 
for atropisomerism. 
 
Scheme 2.9: Synthesis of 2.29 
As expected, the barrier to rotation for compound 2.29 was too high to be measured 
by VT-NMR analysis. The compound was therefore sent with the others to 
collaborators in Pittsburgh in order to attempt separation. This, however, was 
unsuccessful: the rotamers could not be separated on the Whelk-O column using a 
variety of solvent systems. The barrier to rotation of 2.29 is therefore higher than the 
upper limit of what can be measured by VT NMR analysis, and lower than the lower 
limit of what is possible to separate by chiral HPLC. An impurity was observed at 14.4 
minutes, presumably due to decomposition of the compound during transit. Compound 
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2.29 therefore has a barrier to rotation between 20 and 24 kcal/mol. This is insufficient 
for atropisomerism, but may prove useful in chiral transfer reactions. 
 
Figure 2.15: HPLC chromatogram of compound 2.29 
 
2.9 Summary 
In this chapter, a series of 28 enamides 2.8, 2.9, 2.16, 2.21, 2.27-2.29 has been 
synthesised and their barriers to rotation have been analysed by VT NMR and chiral 
HPLC. They all exhibit slow rotation around the N-alkenyl bond: their ΔG‡ barriers to 
rotation range from 9.8-30.6 kcal mol-1. The δΔG‡ barrier to rotation is driven up by: 
a) the size of the substituent at the acyl group, (~ + 1.6 Kcal mol-1), b) 2,6-
disubstitution of the benzyl group (~ + 3 Kcal mol-1), c) the presence of one α’-
substituent (~ + 6.2 Kcal mol-1),  d) the presence of one α-substituent (~ + 10.2 Kcal 
mol-1), e) one α- and one α’-substituents (~ + 15.8 Kcal mol-1)  and f) one α- and two 
α’-substituents (~ + 20.1 Kcal mol-1). As a consequence, it is possible to separate 
atropisomers of tetrasubstituted alkenes such as 2.16c and 2.21b by chiral HPLC with 
2.21b having a half-life towards racemisation of 47.9 years at 298 K. However, a 
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similar, although inferior, effect can be obtained when several effects are combined, 
(e.g. (b) and (c) above in 2.29).  
 
Figure 2.16: Enamides with high barriers to rotation 
Although the barrier to rotation in 2.29 was not sufficiently high enough for individual 
atropisomers to be separated, the results suggest that increasing the acyl group size to 
a t-Bu group (e.g. 2.33) may provide enough increase for atropisomers to be isolated, 
although due to time constraints it was not possible to investigate this theory any 
further. 
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Chapter 3: Radical Cyclisations of N-o-Halobenzyl-N-acylenamides 
3.1 Introduction 
Aryl radical cyclisation onto enamides has not been extensively studied.  There are 
two possible cyclisation manifolds, one with reaction taking place via the acyl side 
chain (3.1 → 3.2, type 1) and one with the amide group exocyclic to the forming ring 
(3.3 → 3.4, type 2).   The majority of published work has focused on the cyclisations 
of type 1. Cyclisation of monosubstituted enamides 3.1, in which the carbonyl group 
is positioned internal to the forming ring, has been shown to lead primarily to 5-exo 
isoindolone products 3.2.138 If the alkene is substituted further, cyclisation can occur 
in either a 5-exo or 6-endo mode depending upon the substitution pattern and electronic 
nature of the alkene.138  
 
Scheme 3.1: Modes of aryl radical cyclisation onto enamides 
Cyclisation of enamides 3.3, where the carbonyl group is exocyclic to the forming ring 
(type 2), has received less attention. Such cyclisations typically lead to 
tetrahydroisoquinolines 3.4 via a 6-endo-trig mode of cyclisation.107,139  This endo 
selectivity was postulated to arise due to cyclisation via the syn-3.3 conformer (the 
only conformer detected in solution at room temperature).139 In this conformer the 
reacting radical is closer to the β-carbon, leading to the observed endo selectivity.  The 
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preponderance of the syn-3.3 conformer over the anti-3.3 conformer was found 
irrespective of the nature of R1.  Ishibashi concluded that these observations ‘strongly 
suggest that exo and endo selectivities of radical cyclisations onto the alkenic bond of 
enamides can be controlled by positional change of the carbonyl group’.140 
 
Figure 3.1 Conformations of 3.3. 
3.1.1  Type 1 Cyclisations 
Ishibashi examined the effect of alkene substitution upon the regiochemistry of 
cyclisation of iodobenzamides 3.1a-c.  Cyclisation of 3.1a-b gave exclusively 5-exo 
products 3.2a-b while substitution of a phenyl group at the α-position 3.1c led to 6-
endo cyclisation 3.5 predominantly.  Experiments utilising different concentrations of 
Bu3SnH concluded that the 6-endo product 3.5 arose from the kinetically favoured 5-
exo product radical followed by a neophyl rearrangement.138,141,142 
 
Scheme 3.2: Cyclisations of type 1 substrates 
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The 6-endo mode of cyclisation was also found to predominate when the alkene was 
constrained within a cyclohexyl ring.  Hence, aryl bromide 3.6 gave a 1.5:1.0 mixture 
of cis 3.7 and spiro-isoindolone 3.8, although it is unclear whether the product 3.7 also 
arose from a similar neophyl rearrangement.143 This approach has been applied to the 
total synthesis of the alkaloids (+)-lycorine (key step 3.9 → 3.10) and (+)-
deoxylycorine in 15 and 13 steps respectively.144–147  In both cases the nitrogen of the 
enamide is exocyclic to the alkene-containing ring.  If the nitrogen is constrained 
within the ring then 5-exo cyclisation is observed as the major product (3.11 → 3.12 
(±)-lennoxamine)).148,149 This highlights that the regioselective outcome is likely to be 
dependent upon a subtle interplay of electronic and conformational effects and is not 
as straightforward as claimed originally by Ishibashi.138 
 
Scheme 3.3: Regiochemistry of type 1 substrate cyclisations 
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3.1.2  Type 2 Cyclisations 
Less information has been reported on the regiochemical outcome of aryl radical 
cyclisation of type 2 reactions.139,140,150 The majority of work has focussed on 6-exo 
verses 7-endo cyclisations, with the latter predominating.151,152 The size of the acyl 
group (R) in 3.13a-c was found not to affect the regiochemical outcome of cyclisation 
with 3.14a-c predominating.  Ring expansion via neophyl rearrangement from the 
corresponding 6-exo cyclized radical was not observed.151 This approach has been 
applied to the cis-ring junction of the cephalotaxine skeleton 3.15151 via a tandem 7-
endo: 5-endo process as well as to the trans-fused benz[d]indeno[1,2-b]azepine 
skeleton 3.16152   and the alkaloid lennoxamine  3.17.153 
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Scheme 3.4: Regiochemistry of type 2 substrate cyclisations 
3.2 Aims of Chapter 
A thorough study upon the factors that affect the regio- and stereo-chemistry of type 2 
cyclisations of trisubstituted (R1, R3 ≠ H) or tetrasubstituted (R1, R2, R3 ≠ H) enamide 
derivatives 3.17 leading to 5-exo 3.19 or 6-endo 3.18 cyclisation has not been 
undertaken.  This chapter will describe efforts in this area utilizing substrates prepared 
in chapter 2 (varying R1, R2, R3, R4, X and Y), more specifically: 
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Scheme 3.5: Substrates and products of type 2 cyclisations used in this study 
• The effect of ring size (n) in substrates 2.8 upon regio- and stereoselectivity in 
the cyclisation process. 
• The effect of acyl group size R, level of halogenation (X, Y) and other aryl 
substitution of substrates 2.8 upon regio- and stereoselectivity in the cyclisation 
process. 
• The outcome of cyclisation of substrates with high barriers to rotation around 
the enamide bond (2.16 and 2.21b), providing information about potential 
asymmetric atropisomeric cyclisations. 
• Application to a natural product skeleton (e.g. cyclisation of 2.29). 
In the case of the enamides with high barriers to rotation (e.g. 2.16c), it was 
hypothesised that cyclisation of enantiomerically pure samples of the enamides might 
lead to chiral transfer if the rate of rotation krot around the N-alkenyl bond of the radical 
intermediate was slower than the rate of cyclisation kc. As has been seen in Chapter 2, 
the halogenation of the aryl ring does not greatly affect the barrier to rotation, and 
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therefore krot for the radical intermediate in each cyclisation can be assumed to be 
similar to krot of the corresponding halogenated compound.  
 
3.3 Choice of Reaction Conditions 
The Bu3SnH-mediated cyclisation is well known and efficacious, but has problems 
including high toxicity, lack of stereospecificity and difficulty of removal from the 
product mixture.154 However, it is one of the more general methods used, and thus 
served as a “control” reaction in order to determine the range of products that should 
be expected from these substrates.  
 
Scheme 3.6: Potential products from cyclisations 
The reaction was performed on enamides 2.8 under the conditions detailed in scheme 
3.6: the solution of starting material in toluene (0.02M) was allowed to reach reflux 
before the mixture of Bu3SnH and ABCN (0.03M and 0.004M respectively) was added 
dropwise via syringe pump, in order to keep the radical concentration low. It was 
important to determine, not only the ratio of endo:exo cyclisation products 3.18:3.19 
but also the stereochemistry of compounds 3.18 (depending on the configuration of 
any R groups, the compound can either be cis or trans).  In addition, the amount of 
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pre-cyclised reduction product 3.20 isolated would also give an indication of the 
relative rate of cyclisation of these molecules.  Products were characterised primarily 
by 1H NMR, and stereochemistry determined by comparison with previously identified 
products84 and analysis of the coupling constants. Ratios of products were determined 
from 1H NMR of crude mixtures. The range of products obtained from this reaction 
varied according to the cyclised substrate.  
 
3.4 Cyclisation Reactions 
 
Scheme 3.7: Possible radical cyclisation pathways 
There are two possible cyclisation pathways for the compounds cyclised in this chapter 
(illustrated for the reaction of 2.8d): the 5-exo pathway to give 3.19a or the 6-endo 
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pathway, giving product 3.18a, (Scheme 3.7).  The latter may arise directly (3.21 → 
3.23) or via a neophyl rearrangement of the intermediate radical 3.22 → 3.23.  
Interestingly, radical cyclisation of the related enamine system 3.24 has been reported 
with the endo:exo ratio being determined by the size of the nitrogen substituent 
(Scheme 3.8).  In this case, as the alkyl substituent got smaller the relative amount of 
the 5-exo isomer 3.26 increased.  In all cases the predominant diastereomer from 6-
endo cyclisation was determined to be the cis isomer 3.25cis and AM1 calculations 
indicated that Bu3SnH reduction occurred preferentially from the less sterically 
demanding face.  Kinetic studies revealed the value for kc 6-endo and kc 5-exo to be 4.6 x 
108 s-1 and 1.5 x 108 s-1 at 80 °C respectively. 
 
Scheme 3.8: Cyclisation onto related enamines 
 
3.4.1 Cyclisation of control substrate 2.8d 
To a solution of 2.8d in toluene (0.02M) at reflux was added a mixture of Bu3SnH 
(0.03M) and ABCN (0.004M) via syringe pump over 2.5 hours. The reaction mixture 
was then refluxed for a further 20 hours, after which it was cooled and the solvent 
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removed under vacuum. The crude product was obtained as a yellow oil (0.12g), which 
was taken up in acetonitrile and washed with hexane. The hexane layer was not found 
to contain any product, and no loss of product was visible in the acetonitrile layer by 
comparison with the crude NMR. The mixture was then purified by column 
chromatography (14:1 to 6:1 pet ether/EtOAc). The products obtained were, as 
depicted in scheme 3.9, the 5-exo product 3.19a and the 6-endo product 3.18a as a 
cis:trans ratio of isomers (1.8:1.0).  
 
Scheme 3.9: Cyclisation onto enamide 2.8d 
The ratios of these products were taken from the crude 400 MHz 1H NMR before 
purification, as this is the only way to guarantee an accurate depiction of what was 
obtained. The cyclisation of compound 2.8d gave the 5-exo (18%), 6-endo cis (48%) 
and 6-endo trans (27%) products 3.19a, 3.18acis and 3.18atrans, as well as some reduced 
starting material 2.8a (6%). For the 6-endo products 3.18a the 1H NMR showed 
mixtures of amide rotamers (3.18acis = 1:0.83, 3.18atrans = 1:0.54), see Figure 3.2.  Only 
one rotamer is detected for the 5-exo product 3.19a. 
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Figure 3.2: 1H NMR spectra (part) of compounds 3.18acis, 3.18atrans (major and 
minor rotamers indicated) and 3.19a. 
Figure 3.3: Calculated conformations of 3.19a using Chem3D 
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The 1H NMR clearly indicates that rotamer 3.19a1, with the aryl group pseudo-axial 
and the carbonyl pointing towards the cyclohexyl axial protons, is the preferred 
conformation in CDCl3.  The C-2 axial protons (blue, 3.10 ppm, 2H, dt, J = 13.2, 5.2 
Hz) are substantially downfield of the other cyclohexyl protons due to the anisotropy 
of the carbonyl group.  Chem3D calculations using the MM2 forcefield suggest that 
the conformations with the oxygen rotated away from the cyclohexyl ring (3.19a2 and 
3.19a4) are significantly higher in energy than 3.19a1.  Cyclohexyl ring flip to give 
3.19a3 where the aryl group is pseudo-equatorial is slightly higher in energy than 
3.19a1 and not observed (the axial protons in red at C-3 would be expected to be 
downfield with a more complex pattern in the 1H NMR). On the other hand, the two 
rotamers of lowest energy calculated for the 6-endo cis conformer 3.18acis are 
approximately the same in energy (within the error of the calculation) and this is 
reflected in their distribution in the 1H NMR.  The stereochemical assignment was 
made based upon nOe data, coupling constants (Ha, 4.82 ppm, dt, J = 12.6, 4.4 Hz) and 
comparison to known data.84,155  
 
Figure 3.4: Calculated conformations of 3.18acis using Chem3D 
A similar Chem3D analysis for the trans isomer 3.18atrans indicates that the lowest 
energy conformations of the two rotamers 3.18aT1 and 3.18aT2 are different, of which 
the conformer with the lowest ground state energy is 3.18T2.  In this conformer the 
carbonyl points towards the ring junction proton Ha, which will appear further 
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downfield than in 3.18aT1.  This is confirmed by the 1H NMR data which shows the 
major isomer 3.18aT2 (Ha = 3.38ppm) and minor isomer 3.18aT1 (Ha = 3.11 ppm) 
respectively.  Interestingly, the known compound 3.28 has a relatively low barrier to 
amide rotation (ΔG‡rot = 12.4 kcal mol-1) determined by VT 1H NMR (Tc = 263 K).   
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Figure 3.5: Calculated conformations and amide bond rotation of 3.18atrans 
Work by Milan Fowkes156 within the Clark research group has shown that although all 
the 1H NMR rotamer peaks are broadened, they have not coalesced by 323 K (at 600 
MHz), indicating a value ΔG‡rot > 14.9 kcal mol-1 and a Chem3D dihedral calculation 
suggests a barrier of at least 16.1 kcal mol-1.  The observed diastereoselectivity 
3.18acis/trans (1.8:1.0) is similar to that observed in the related enamide system 3.25, 
(2.3:1.0), Scheme 3.8, presumably for similar kinetic reasons.157  However, the 
formation of the diastereomers being thermodynamically controlled could not be 
discounted at this stage (although unlikely), as the relative ground state energy 
between them, calculated by Chem3D at 0.6 kcal mol-1, was very similar to that 
measured from the 1H NMR (0.7 kcal mol-1, assuming an equilibrium constant of K = 
1.8 and ΔG = -RTlnK).  Radical cyclisation would normally be considered to be 5-
exo-selective, however in this case the 6-endo cis product 3.18acis is the major 
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observed product, and the 6-endo products are clearly in the majority (6-endo:5-exo = 
4.2) with 6% reduction prior to cyclisation 2.8a. This can be rationalised as being due 
to the ground state structure of the starting materials.  An X-ray structure of the related 
enamide 3.29 clearly shows its axially chiral nature (there is a 74˚ angle between the 
planes of the enamide alkene and the amide groups).  This places the ortho aromatic 
hydrogen closer in space, and at the optimal geometry, to the 6-endo carbon than the 
5-exo carbon. It is likely that in 2.8d the reacting radical site similarly positions the 
reacting radical centre closer in space to the 6-endo carbon than the 5-exo carbon, 
explaining the observed regioselectivity.  
 
Figure 3.6: Spatial explanation for the predisposition towards 6-endo 
cyclisation. 
Finally, in order to discount the possibility that the 6-endo cyclisation was arising via 
a neophyl rearrangement of the 5-exo intermediate 3.21, (Scheme 3.7, pg 68) another 
group member investigated the cyclisation under a variety of Bu3SnH concentrations.
84 
They concluded that the reaction was not proceeding via a neophyl rearrangement and 
measured the rates of 5-exo (3.5 x 108 s-1) and 6-endo (1.8 x 109 s-1) cyclisation at 110 
°C.  These are approximately 4 and 2 times greater than the corresponding cyclisations 
of enamine 3.24a at the same temperature.  
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3.4.2 Effect of cycloalkenyl ring expansion 
Radical cyclisations of 2.8o and 2.8t were next investigated, so as to judge the effect 
of cycloalkenyl ring expansion on the product ratios by comparison with the 
cyclisations of 2.8d.  In all cases, the 3.18cis isomers consisted of two rotamers with 
the major rotamer assigned to that with the C=O pointing towards the benzyl CH2 
protons (2.8d 1.00:0.83, 2.8o 1.00:0.95, 2.8t 1.00:0.78). 
Scheme 3.10: Cyclisation products: Effect of ring expansion.  Major rotamer is 
shown. 
Cyclisation 
compound 
n Yield 
Ratio 
3.18cis:3.18trans:3.19:3.30 
Ratio 
3.18cis:3.18trans 
Ratio 
6-endo:5-exo 
2.8d 1 100% 48:27:18:6 1.8:1.0 4.2:1.0 
2.8o 2 100% 86:0:14:0 cis only 6.1:1.0 
2.8t 3 74%a 50:0:11:13 cis only 4.5:1.0 
a 26% of unreacted starting material was recovered. 
Table 3.1: Ratio of products obtained in cyclisations of 2.8d, 2.8o, and 2.8t 
As before, reduction of the intermediate radical via the β-face is less sterically 
demanding (red trajectory) and for the cycloheptenyl 2.8o and cyclooctenyl 2.8t 
derivatives leads to only the cis diastereomer being observed. An alternative 
explanation may be that epimerization under the reaction conditions leads to the 
thermodynamically more stable cis-ring junctions.  While the thermodynamic ring 
junction in simple 7:5 bicyclic fused systems is known to be cis158, it is unclear whether 
7:6 and 8:6 systems follow this pattern.  
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Figure 3.7: Trajectories of reduction of the intermediate radical (black atom). 
When the cyclooctenyl substrate 2.8t was cyclised, however, the reduced product was 
visible in the crude NMR (13%) indicating a slower cyclisation than 2.8d or 2.8o, 
alongside the expected 6-endo cis (50%) and 5-exo (11%) products and 26% of starting 
material. The TLC used to monitor the reaction was in this case misleading, as the 
spots for each compound were not sufficiently dissimilar in Rf values. The ratio of 
3.18tcis 6-endo cis product to 3.19t 5-exo product (4.5) was in between the values for 
the cyclisation’s of cyclohexenyl 2.8d or cycloheptenyl 2.8o substrates (4.2 and 6.1 
respectively), indicating that 6-endo cyclisation is similarly favoured in the expanded 
ring systems. The ratios for 2.8d and 2.8t are however very similar (4.2 and 4.5 
respectively). This can then be correlated to the barrier to rotation: a similar odd trend 
was seen there, (cf Chapter 2) where cyclohexenyl and cyclooctenyl compounds 2.8d 
and 2.8t had a lower barrier to rotation than cycloheptenyl substrate 2.8o, presumably 
due to the folding of the cyclooctenyl ring. It seems that with respect to the size of the 
cycloalkenyl ring, the higher the barrier to rotation, the more 6-endo cyclisation takes 
place, although unfortunately not enough to completely exclude the 5-exo pathway. 
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3.4.3 Effect of increased size of acyl group 
The study of the acetamides synthesised in Chapter 2 next required the cyclisation of 
compounds with varying acyl group size R, as depicted in Scheme 3.11. The 6-endo 
product 3.18 was expected to remain predominant, in particular the cis product; it was 
also hypothesised that the cyclisation would be harder to initiate and become slower 
as the N-cycloalkenyl bond became more hindered by the increase in size of the acyl 
group (R), and an increased amount of reduced product 3.30 (figure 3.7, pg 76) and 
starting material 2.8 was therefore expected, given the disappointing inefficiency of 
TLC in detecting the end of the reaction observed in the previous section. 
Scheme 3.11: Expected cyclisation products of substrates 2.8d-s 
Cyclisation 
compound 
Yield Ratio 
3.18cis:3.18trans:3.19:3.30 
Ratio 
3.18cis:3.18trans 
Ratio 
6-endo:5-exo 
2.8d 100% 48:27:18:6 1.8:1.0 4.2:1.0 
2.8j 71%a 41:trace:30:trace cis only 1.4:1.0 
2.8m 100% 71:trace:20:9 cis only 3.6:1.0 
2.8o 100% 86:0:14:0 cis only 6.1:1.0 
2.8q 71%a 40:0:21:10 cis only 1.9:1.0 
2.8s 70%b 50:0:20:trace cis only 2.5:1.0 
a29% recovered starting material; b30% recovered starting material. 
Table 3.2: Ratio of products from cyclisation of 2.8d, 2.8j, 2.8m, 2.8o, 2.8q and 
2.8s. 
When the acyl substituent size was increased from R=Me to R=Et, 2d → 2j and 2.8o 
→ 2q, the relative amounts of 5-exo cyclisation products 3.19 increased in both series 
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(n = 1 and 2). This trend was reversed somewhat on moving from R=Et to R=i-Pr, 2j 
→ 2m and 2.8q → 2s, but this was less evident for the n = 2 series and the values were 
still less than the R=Me analogues 2d and 2o. The overall effect of the increase in size 
of the acyl substituents seemed to be to encourage 5-exo cyclisation to the detriment 
of 6-endo, while also slowing the rate of reaction sufficiently that starting material and 
traces of reduced product were observed in the crude reaction mixtures. The reasons 
for this change in regioselectivity are unclear and would require further detailed high 
level modelling studies of the transition states which is not within the remit of this 
project.  However, irreversible radical cyclisations under kinetic control have early 
transition states and ground-state structures can make good transition-state models.159 
Assuming the cyclisations are irreversible then knowledge of ground state 
conformations of the radical precursors may give some insight into the observations.  
Solid state X-ray structure analysis of a functionalised enamides69,71,72 have shown that 
the size of the acyl group effects the dihedral angle between CH=C-N-C(O) so that 
larger acyl groups cause an increase in this angle.  This in turn alters the positioning 
of the aryl radical in relation to the π framework and the regioselectivity. 
 
Figure 3.8: Dihedral angles found in X-ray structures of enamides. 
However, it seems clear at least that the outcome of the cyclisation can be controlled 
by alteration of the acyl substituent (R), although not to the exclusion of any particular 
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pathway. It is unfortunate that despite many attempts it was not possible to make the 
t-butyl substituted analogue 2.8 (R=t-Bu), as this could have provided valuable insight.  
 
3.4.4 Effect of 2,6-dibromo aryl substitution 
One disadvantage of the Bu3SnH method is the formation of pre-cyclised reduction 
products by competitive reduction of the initial aryl radical (3.30, Scheme 3.10, pg 
75).  This amount of reduction was found to increase with ring and acyl group size 
(cyclised:reduction 2.8d = 16:1, 2.8m = 10:1, 2q = 6:1). In order to lower these levels 
the cyclisation of the 2,6-dibromobenzyl derivatives was next investigated, illustrated 
using 2.8h, Scheme 3.12.  
 
Scheme 3.12: Tin-mediated cyclisation of 2.8h. 
Theoretically, if cyclisation of the dibromide 2.8h proceeds with a similar selectivity 
to 2.8d then the ratio of the corresponding brominated cyclised:reduced products 
(3.18h+3.19h:2.8d) will be 93:6.  If two equivalents of Bu3SnH are used during the 
cyclisation then 3.18h and 3.19h will be further reduced to 3.18a and 3.19a 
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respectively but the 6% of reduced 2.8d will in turn react to give another 93:6 ratio of 
3.18a+3.19a:2.8a. This would lead ultimately to a reaction that theoretically will only 
produce 0.4% of pre-cyclised reduction 2.8a.  In order to detect the intermediates 
3.18h and 3.19h, 2.8h was reacted with only 1.5 equivalents of Bu3SnH. Cyclisation 
of 2.8h resulted in six cyclised products: the non-brominated products 3.18acis (11%), 
3.18atrans (2%) and 3.19a (10%), and the brominated products 3.18hcis (21%), 
3.18htrans (17%) and 3.19h (39%). The reduced products 2.8d and 2.8a are not 
observed in the crude mixture, nor isolated during purification. Assuming no 
epimerization or reversibility under the reaction conditions the overall cis:trans ratio 
for all the 6-endo products from 2.h (1.7:1.0) is similar to the control 2.8d (1.8:1.0), 
however the endo:exo ratio is significantly decreased  [2.h (1.0:1.0), 2.8d (4.2:1.0)]. 
However, the fact that the individual cis:trans ratios for 2-bromobenzyl derivative 
3.18a (5.5:1.0) and 2,6-dibromobenzyl derivative 3.18h (1.2:1.0) are different is 
highly suggestive that 3.18hcis is reduced to 3.18acis significantly faster than 3.18htrans 
is reduced to 3.18atrans. The major rotamer of 3.18hcis is opposite to that for 3.18acis 
while 3.18htrans exists as one rotamer but 3.18atrans exists as two at room temperature.   
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Figure 3.9: Dihedral angles found in X-ray structures of enamides. 
These observations were found to be general when comparing the effect of ring size.  
Thus the corresponding 2,6-dibromobenzyl derivatives all gave significantly more 5-
exo product compared to their 2-bromobenzyl analogues (endo:exo = 2.8d vs 2.8h, 
4.2:1.0 to 1.0:1.0; 2.8o vs 2.8p, 6.1:1.0 to 3.3:1.0; 2.8t vs 2.8u, 4.5:1.0 to 3.0:1.0), 
Table 3.3.  In addition, cyclisations of 2,6-dibromobenzyl derivatives did not lead to 
any identified pre-cyclisation aryl radical reduction as theorised in Scheme 3.11. 
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Cyclisation 
compound 
n R  X Ratio 
3.18cis:3.18trans 
Reduction  
% of total 
mixture   
Combined 
Ratio  
6-endo:5-exo 
2.8d 1 Me H 1.8:1.0 6 4.2:1.0 
2.8h 1 Me Br 1.7:1.0 0 1.0:1.0 
2.8o 2 Me H cis only 0 6.1:1.0 
2.8p 2 Me Br cis onlya 0 3.3:1.0b 
2.8t 3 Me H cis only 13c 4.5:1.0 
2.8u 3 Me Br cis onlyd 0e 3.0:1.0 
Unquantifiable trace levels of materials were ignored. a 3.18pcis:3.18ocis = 2.0:1.0; b 
3.19pcis only; c 27% unreacted starting material; d 3.18ucis only e 9% unreacted 
starting material; f 3.19ucis only. 
Table 3.3: Effect of 2,6-dibromo- vs 2-bromobenzyl derivatives on cyclisation 
The effect of the acyl group was also probed and the results compared to the analogous 
2-bromobenzyl derivatives, Table 3.4.  The same pattern of observation was recorded.  
In each case the 2,6-dibromobenzyl derivatives provided more 5-exo product 
compared to their 2-bromobenzyl derivatives, so much so that it became the major 
product for 2.8k, Table 3.4.   
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a 3.18kcis and 3.19k only; b 2:1 ratio of 3.18ncis:3.18ntrans, no 3.18mcis and 3.19m 
observed,  c 3.18pcis:3.18ocis = 2.0:1.0; d 3.19pcis only; e 3.18scis and 3.19s only.  
Table 3.4: Effect of 2,6-dibromobenzyl derivatives on cyclisation (effect of R 
group) 
It seems the extra bromo substituent has a profound effect on the regioselectivity of 
cyclisation and determines the relative stability of the rotamer products. This is highly 
suggestive that the extra substituent is crucial in determining the ground state 
conformation of the substrates. 
 
3.4.5 Cyclisation of substrates with high barriers to rotation around the 
enamide bond 
Cyclisation of substrates with relatively high barriers to rotation around the enamide 
bond such as 2.16b, 2.21b, 3.3284 and 3.33156 and those with sterically congested C-Br 
bonds (2.9) were next investigated.  It was expected that a) initiation and/or cyclisation 
would be difficult due to the substrates being more sterically congested, and that b) 6-
endo cyclisation would be disfavoured or slowed as there are significant steric clashes 
as the axially chiral radical moves towards planarity during cyclisation.  The higher 
barriers to rotation, along with larger dihedral angles between the CH=CNC(O) might 
Cyclisation 
compound 
n R  X Combined 
Ratio 6-endo:5-exo 
2.8d 1 Me H 4.2:1.0 
2.8h 1 Me Br 1.0:1.0 
2.8j 1 Et H 1.4:1.0 
2.8k 1 Et Br 0.6:1.0a 
2.8m 1 i-Pr H 3.6:1.0 
2.8n 1 i-Pr Br 1.4:1.0b 
2.8o 2 Me H 6.1:1.0 
2.8p 2 Me Br 3.3c:1.0d 
2.8r 2 i-Pr H 4.0:1.0 
2.8s 2 i-Pr Br 2.5:1.0e 
83 
 
be expected to favour 5-exo cyclisation with the formation of spiro derivatives.  
Unfortunately, reaction of 2.9, 3.32 and 2.16b with 1.5 eq Bu3SnH / 0.2 eq AIBN or 
ACBN in toluene at reflux led to pre-cyclisation reduction only (2.9 5%, 3.32 not 
measured84, 2.16b 13%) along with recovered starting material, indicating that 
cyclisation was particularly slow.  This is not surprising as the rate of Bu3SnH 
reduction of an aryl radical has been measured at 5.9 x 108 M-1 s-1,160 indicating that 
the cyclisation reactions only need to be slowed by 1-2 orders of magnitude for 
reduction to predominate.  
 
Figure 3.10: Further acetamide substrates for cyclisation 
It came as a surprise therefore when it was reported that cyclisation of 3.33 under the 
same conditions proceeded to give a 5.0:2.5:1.0:1.0 mixture of 3.33:3.34:3.35:3.36 
products (1:1 ratio of 6-endo:5-exo cyclisation).156 
 
Scheme 3.13: Cyclisation of 3.33 
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Encouraged by this result, the cyclisation of 2.21b was next investigated, which shares 
a similar substitution pattern around the alkene. A 31:37:32 mixture of the 6-endo 
3.37cis, the 5-exo 3.38 and the reduced product 3.39 was obtained at the end of the 
reaction. No 6-endo trans product 3.37trans was visible in the crude mixture or 
recovered after purification. Both cyclized products were found to oxidize in air over 
time to the corresponding imides 3.40cis and 3.41 (each as one rotamer as depicted in 
Scheme 3.14). Amide 3.38 and imide 3.41 were detected as one diastereomer each, but 
stereochemistry could not be determined.  
 
Scheme 3.14: Cyclisation and subsequent oxidation of 2.21b 
These findings reinforced what had been observed upon cyclisation of the simpler 
enamides: increased steric hindrance and higher barriers to rotation led to a larger 
proportion of both 5-exo product and pre-cyclisation reduced product, compared to the 
original enamide 2.8d.  Increased hindrance of the 6-position of the cyclohexene ring 
rendered 5-exo cyclisation more favourable.  The 6-endo 3.37cis cyclisation product 
was identified by nOe experiments by irradiation of the Ha proton at 4.68ppm. Due to 
the high barrier to rotation around the N-cycloalkenyl bond of this compound (ΔG‡ 
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=30.6 kcal mol-1), as well as the success in separating the individual atropisomers by 
chiral HPLC (t½ = 47.9 years at 298 K), this substrate was a promising candidate to 
investigate chirality transfer.  However, at the reaction temperature for cyclisation (110 
°C) this substrate has a half-life of only 3.5 hours.  Nevertheless, studies will be carried 
out by Curran and coworkers, into the possibility of chiral transfer reactions. This work 
has not been completed at the time of writing. 
 
3.4.6 Stabilising the 6-endo cyclized radical intermediate 
The possibility of cyclising the substrate 2.27 was next investigated, which would 
generate a particularly stabilised benzylic radical 3.44 upon 6-endo cyclisation.   
 
 
Scheme 3.15: Cyclisation and subsequent oxidation/ring opening of 2.27 
The reaction provided a 22:58:20 ratio of three products 3.42cis, 3.42trans and 3.43 
respectively but no 5-exo product was detected. Both 3.42cis and 3.42trans existed as 
1.00:0.89 mixtures of amide rotamers, the major rotamer for each is shown in Scheme 
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3.15.  The 3.42cis and 3.42trans isomers were identified from the coupling constants of 
the doublets for the Ha signals (3.42cis major rotamer: 6.28 ppm J = 6.0 Hz, minor 
rotamer: 5.30 ppm, J = 6.0 Hz, and 3.42trans minor rotamer: 4.80 ppm J = 10.5 Hz, 
major rotamer: 4.63 ppm, J = 10.5 Hz).  The enhanced stability of the radical 
intermediate 3.44 suggests that either the 5-exo cyclisation is reversible or the extra 
aryl group precludes efficient orbital overlap at the ipso position. Compound 3.43 is 
also formed in significant quantities. This could be formed either by trapping of 
advantageous oxygen by the captodatively stabilized radical 3.44 → 3.46 or by 
oxidation of the long-lived intermediate 3.44 to the acyl iminium ion 3.45 via a polar 
cross-over process followed by trapping by water to give 3.46.  Once formed aminol 
3.46 ring-opens to give the more stable keto-amide 3.43. Contrary to intuition, 
oxidation of tertiary radicals to cations under reductive Bu3SnH conditions has been 
reported previously.6 This is therefore the only substrate studied thus far that has 
exhibited a preference for the 6-endo trans pathway 3.42trans over the 3.42cis. It is 
probable that the labile Ha proton of 3.42cis may undergo equilibration to the more 
thermodynamically stable 3.42trans under the reaction conditions, although this wasn’t 
tested. 
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Scheme 3.16: Potential mechanism of oxidation/ring opening 
 
3.4.7 Towards natural product skeletons 
The 6-endo product 3.42cis contains the tetracyclic core of the alkaloid (-)-
norcheldonine 2.25. It was next determined whether the addition of electron donating 
groups to the aryl bromide portion of the molecule was tolerated, as this would provide 
the right hand portion of the natural product skeleton. 
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Scheme 3.17: Cyclisation approach towards the (-)-norchelidone skeletal 
framework 
Little difference was expected between the cyclisation results of 2.8d and 2.28. The 
expected range of products 3.47cis, 3.47trans and 3.48 was obtained in the ratio 
45:36:19, with trace amounts of reduced product 3.49 observed in the crude reaction 
mixture. This was, as expected, similar to the product ratio for the cyclisation of 2.8d 
(48:27:18), and therefore it can be concluded that adding electron donating substituents 
as well as increasing the size of the 2-bromobenzyl group in this manner (extra 
substitution meta to the reacting bromine, rather than ortho as it was with 2.9) does 
not interfere with cyclisation, but nor does it affect the outcomes of said cyclisation. 
Given this success in cyclising 2.27 and 2.28, it was expected that 2.29 would cyclise 
at the very least in a 6-endo fashion (the extra aryl substitution was para to the reacting 
bromine in the 2-bromobenzyl substituent, and it was considered unlikely that the 
methoxy groups would interfere). This, however, proved not to be the case: compound 
2.29 showed no sign of cyclisation or reduction product either in the crude reaction 
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mixture or after repurification of the starting material was attempted by column 
chromatography. Only starting material was observed. This would indicate that the 
aryl halide bond in 2.29 is particularly difficult to break under normal radical 
cyclisation conditions. The reasons for this were unknown and further study and 
cyclisation attempts would be necessary to fully understand the lack of cyclisation 
observed. 
 
Scheme 3.18: Attempted cyclisation of 2.29 
 
3.5  Summary 
In this chapter the effect of an increased barrier to rotation in compounds 2.8, 2.9, 2.16, 
2.21, 2.27, 2.28 and 2.29 on the efficacy and products of their radical cyclisations has 
been studied. The amount of reduced starting material formed has been minimised by 
dibromination of the starting material aryl group, so as to maximise the overall yield 
of cyclisation products. The ratio of 5-exo-trig to 6-endo-trig cyclisation product varies 
according to the substitution level of the aryl moiety, the acyl group (increased aryl 
substitution and acyl group size both increase the proportion of 5-exo-trig product 
3.19) or the cycloalkane ring (significant steric hindrance of the ring can completely 
remove the 5-exo pathway).  
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Scheme 3.19: Cyclisation of 2.8d. 
Substitution at the meta position of the aryl ring was found to have little effect on the 
outcome of cyclisation (2.27), but ortho- and para-substitution were found to 
completely prevent cyclisation. Expansion of the cycloalkenyl ring causes an increase 
in stereospecificity of the 6-endo cyclisation so as to only furnish the cis isomer of the 
6-endo cyclisation product, while the ratio of 6-endo cyclisation to 5-exo follows the 
same trend as the barriers to rotation (an increase for the cycloheptenyl substrates, 
followed by a smaller decrease for the cyclooctenyl substrates). Significant steric 
hindrance of the cycloalkenyl ring (an extra aryl ring, for example) was found to 
completely prevent 5-exo cyclisation, although some alternative ring-opened product 
was isolated instead. It was thought to be possible to conduct chiral transfer 
experiments on compound 2.21b, as it cyclised readily to a smaller range of products 
than observed with initial compound 2.8d (no 6-endo-trans cyclisation product was 
observed) and had a high barrier to rotation. This compound, along with all cyclised 
products, were accordingly sent to Curran and co-workers in Pittsburgh, although this 
work was unfortunately not complete at the time of writing. None of the compounds 
cyclised in this chapter provided the single reaction pathway that was hoped for, but 
the results were nonetheless of interest and could merit further investigation.  
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Figure 3.11: Possible structure for further investigations into substituent 
effects on radical cyclisation. 
In particular, a combination of a dihydronaphthyl cycloalkenyl moiety, a 
dibrominated aryl ring and an isopropyl acyl group such as in 3.50 could be used 
to remove the possibility of the 6-endo trans and 5-exo cyclisation pathways and 
the reduction pathway, and render the reaction regio- and stereospecific despite the 
reaction conditions. Equally, the synthesis of the natural product skeleton from 
2.29 should be reattempted and further investigated.  
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Chapter 4: Alternative Cyclisation Methods for N-o-Halobenzyl-N-
acetylenamides 
4.1 Introduction 
Having established in Chapter 3 that N-acetylenamides 2.8 could be cyclised using 
organostannane radical methods, alternative methods of cyclisation were investigated. 
The tin method used in Chapter 3 is well known to be toxic, reductive and 
indiscriminate, as well as leaving an organostannane residue that renders purification 
extremely difficult. Therefore, several methods were investigated that might remove 
these difficulties.  
4.1.1 Samarium-mediated cyclisation 
Effective replacement methods for the generation of aryl radicals without using tin 
hydrides have in the past included organosilane- and samarium diiodide-mediated 
reations.94,121,161–163 The samarium diiodide method has been used to generate radicals 
from organic halides since its inception93 by Kagan in 1981 (Scheme 4.1). 
 
Scheme 4.1: Dimerisation of benzyl bromide using SmI2. 
The use of SmI2 to generate aryl radicals is of slightly more recent date: the 
intramolecular reaction of aryl radicals generated by SmI2 onto an alkene was reported 
by Molander and Harring in 1990.94  Curran et al163 formed the BCD ring system of 
penitrem D 4.4 from the aryl iodide 4.3, Scheme 4.2, via a 6-exo-trig cyclisation in 54-
90% yield. The addition of HMPA as an additive and co-solvent (acetone) produced 
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4.5. They also report a palladium Heck cyclisation of the same substrates, resulting in 
products 4.6 with increased functionality in better yield (78-84%), which will be  
discussed in greater detail in section 4.1.4.   
 
Scheme 4.2: Intramolecular cyclisations mediated by SmI2 and Pd(PPh3)4  
The 6-exo-trig cyclisation protocols described for 4.3 in Curran’s work should be 
transferable to compounds 2.8, as the tin and samarium methods are seen to work 
almost equally well for compounds 4.3. In Curran’s work HMPA was used as a co-
solvent, to enable the reaction to be carried out under milder conditions than would 
have been necessary in its absence. This was first reported as a way to facilitate SmI2-
mediated reductions by Inanaga164 but is equally useful for cyclisations.163 This renders 
the method more toxic due to the presence of HMPA, a known carcinogen, but the 
ability to conduct radical cyclisations at lower temperatures would be attractive for 
these substrates if individual atropisomers were used.  This would allow potential 
chiral transfer from substrates to cyclisation products to occur at a lower temperature 
than with the tin hydride methods described in the last chapter.  
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4.1.2 Iron-mediated cyclisation 
The use of iron in heterocycle synthesis has been extensively investigated, although at 
the present time iron catalysts have mostly been used for intermolecular, rather than 
intramolecular, cyclisation.165 Guan has recently reported the iron-catalysed 
dehydrogenative [4+2] intermolecular cycloaddition of a series of enamides and 
anilines with alkenes, using FeCl3,
166 to furnish a wide array of nitrogen-containing 
heterocycles (Scheme 4.3) in good yield, with a wide functional group tolerance. 
 
Scheme 4.3: [4+2] Cycloaddition reported by Guan. 
In 2016 Sweeney and coworkers reported a “novel and sustainable iron(III)-catalysed 
arylative spirocyclization reaction” using Fe(acac)3 and an aryl Grignard reagent 
(Scheme 4.4)167 to generate spirocycles 4.7 from aryl halides such as 4.6. 
 
Scheme 4.4: Fe(acac)3-mediated cyclisation reported by Sweeney. 
Although this method was found to work best with aryl iodides, the reaction of the aryl 
bromide furnished 30% of the same 5-exo-trig product 4.7. Replacement of either of 
the two oxygen atoms with nitrogen was found to yield the corresponding amine 
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products, also in excellent yield.   This can therefore be considered a potentially useful 
method for obtaining nitrogen-containing heterocycles. Alteration of the Grignard 
reagent used was also found to affect the outcome of the reaction: aryl Grignard 
reagents were found to induce superior yields compared to alkyl Grignard reagents, 
with only EtMgBr furnishing a respectable yield (36%).  If the reaction proceeds via a 
free radical (as opposed to a metal complexed radical) this approach would be expected 
to yield the same 5-exo-trig and 6-endo-trig cyclisation products as produced via the 
Bu3SnH mediated pathway described in the last chapter.  
 
4.1.3 Cobalt-mediated cyclisation 
Work done by Jones in 1994 established that cobalt dihalides could be used to mediate 
aryl radical cyclisations in the presence of a Grignard reagent.168 Anhydrous cobalt 
dichloride was used in conjunction with methylmagnesium bromide in THF to 
accomplish the cyclisation of a group of ortho-iodoacryloylanilides 4.8 (Scheme 4.5). 
The cyclisation of the bromine analogue was also successful, albeit with a lower yield 
(45% compared to 71%).  The ratio of regioisomers was similar to that obtained using 
conventional reductive Bu3SnH processes. 
 
Scheme 4.5: Cobalt-mediated cyclisation of iodoanilides 4.8. 
As was predicted, the substitution of the alkene affected the regioisomer obtained as 
product: unsubstituted alkenes (R1=R2=H) or substituted (R1=H, R2=Me) favoured the 
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5-exo-trig cyclisation product 4.9, whereas alkenes with higher substitution at R1 
(R1=Me, R2=H) favoured the 6-endo-trig cyclisation pathway to give 4.10. By 
analogy, therefore, the cyclisation of compounds 2.8 was expected to proceed via the 
6-endo-trig cyclisation pathway. 
 
4.1.4 Heck cyclisation 
As discussed in section 4.1.1, Curran’s work on radical cyclisations using samarium 
was extended to palladium Heck cyclisations of the same substrates, to yield similar 
cyclic skeletons (Scheme 4.6).  
 
Scheme 4.6: Palladium Heck cyclisation reported by Curran. 
The key difference between the products of radical and of Heck cyclisations was that 
the Heck reaction product retained a double bond, thereby preserving some of the 
functionality of the starting material. This would be desirable for further 
functionalisation of compounds synthesised in this work, particularly in the case of 
2.29. The regiochemistry of the cyclisation was the same as when a samarium-based 
radical method was used: the lack of 7-endo-trig cyclisation product was in this case 
unremarkable, given the steric constraints of the cyclobutene ring. However, the exo-
trig cyclisation pathway has been reported to predominate in cases where similar 
substrates were cyclised.169,170 More complicated palladium catalysts can also be used 
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to mediate Heck-type reactions to accomplish stereospecific cyclisations of substrates 
related to compounds 2.8 with high yields, and have been reported to only generate 
the 5-exo-trig product, as found by Hartwig.66,123,169,171 Of particular interest is the 
synthesis of compounds containing quaternary carbons: the first reported asymmetric 
Heck-type cyclisation using palladium to produce such compounds was reported  in 
1989.116 Several combinations of reagents have been reported, with varying degrees of 
success.123,169,172,173 Overman and Ashimori reported the asymmetric synthesis of 
oxindoles169 using palladium and R-(+)-BINAP, as detailed in scheme 4.7.   
 
 Scheme 4.7: Overman’s asymmetric oxindole synthesis.169 
The conditions used by Overman involved, in both cases shown in Scheme 4.7, a chiral 
ligand. The fact that compound 4.11 exists as a mixture of interconverting anilide 
atropisomers suggests that chiral induction is produced by kinetic resolution.  In other 
words, one atropisomers cyclises preferentially to give the observed product.  It would 
be preferable to be able to cyclise such aryl halides onto an alkene without the need 
for chiral catalysts, and compounds 2.8, with higher barriers to rotation, would seem 
to be uniquely suited to this if individual atropisomers were isolated. The conditions 
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used by Curran (Scheme 4.6), or the combination of Pd(dba)2, a ligand and 
trimethylamine which was found to be effective in reacting aryl bromides with vinyl 
substrates66,123,171 would perhaps be more suited to the purposes of this project, without 
any need for chiral catalysts or ligands. Additionally, in 2013 Wang and Pan reported 
a palladium- and ligand-free Heck reaction of aryl iodides with alkenes (Scheme 4.8), 
using InCl3 and NaOAc, which gave 96% conversion to the desired product.
174 If 
suited to the compounds described in this project, this version of the Heck reaction 
could provide a much simpler route to the desired cyclised compounds than the 
palladium method.  
 
Scheme 4.8: Indium-mediated Heck reaction. 
 
4.2 Aims of chapter 
In the previous chapter a range of potentially atropoisomeric enamide substrates were 
reacted using Bu3SnH to assess the regiochemical outcome of their cyclization 
reactions.  Investigations into substrates exhibiting varying levels of restricted rotation 
around the enamide were undertaken in order to determine if cyclization of individual 
hindered atropisomers would be possible.  Unfortunately the high temperatures 
required to cyclize the more hindered enamides precluded this approach to produce 
enantiomerically enriched products. In this chapter a number of other protocols were 
investigated (initially with control substrates 2.8d and 2.8e) by with varying reaction 
conditions, as detailed in section 4.1, with varying degrees of success. The yields, 
conditions, and regiomeric outcomes of each set of reactions were analysed with 
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regards to their efficacy and compared to the tin-mediated method used in Chapter 3. 
Ultimately the best method would be applied to the cyclisation of a selection of the 
compounds synthesised in Chapter 2, to assess the scope of the process. More 
specifically it was desirable to address: 
 
Scheme 4.9: Compounds used for testing conditions and compound 2.29. 
• The effectiveness and differences between cyclisation reactions mediated by 
samarium, cobalt, iron and palladium.  
• The possibility of optimising a method for cyclization of compounds 
synthesised in Chapter 2 at ambient temperatures. 
• The differences between cyclisations undertaken in this chapter and those 
mediated by tin in Chapter 3. 
• Any possible applicability to the construction of a natural product skeleton, 
particularly from compound 2.29. 
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4.3 Preliminary attempts 
Initially, compound 2.8d was cyclised using each of the methods described in section 
4.1, so as to determine whether such conditions would furnish any useful results. In 
each case, compound 2.8d was subjected to the reaction conditions deemed most likely 
to be successful from literature research into each method of cyclisation mediation. 
Unfortunately, the iron, cobalt and indium cyclisation methods proved unsuited, as no 
reaction was observed in the case of either the indium or cobalt cyclisations, while iron 
cyclisation produced only trace amounts of 3.18acis that was not recoverable by column 
chromatography.  
 
Scheme 4.10: Iron-mediated cyclisation of 2.8d. 
For example, reaction of 2.8d with Fe(acac)3 (0.01eq), TMEDA (0.1eq) and EtMgCl 
(1.2eq) in THF at reflux produced only trace amounts of 3.18acis (Scheme 4.10), while 
reaction of 2.8d with CoBr2 (0.5eq) and MeMgBr (2eq) in THF at room temperature, 
and with InCl3 (0.05eq) and NaOAc (2eq) in THF at room temperature both resulted 
in no cyclisation and recovery of starting material. These methods were abandoned 
due to time constraints. However, samarium and palladium cyclisations proved more 
fruitful. 
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4.3.1 Samarium cyclisations 
Initially, cyclisation of 2.8d using a samarium method was attempted without any 
additives. The regioselectivity of cyclization should be similar to those using the tin 
hydride method, as the only difference would have been how the radical was 
generated.  
 
Scheme 4.11: Samarium-mediated reaction of 2.8d. 
Thus, to a solution of 2.8d (1eq) in THF (0.08M) was added SmI2 in THF (1.1eq), 
dropwise over several minutes. This solution was stirred at room temperature under 
nitrogen until the SmI2 was seen to have fully oxidised: the colour of the solution had 
changed from dark blue to yellow. The reaction mixture was washed with NH4Cl and 
brine, extracted into EtOAc and dried. The 1H NMR of the crude reaction mixture 
showed no reaction: only starting material was recovered. As some literature reports 
utilise additives (e.g. HMPA) to mediate reactions the conditions were varied as 
reported in Table 4.1. 
 
Scheme 4.12: Samarium diiodide-mediated radical cyclisation of 2.8d, see Table 
4.1. 
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Entry Eq of SmI2 Additive Eq of additive Temp Yield 
1 1.1 / 0 RT 0 
2 2.2 / 0 RT 0 
3 2.2 / 0 Reflux 0 
4 1.1 DMI 8 RT 0 
5 1.1 DMSO 8 RT 0 
6 1.1 HMPA 8 RT 0 
7 1.1 HMPA 3 RT 0 
8 2.2 HMPA 3 Reflux 0 
9 5 HMPA 10 RT 66% 
10 5 HMPA 10 Reflux 0 
11 5 DMI 10 RT 0 
12 5 DMSO 10 RT 0 
13 2 HMPA 10 RT 0 
14 2 HMPA 5 RT 0 
Table 4.1: Screening of samarium diiodide reaction conditions 
Initially the reaction was attempted with no additive, with variation of the temperature 
and the amount of SmI2 used. These were all unsuccessful and returned quantitative 
yields of the starting material 2.8d (entries 1-3). In an attempt to avoid the use of 
HMPA, commonly used to promote samarium diiodide reactions but known to be 
extremely toxic, the first additives used were 1,3-dimethyl-2-imidazolidinone (DMI), 
a common alternative to HMPA, and DMSO (entries 4-5). These were equally 
unsuccessful and the literature procedure using HMPA was therefore used.94 This, 
however, proved futile in the first instance, as the cyclisation remained unsuccessful 
(entries 6-8) even at reflux. Finally, a successful SmI2 cyclisation method was found: 
this used 5 equivalents of SmI2 and 10 of HMPA, and the reaction was left stirring 
overnight at room temperature as the blue colour of the SmI2 had not disappeared after 
5 hours (entry 9). The solvent was found to have evaporated overnight, but a 1H NMR 
of the crude product obtained after workup showed the reaction to have produced the 
products 3.1acis, 3.1atrans, 3.2a and the starting material 2.8d in the approximate ratio 
14:39:14:33 for an overall yield of cyclised products of 66% (entry 9). This is therefore 
inferior in conversion to the tributyltin hydride method (100% conversion) and while 
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the 6-endo cyclisation 3.1a remains prevalent the trans product 3.1atrans is now the 
major one (Bu3SnH ratio cis:trans = 1.8:1.0, SmI2 cis:trans = 1.0:2.8). The 
regiochemistry 6-endo:5-exo remains similar to that of the Bu3SnH reaction (Bu3SnH 
ratio endo:exo = 4.2:1.0, SmI2 endo:exo = 3.8:1.0).  Assuming both proceed via the 
same free aryl radical intermediate, the key difference between the two methods was 
the temperature and the method of termination.  The predominance of the 3.1atrans 
product at room temperature (SmI2), compared to the predominance of 3.1acis at 
120 oC (Bu3SnH), would seem to confirm that 3.1atrans is the kinetic product of the 
reaction as postulated in Chapter 3 (page 75). Alternatively, the different termination 
mechanisms may play a part in determining the stereochemistry. While the Bu3SnH 
reaction is terminated by reduction of the intermediate radical by Bu3SnH, the SmI2 
process is likely terminated via a radical-polar crossover reaction to give the 
corresponding anion (although this will be relatively unstable).  Quenching by the 
addition of a proton would then give rise to the observed products.  Attempts to 
optimise these conditions by refluxing the reaction mixture (entry 10), by replacing 
HMPA with the equivalent amount of DMI or DMSO (entries 11-12) or by reducing 
either the amount of SmI2 or the amount of HMPA used were unsuccessful. The 
required reaction conditions were deemed to not be an improvement over the tin 
method, particularly considering the toxicity of HMPA, although the ambient 
temperature was an advantage. 
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4.3.2 Palladium Heck cyclisation 
Due to the failure of the indium Heck cyclisation method, palladium Heck cyclisation 
was first attempted with the iodine derivative 2.8e. A solution of 2.8e (1eq), Pd2(dba)3 
(0.1eq), (t-Bu)3P (0.2eq) and triethylamine (1.1eq) in toluene was stirred at room 
temperature for 24 hours. The reaction mixture was then poured into saturated LiCl 
solution and washed with ether. The ether layer was concentrated under vacuum to 
give a brown oil, which was purified by column chromatography to obtain the 5-exo 
cyclised product 4.13a as a yellow oil (30mg, 47%). No 4.13b or 6-endo product was 
observed in the crude reaction mixture by 1H NMR, confirming that the palladium 
Heck cyclisation of this and of similar compounds169,170 prefer the exo-trig pathway 
due to the mechanistic differences of Heck verses radical pathways. 
 
Scheme 4.13: Palladium Heck cyclisation of 2.8e. 
The product 4.13a was identified by 1H NMR spectroscopy and existed as one amide 
rotamer at room temperature (H2axial and H
2’
axial at 3.1 and 3.9 ppm respectively): this 
downshift marks the influence of the oxygen on the two protons in question, and 
therefore indicates that the amide conformer obtained has the oxygen pointing towards 
the cyclohexenyl ring.  The presence of two cyclic alkane signals downshifted rather 
than one indicates that the preferred conformer is 4.13a1 (Figure 4.1), as 4.13a2 would 
only have one downshifted proton H3’axial. 
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Figure 4.1: Ring flip in product 4.13a. 
The oxidative nature of the cyclisation and the fact that a single product that was 
obtained at room temperature from this cyclisation was also encouraging: increased 
stereo- and regioselectivity at room temperature would be highly useful for other 
substrates. It must be evident from mechanistic considerations that product 4.13a 
cannot be the direct result of the Heck reaction (Scheme 4.14): it must be obtained via 
palladium-mediated olefin migration from either the initial cyclisation product 4.13b 
or from the previous intermediate 4.14a via a Pd migration (Scheme 4.14).  
Scheme 4.14: Palladium-mediated Heck reaction and olefin migration. 
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Olefin migration during a Heck reaction has been observed and reported in 
cycloalkenes for similar compounds, where the product range was also a set of 
spirocycles.175 
The majority of reactions described in this thesis utilise the less reactive aryl bromides, 
consequently the reactivity of the bromine analogue 2.8d was next investigated, so as 
to have a basis for comparison with the other cyclisations attempted in this chapter, as 
well as those accomplished in Chapter 3. Reaction using the same conditions as the 
iodine compound 2.8e, yielded the products 4.13a, 4.13b (ratio 3:1) and the starting 
material 2.8d (ratio 2:1 2.8d:4.13). The reactivity of the starting material is 
demonstrably lower than that of the iodine analogue, but the reaction still takes place. 
The palladium Heck cyclisation can therefore be considered as a candidate for further 
optimisation for the purposes of cyclising compounds 2.8. 
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Scheme 4.15: Palladium Heck cyclisation of 2.8d. 
The degree of olefin migration in the product is determined by the halogen in the 
starting material: instead of a single olefin migration product 4.13a, the isomer 4.13b 
is also obtained, albeit in low yield as an inseparable mixture. In order to verify that 
the compounds 4.13a and 4.13b were indeed the structures identified by NMR 
analysis, a mixture was subjected to reducing conditions (Pd/C, H2, EtOH) to give 
quantitative yield of the cyclohexane compound 3.19, previously identified as the 
product of 5-exo-trig radical cyclisation. Interestingly, 4.13b underwent slow 
oxidation in air to imide 4.13c, while 4.13a remained stable. Major and minor amide 
rotamers are visible in the NMR spectra for 4.13b, in a 1:0.63 ratio: when oxidised to 
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4.13c, the spectrum is simplified to only one rotamer.  This suggests that the preferred 
conformation of the amide is for the oxygen to point towards the cyclohexenyl ring, 
as orbital overlap principles would place the carbonyls parallel to each other in 4.13c.  
 
Scheme 4.16: Migration and oxidation decomposition pathways for 4.13b. 
The observed difference in alkene migration between the cyclisation of the bromo and 
iodo compounds is noteworthy: cyclisation of the iodinated 2.8e gave the isomerised 
product 4.13a only, whereas cyclisation of the brominated 2.8d produced both 4.13a 
and the non-isomerised compound 4.13b. This may be due to two reasons. The faster 
the oxidative addition of the C-X bond with the palladium precatalyst, the faster the 
synthesis of initial kinetic product 4.13b. Thus for the iodo compound 2.8e there is 
more time for equilibration of product 4.13b ↔ 4.13a via 4.14b. Alternatively, the rate 
of migration 4.14a → 4.14b may be determined by the Pd-X bond, with the larger Pd-
I bond preferring to be further away from the congested spiro center.   
The propensity of Pd(dba)2 and P(t-Bu)3 to mediate olefin migration has been 
reported176 when used together in a 1:1:1 catalytic system with isobutyryl chloride: it 
is evident from these test reactions that a similar pre-catalyst and ligand can mediate 
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this migration without the chloride. A longer reaction time or higher reaction 
temperature might be expected to increase the proportion of isomerised product 4.13a, 
as “intermediate” compound 4.13b would have a higher propensity to isomerise to the 
more stable 4.13a under such conditions.  
 
4.3.3 Choice of reaction to pursue 
Given the lack of initial success experienced with the cyclisation reactions using 
cobalt, iron and indium reagents, these were not deemed suitable for further 
investigation. The extreme toxicity of HMPA, as well as the number of equivalents 
required of samarium diiodide and HMPA, made the samarium-mediated radical 
cyclisations almost equally unattractive. By comparison, the low catalyst loading, low 
temperature and relative ease of purification of the palladium Heck reactions made 
them the logical choice for further investigation. It was therefore decided to attempt 
the optimisation of this reaction to furnish a single product in better yield than had 
been observed with the test reaction. 
 
4.4 Palladium Heck reaction screening 
Despite the poorer conversion and mixture of products produced 2.8d was chosen to 
screen reaction conditions as it was much easier to make than the iodo derivative 2.8e, 
comparison with results from chapter 3 would be more meaningful and more insight 
into the formation of regioisomeric alkene products 4.13a and 4.13b might be possible. 
A series of cyclisation reactions using varying conditions was therefore conducted 
(Scheme 4.17).  
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Scheme 4.17: Conditions for screening of the palladium Heck cyclisation of 2.8d. 
4.4.1 Pre-catalyst and ligand variation 
The effect of the pre-catalyst and ligand was first screened. The base, solvent, 
temperature and time of the reaction were all kept constant while all combinations of 
the chosen pre-catalysts and ligand were tested. The choice of pre-catalyst and ligand 
must be considered to make up an important part of the catalytic system: the Pd(0) pre-
catalyst must be oxidised to the corresponding Pd(II) compound by the ligand before 
reaction can take place. The nature of this ligand would therefore be of some 
importance: it has been reported that phosphine ligands are particularly well-adapted 
to oxidation of the pre-catalyst. The pre-catalysts and phosphine ligands in this study 
were chosen as being highly suited to Heck reactions177,178 from the literature as well 
as their commercial availability. The combination of Pd(OAc)2 and PPh3 was expected 
to work well, given the success experienced by Grigg in cyclising enamides 4.15 
(Scheme 4.18).179 He described the series of iodoenamides 4.15 as undergoing 
“smooth regiospecific 5-exo-trig cyclisation” to give the desired spirocycles in good 
yield.  Interestingly structures 4.15 contain two potential atropisomeric bonds, the 
enamide bond (in blue) similar to substrates 2.8d but also the o-iodo benzamide moiety 
(in red) giving rise to two diastereomeric atropisomeric intermediates.  A recent 
attempt was made to measure both rotation barriers for the enamide and benzamide 
rotation in the Grigg compound 4.15 (n = 1) by VT 1H NMR.  While the enamide 
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rotation (blue bond) in 4.15 was similar in magnitude to that in 2.8d the benzamide 
rotation (red bond) was too high to measure by this technique (indicating a value of > 
20 kcal mol-1).  The Grigg compounds therefore have somewhat more complicated 
rotation dynamics compared to the ones in this study. 
 
Scheme 4.18: Iodoenamide cyclisation reported by Grigg. 
The use of the Grigg conditions (Pd(OAc)2 and PPh3), however, proved disappointing 
when applied to compound 2.8d. An overall yield of 11% was recorded, comprising 
both possible regioisomers (entry 5, table 4.2) and changing the phosphine ligand did 
not render the palladium acetate more reactive (entries 4 and 6). Pd(dba)2 gave even 
poorer conversions (entries 10-12) but Pd2(dba)3 and Pd(PPh3)4 provided much more 
promising results (entries 1-3, 7-9).   
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Entry Pre-catalyst Ligand Results (%) 
4.13a 4.13b Overall yield 
1 Pd2(dba)3 P(t-Bu)3 23 8 31 
2 Pd2(dba)3 PPh3 2 2 4 
3 Pd2(dba)3 P(o-Tol)3 17 9 26 
4 Pd(OAc)2 P(t-Bu)3 10 7 16 
5 Pd(OAc)2 PPh3 4 7 11 
6 Pd(OAc)2 P(o-Tol)3 3 2 5 
7 Pd(PPh3)4 P(t-Bu)3 29 45 74 
8 Pd(PPh3)4 PPh3 1 30 31 
9 Pd(PPh3)4 P(o-Tol)3 0 9 9 
10 Pd(dba)2 P(t-Bu)3 3 0 3 
11 Pd(dba)2 PPh3 2 0 2 
12 Pd(dba)2 P(o-Tol)3 9 7 16 
Table 4.2: Pre-catalyst (0.1eq) and ligand (0.2eq) variation (Conditions: NEt3 
(1.1eq), Toluene, Reflux, 24hrs). 
 
Interestingly, when pre-catalyst Pd2(dba)3 was used, the favoured product was the 
isomerised compound 4.13a, whereas when Pd(PPh3)4 was used, the regiochemistry 
was reversed and product 4.13b was favoured, albeit in relatively poor conversions. 
The use of the Pd(PPh3)/ligand combination did not appear to favour olefin migration 
while some migration was observed with the ligand P(t-Bu)3, minimal was observed 
with PPh3 (4.13a:4.13b = 1:30) and none was seen with P(o-Tol)3, although the yield 
was low (9%). The combination of Pd(PPh3)4 and P(t-Bu)3 (entry 7) produced the 
highest overall yield (74%), but with the lowest regioselectivity in this series 
(4.13a:4.13b = 29:45). In an attempt to increase the relative amount of isomerised 
product 4.13a the reactions were attempted at higher temperature or for a longer period 
of time, using the same reagents.  However, when the reaction was run in DMF at  
140 oC for 48 hours, the proportion of isomerised product 4.13a was actually found to 
decrease.  
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Scheme 4.19: Increasing the temperature and time of the reaction does not 
increase the proportion of isomerised product. 
On the other hand, while Pd2(dba)3 and P(t-Bu)3 (entry 1) produced the same overall 
yield as Pd(PPh3)4 and PPh3 (entry 8), there was a reversal in regioselectivity (compare 
entry 1 4.13a:4.13b = 23:8 to entry 8 = 1:30). This time reaction at a higher 
temperature (140 oC in DMF for 48 hours) produced 4.13a only, and no 4.13b (vide 
infra).  The factors which control the regiochemistry must therefore be a complex 
interplay of catalyst, ligand, solvent, halide, temperature and time negating the 
simplistic argument highlighted previously. Lindhardt and Skrydstrup176 merely noted 
the need for a bulky pre-catalyst: it is now evident that this cannot be the only 
requirement. The question of why the choice of the Pd(PPh3)4 as a pre-catalyst (and as 
a catalyst, given that the presence of PPh3 as the ligand discourages the olefin 
migration almost completely) affects the reaction in this way is unknown, and a survey 
of the literature indicates that it is not a commonly seen trend. Olefin migration has 
been reported in systems where Pd(PPh3)4 has been used as a pre-catalyst, and where 
PPh3 has been used as a ligand to other pre-catalysts.
170,180,181 It is possible that the 
bulkiness of the PPh3 ligand, combined with the aryl and cyclohexenyl bulk of 
compound 2.8d, impedes the isomerisation. 
Due to the difficulty of manipulation associated with Pd(PPh3)4 (air, light and moisture 
sensitivity), a large proportion of the rest of the screening was carried out with 
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Pd2(dba)3 and P(t-Bu)3 instead of the combinations detailed in entries 7 and 8, but with 
an end goal of applying any yield or selectivity-increasing changes to either 
combination of reagents once the remaining conditions had been optimised.  
 
4.4.2 Solvent and temperature variation 
The next variables studied were the solvent and temperature of the reaction, as reported 
in Table 4.3. Most of the solvents tested proved to show no improvement over toluene, 
either at room temperature or at reflux/high temperature. However, 
dimethylformamide (DMF) proved superior to toluene at low temperature (compare 
entries 13 and 15, overall yields 1% and 12%) when the pre-catalyst/ligand 
combination was Pd2(dba)3/P(t-Bu)3, although the overall yield at high temperature 
was slightly lower than with toluene (29% with DMF, 31% with toluene). 
Entry Pre-catalyst Ligand Solvent Temp. Results (%) 
4.13a 4.13b Overall yield 
13 Pd2(dba)3 P(t-Bu)3 Toluene RT 0 0 1 
14 Pd2(dba)3 P(t-Bu)3 THF RT 0 0 0 
15 Pd2(dba)3 P(t-Bu)3 DMF RT 12 0 12 
16 Pd2(dba)3 P(t-Bu)3 DMF 140 29 0 29 
17 Pd2(dba)3 P(t-Bu)3 CH3CN RT 0 0 0 
18 Pd2(dba)3 P(t-Bu)3 DCE RT 0 0 0 
19 Pd2(dba)3 P(t-Bu)3 Dioxane RT 0 0 0 
20 Pd(PPh3)4 P(t-Bu)3 THF Reflux 0 0 0 
21 Pd(PPh3)4 P(t-Bu)3 CH3CN Reflux 1 10 11 
22 Pd(PPh3)4 P(t-Bu)3 DMF 140 21 79 100 
23 Pd(PPh3)4 PPh3 DMF 140 4 85 89 
Table 4.3: Solvent and temperature variation (Conditions: Pre-catalyst (0.1eq), 
Ligand (0.2eq), NEt3 (1.1eq), 48hrs). 
 
This prompted a cyclisation attempt using the Pd(PPh3)4/PPh3 combination, at 140 °C 
in DMF, which furnished an overall yield of 89%, 85% of which was 4.13b (4% 
4.13a), as well as with Pd(PPh3)4/P(tBu)3, furnishing 100% product in a 21:79 ratio of 
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4.13a to 4.13b. These conditions therefore produced a high product yield combined 
with a considerably decreased propensity of 4.13b to isomerise to 4.13a. DMF was 
therefore carried forward as the solvent of choice, despite the high temperature needed 
for high yields to be recorded. While unfortunate, the necessity for high temperature 
to mediate the Heck reaction of aryl bromides has been well documented182, 
particularly in cases where the aryl bromide is electron-rich, as with compound 2.8d.  
4.4.3 Base variation and use of additives. 
Other bases that had been reported to work in the Heck reaction were next tested: 
DABCO (1,4-diazabicyclo[2.2.2]octane)121,177 and Ag2CO3.
180 Neither of these were 
found to be an improvement on triethylamine, either in overall yield or 
regioselectivity: the base was concluded to not be mechanistically important, and 
therefore the cheaper and more commonly used triethylamine was used.  
Entry Base Results (%) 
4.13a 4.13b Overall yield 
24 NEt3 21 79 100 
25 DABCO 15 73 88 
26 Ag2CO3 20 63 83 
Table 4.4: Base variation (Conditions: Pd(PPh3)4  (0.1eq), P(t-Bu)3 (0.2eq), Base 
(1.1eq), DMF, 48hrs). 
Additives were then employed in a final attempt to suppress alkene migration, while 
keeping the overall yield as high as possible. Unfortunately, the use of silver nitrate 
(AgNO3) with either Pd2dba3 or Pd(PPh3)4 as the precatalyst proved ineffectual in 
improving the reaction, and instead seemed to inhibit it (entries 27-28). 
Tetrabutylammonium bromide (NBu4Br) was found to maintain a high overall yield 
no matter the number of equivalents used, but favoured olefin migration, resulting in 
an increased proportion of the alkene migration product 4.13a (entries 29-31). The 
combinations detailed in entries 22 and 23, Table 4.3 remained therefore the most 
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effective, as having the highest overall yield of product. Of these, the combination of 
Pd(PPh3)4/PPh3 was the more attractive, due to the increased yield and increased 
reactivity of the obtained product 4.13b (notably olefin migration to 4.13a and 
oxidation to 4.13c, neither of which were available with 4.13a).  
Entry Pre-catalyst Additive (no eq) Results (%) 
4.13a 4.13b Overall yield 
27 Pd2(dba)3 AgNO3 (1.1eq) 0 0 0 
28 Pd(PPh3)4 AgNO3 (1.1eq) 6 13 20 
29 Pd(PPh3)4 NBu4Br (1.1eq) 46 42 87 
30 Pd(PPh3)4 NBu4Br (3eq) 42 53 95 
31 Pd(PPh3)4 NBu4Br
 (10eq) 38 56 94 
Table 4.5: Additive variation (Conditions: Pre-catalyst (0.1eq), P(t-Bu)3 (0.2eq), 
NEt3 (1.1eq), DMF, 48hrs). 
 
 
4.5 Palladium Heck reactions of other compounds 
The conditions detailed in Section 4.3.2 were used to attempt the cyclisation of a 
selection of the compounds synthesised in Chapter 2, to ascertain the degree of 
influence held by the N-alkenyl barrier to rotation in the success or otherwise of 
palladium-mediated Heck cyclisations.  
4.5.1 Cyclisation of substrates with lower barriers to rotation (< 15.0 kcal mol-1). 
The compounds in Figure 4.2 were cyclised to give the results detailed in Table 4.6. It 
was hypothesised, given the bulkiness of the mediating complex [Pd(PPh3)4]
II, that the 
compounds with higher barriers to rotation, due to steric congestion (> 15 kcal mol-1), 
would be less likely to cyclise using this method.   
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Figure 4.2: Compounds for cyclisation (barriers to rotation < 15 kcal mol-1). 
The increase in cycloalkenyl ring size (2.8d → 2.8o → 2.8t) afforded in an increase in 
both yield and regioisomeric selectivity. While the regioselectivity for 2.8o was 
complete (for 4.13b, n = 2), the eight membered analogue showed a reversal in 
selectivity for 4.13a (n =3, along with some oxidised 4.13c). Like 2.8d, the other 
cyclohexenyl compounds derived from cyclisation of 2.9 and 2.28 were also highly 
selective for 4.13b. 
 
Starting material n ΔG 
(kcal/mol) 
4.13b 4.13a SM 4.13c3 
2.8d 1 10.5 85 4 11 0 
2.8o 2 12.0 100 tr tr 0 
2.8t 3 11.3 tr 83 0 17 
2.9 1 10.8 1001 tr tr 0 
2.28 1 10.4 892 tr 11 0 
1 Structure 4.18b. 2 Structure 4.19b. 34.13c = oxide. 
Table 4.6: Results of palladium-mediated Heck cyclisation.  Effect of ring size. 
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Overman noted that in order to lose the palladium hydride, as happens here in the final 
step, the palladium and the hydrogen being eliminated must be syn.175 After initial 
formation of 4.13b in each case, subsequent re-addition of Pd-H would furnish 4.14a 
which may eliminate from either the 2-position (regenerating 4.13b) or the 4-position 
on the ring (giving 4.13a): elimination would occur on whichever hydrogen is syn to 
the palladium.  
 
Scheme 4.20: Olefin migration in product 4.13. 
According to MM2 calculations, the dihedral angles between the hydrogen and the 
palladium for the cyclohexene derivative from 2.8d are in fact very similar: 53.5o for 
H4 and 56.8o for H2. It seems likely, therefore that the preference for 4.13b in all the 
cyclohexenyl derived substrates (2.8d, 2.9, 2.28) originates in a lack of isomerisation 
due to the bulk of the mediating compound suppressing 4.13b → 4.14a. The change 
in regioisomeric selectivity for the cyclisation of the cyclooctenyl derivative 2.8t could 
be rationalised by a difference in the folding pattern of the cycloalkenyl ring 
facilitating 4.13b (n = 3) → 4.14a (n = 3) and preferential elimination of hydrogen in 
the 4 position.  Modelling using the MM2 forcefield bore out this hypothesis: in an 
energetically minimised configuration of 4.14a (n = 3), the dihedral angle between H2 
and the palladium was 33.5o, whereas the angle between H4 and the palladium was 
15.1o. This would in all probability be sufficient to account for the change in 
regioselectivity of the alkene formation.  
119 
 
The effect of the bulk of the acyl group on the cyclisation was next examined. The 
reaction conditions were kept the same so direct comparisons of conversion could be 
made, Table 4.7.  The increase in size of the acyl group (2.8d → 2.8j → 2.8m) had a 
strong effect on the yield/conversion of the reaction: the larger the acyl group, the 
lower the overall yield.  In all cases (as observed for the cyclohexenyl derivatives 
(2.8o, 2.8t, 2.9 and 2.28) the major product was 4.13b (presumably for the same 
reasons). 
 
Starting material ΔG (kcal/mol) 4.13b 4.13a SM 4.13c 
2.8d (R = Me) 10.5 85 4 11 0 
2.8j (R = Et) 11.3 28 3 69 0 
2.8m (R = iPr) 12.2 7 tr  93 17 
Table 4.7: Results of palladium-mediated Heck cyclisation.  Effect of acyl group 
size. 
Further study and mechanistic work would be required to fully understand the reasons 
for the low conversions in cyclisations of compounds 2.8j and m. 
 
4.5.2 Cyclisation of substrates with greater barriers to rotation (> 15.0 kcal mol-1). 
To a certain extent the hypothesis was validated, as the compounds with the highest 
barriers to rotation, 2.16b, 2.21b and 2.29, underwent no reaction when subjected to 
the optimised conditions. Given the high level of substitution of the alkene in 2.16b 
and 2.21b, and the bulk of the aryl group in 2.29, this is unsurprising.  Additionally, 
the compound with the next highest barrier to rotation (2.27) showed low conversion 
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(28%) to the cyclised product 4.20, indicating that the reaction was indeed inhibited 
by slower rotation around the N-cycloalkenyl bond. 
 
Starting material ΔG (kcal/mol) 
 2.16b 19.9 No reaction 
2.21b 30.6 No reaction 
2.27 17.9 4.20 (28%), recovered SM (72%) 
2.29 >20 No reaction 
Table 4.8: Results of palladium-mediated Heck cyclisation, (barriers to rotation 
> 15 kcal mol-1). 
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4.6 Summary 
In this chapter, the cyclisation of compound 2.8d was initially studied using different 
methods in order to attempt to provide a viable alternative to the toxic and reductive 
tin method. Of the methods tested, two showed promise: samarium diiodide-mediated 
cyclisation was successful when a large amount of the mediating species was present, 
along with HMPA. This method produced similar results to the tin hydride cyclisations 
discussed in Chapter 3, with a difference in product stereoselectivity due to the low 
temperature of the reaction and a different termination mechanism. Further 
optimisation of this method was not attempted due to safety and time considerations. 
The palladium-mediated Heck cyclisation, however, was successful even at low 
temperature (for aryl iodides), although a different regiochemistry of cyclisation (5-
exo favoured over 6-endo cyclisation) occurred.  A high temperature was necessary to 
optimise the yield and regioselectivity of the reaction with regards to the aryl bromide 
starting material 2.8d. Two alkene regioisomers of the 5-exo-trig product were isolated 
(4.13a and 4.13b), confirming the preference of the Heck reaction for the exo 
pathway.169,170 The reaction conditions were optimised to those depicted in Scheme 
4.21. 
 
Scheme 4.21: Optimised conditions for Heck cyclisation of 2.8d. 
The amount of olefin migration product was minimised by the presence of bulky pre-
catalyst Pd(PPh3)4 and ligand PPh3, which impeded the isomerisation process. These 
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conditions were then used to attempt the cyclisation of several compounds synthesised 
in Chapter 2, to assess the effect of the barrier to N-cycloalkenyl rotation on the Heck 
reaction. Increased aryl bulk was found to sterically hinder (in conjunction with the 
palladium catalyst) the alkene sufficiently to prevent isomerisation, although in cases 
where the barrier to rotation was above 17.9 kcal mol-1 cyclisation was not observed 
due to the steric constraints around the starting material alkene or around the aryl 
halide. Palladium Heck conditions were successful in mediating most cyclisations 
accomplished with the tin method, and the failure to mediate cyclisations with high 
barriers to rotation was expected given the bulkiness of the mediating species. 
However, the goal of the palladium cyclisations was not attained, as high temperatures 
would impede chiral transfer, and the lack of 6-endo-trig cyclisation product prevents 
the attempt to cyclise 2.29 into a natural product analogue in any case. Alternative 
methods must provide the basis for future work, and the copper-based methods studied 
by Clark86,183–185 could provide an excellent starting point.  
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Chapter 5: Experimental 
5.1 General Information and Procedures 
Unless otherwise stated, the chemicals and solvents used  in these  syntheses  were  
obtained  from  commercial  suppliers  and  were  used  without further purification. 
All reactions were performed using oven dried  glassware  and  heat  transfer  was  
achieved  using drysyn© apparatus.  Sodium hydride dispersion  in  mineral  oil  (60%  
w/w)  was washed three times with hexane under a constant flow of nitrogen to remove 
the oil prior  to  use.  Where  petroleum  ether  was  used  it  was  the  40-60°C  fraction  
and  all water used was deionised.  Reactions  were  followed  by  TLC,  performed  
on Merck  silica  gel  60  F-254  TLC  sheets; the TLC plate was then visualized with 
UV fluorescence (254 nm) and then stained with potassium permanganate. Flash 
chromatography was carried out using Merck silica gel 60, 35-75μm as the stationary 
phase. NMR spectra were obtained at 298 K unless otherwise stated. 1H and 13 C 
NMR were recorded   on   Bruker   DPX-300,   DPX-400   and   DRX-500   instruments   
and are referenced to tetramethylsilane (TMS) at 0.00 ppm. Chemical shifts (δH) are 
quoted in parts per million (ppm), coupling constants J are quoted in hertz (Hz), and 
data is quoted as (δH, integration, multiplicity).  Proton  and  carbon  NMR  
assignments  were routinely  confirmed  by 1H-1H  (COSY), 1H-13C  (HMQC) and 
1H-13 C  (HMBC) experiments. For  variable  temperature  NMR,  samples  were  
submitted  to  the  NMR service  and  analysed  on  a  Bruker  DPX500  spectrometer.  
Spectra  obtained  were analysed  using  Mestrec© and  NUTS© software  prior  to  
lineshape  analysis  using WINDNMR or TopSpin. Low resolution mass spectra were 
recorded on Bruker Esquire 2000 for electro spray conditions.  Accurate  mass  
spectroscopy  was  available  through  the  in  house  mass spec.  service  using  either  
Bruker  HCT  or  Bruker  HCT  Ultra  machines  to  perform accurate  mass  ESI  
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analysis.  Only molecular ion fractions from molecular ions and other major peaks are 
reported as mass/charge (m/z) ratios.  IR was recorded using a Perkin-Elmer Avatar 
320 FTIR spectrometer.  Solids  were compressed  into  a  thin  tablet  and  oils/non-
volatile  liquids  were  analysed  as  films over a diamond sensor. Absorption maxima 
(υmax) are recorded in wavenumbers (cm-1).  Analytical  chiral  HPLC  was  performed  
by  the  Curran  group  in  Pittsburgh  and  was conducted using either an (S,S)-Whelk-
O 1 column (Pirkle, 250 mm x 4.6 mm ID) or a Chiralcel OD column (Daicel, 250 mm 
x 4.6 mm ID).  
 
5.2 Compounds synthesised in Chapter 2. 
5.2.1 General procedure for the synthesis of oximes 2.10 from ketones 
The commercially available cyclohexanone oxime (2.10a) was used, but otherwise the 
oximes were synthesised in the following manner. The ketone (1eq), hydroxylamine 
hydrochloride (1.1eq) and sodium acetate (1.1eq) were dissolved in methanol and 
heated at reflux for 24 hours. The solvent was removed from the crude reaction mixture 
under vacuum, after which the residue was taken up in ethyl acetate and water, washed 
with brine, dried with magnesium sulphate, the solvent removed under vacuum and 
the product used without further purification. 
Cycloheptanone oxime (2.10b)186 
 
The general procedure for the synthesis of oximes was used: cycloheptanone (5mL, 
42.4mmol), hydroxylamine hydrochloride (3.24g, 46.6mmol) and sodium acetate 
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(3.82g, 46.6mmol) were dissolved in methanol (30mL), heated to reflux and stirred for 
24 hours. A brown oil was obtained (5.16g, 96%) and immediately used to synthesise 
the acetamides. 
Cyclooctanone oxime (2.10c)187 
 
The general procedure for the synthesis of oximes was used: cyclooctanone (5.00g, 
40.0mmol), hydroxylamine hydrochloride (3.10g, 44.0mmol) and sodium acetate 
(3.60g, 44.0mmol) were dissolved in methanol (30mL), heated to reflux and stirred for 
24 hours. A dark brown oil was obtained (4.78g, 85%) and immediately used to 
synthesise the acetamides. 
3-Methyl-2-butanone oxime (2.10d)187 
 
The general procedure for the synthesis of oximes was used: 3-methyl-2-butanone 
(20mL, 187mmol), hydroxylamine hydrochloride (14.3g, 206mmol) and sodium 
acetate (16.9g, 206mmol) were dissolved in methanol (100mL), heated to reflux and 
stirred for 24 hours. A yellow oil was obtained (10.1g, 53%) and immediately used to 
synthesise the acetamides. 
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Tetralone oxime (2.10e)84 
 
The general procedure for the synthesis of oximes was used: α-tetralone (21.0g, 
144mmol), hydroxylamine hydrochloride (11.0g, 158mmol) and sodium acetate 
(12.96g, 158mmol) were dissolved in methanol (100mL), heated to reflux and stirred 
for 24 hours. A light brown solid was obtained (23.0g, 99%) and immediately used to 
synthesise the acetamide. 
6,7-Dimethoxy-3,4-dihydronaphthalen-1-one oxime (2.10f) 
 
The general procedure for the synthesis of oximes was used: 6,7-dimethoxy-3,4-
dihydronaphthalen-1-one (2.00g, 9.7mmol), hydroxylamine hydrochloride (0.76g, 
11.0mmol) and sodium acetate (0.90g, 11.0mmol) were dissolved in methanol (20mL), 
heated to reflux and stirred for 24 hours. A brown oil was obtained (1.69g, 79%) and 
immediately used to synthesise the acetamide. 
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5.2.2 General procedure for the synthesis of alkenylacetamides 2.11 from the 
oximes 2.10.69 
The oxime (1eq), cupper iodide (0.1eq), sodium bisulfite (3eq) and the appropriate 
anhydride (2eq) were dissolved in 1,2-dichloroethane under nitrogen and reacted 
together at 120 °C for 24 hours. The reaction mixture was then cooled to room 
temperature, diluted with ethyl acetate (30mL), washed with 2M sodium hydroxide 
solution (100mL) and brine (saturated solution, 100mL), dried with anhydrous sodium 
sulphate and the solvent removed under vacuum. A brown oil was obtained, and was 
used without further purification.  
 
N-Cyclohexenylacetamide (2.11a)69 
 
The general procedure for the formation of alkenylacetamides (5.2.2) was used. 
Cyclohexanone oxime 2.10a (1.15g, 10.16mmol), copper iodide (0.2g, 1.02mmol), 
sodium bisulfite (3.17g, 30.5mmol) and acetic anhydride (2.08g, 20.3mmol) were 
dissolved in 1,2-dichloroethane (30mL) under nitrogen and reacted together for a 
period of 24 hours at 120 °C. Yield 0.63g, 45%, brown oil. δH (300 MHz, CDCl3) 6.43 
(1H, br s, NH), 6.06 (1H, s, C=CH), 2.10 (2H, m, cy), 2.02 (3H, s, COCH3), 1.88 (2H, 
s, cy), 1.74 – 1.62 (2H, m, cy), 1.62 – 1.51 (2H, m, cy). 
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N-(Cyclohex-1-en-1-yl)propionamide (2.11b)69,84  
 
The general procedure for the formation of alkenylacetamides (5.2.2) was used. 
Cyclohexanone oxime 2.10a (2.0g, 17.7mmol), copper iodide (0.34g, 1.77mmol), 
sodium bisulfite (5.62g, 53.1mmol) and propionic anhydride (4.69g, 35.4mmol) were 
dissolved in 1,2-dichloroethane (40mL) under nitrogen and reacted together for a 
period of 24 hours at 120 °C. Yield 0.52g, 19%, brown oil. δH (400 MHz, CDCl3) 7.44 
(1H, br s, NH), 6.07 (1H, br s, C=CH), 2.25 (2H, q, J = 8.0 Hz, COCH2CH3), 2.15 
(2H, m, cy), 2.08 (2H, m, cy), 1.66 (2H, m, cy), 1.57 (2H, m, cy), 1.15 (3H, t, J = 7.5 
Hz, COCH2CH3). 
N-(Cyclohex-1-en-1-yl)isobutyramide (2.11c)69,84  
 
The general procedure for the formation of alkenylacetamides (5.2.2) was used. 
Cyclohexanone oxime 2.10a (2.0g, 17.7mmol), copper iodide (0.34g, 1.77mmol), 
sodium bisulfite (5.62g, 53.1mmol) and isobutyric anhydride (5.59g, 35.4mmol) were 
dissolved in 1,2-dichloroethane (50mL) under nitrogen and reacted together for a 
period of 24 hours at 120 °C. Yield 0.61g, 20%, brown oil. δH (250 MHz, CDCl3) 7.15 
(1H, br s, NH), 6.08 (1H, br s, NC=CH), 2.53 – 2.29 (1H, m, COCH(CH3)2), 2.21-2.11 
(2H, m, cy), 2.12 – 2.04 (2H, m, cy), 1.75 – 1.63 (2H, m, cy), 1.61 – 1.51 (2H, m, cy), 
1.15 (6H, d, J = 7.0 Hz, COCH(CH3)2). 
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N-Cycloheptenylacetamide (2.11d) 
 
The general procedure for the formation of alkenylacetamides (5.2.2) was used. 
Cycloheptanone oxime 2.10b (4.0 g, 31.5mmol), copper iodide (0.60g, 3.15mmol), 
sodium bisulfite (9.83g, 94.5mmol) and acetic anhydride (6.43, 63.0mmol) were 
dissolved in 1,2-dichloroethane (200mL) under nitrogen and reacted together for a 
period of 24 hours at 120 °C. Yield 1.36g, 28%, brown oil, identified by comparison 
with compound 2.11a spectra. δH (300 MHz, CDCl3 7.05 (1H, s, NH), 6.13 (1H, t, J = 
7.0 Hz, C=CH), 2.39 – 2.23 (2H, m, cy), 2.10 (2H, d, J = 6.5 Hz, cy), 2.05 (1H, s, cy), 
2.01 (3H, s, COCH3), 1.72 (2H, d, J = 5.5 Hz, cy), 1.54 (2H, dd, J = 14.0, 8.0 Hz, cy), 
1.26 (1H, t, J = 7.0 Hz, cy). 
N-(Cyclohept-1-en-1-yl)propionamide (2.11e) 
 
The general procedure for the formation of alkenylacetamides (5.2.2) was used. 
Cycloheptanone oxime 2.10b (1.0g, 7.0mmol), copper iodide (0.13g, 0.7mmol), 
sodium bisulfite (2.19g, 21.0mmol) and propionic anhydride (1.82g, 14.0mmol) were 
dissolved in 1,2-dichloroethane (20mL) under nitrogen and reacted together for a 
period of 24 hours at 120 °C. Yield 0.11g, 9%, brown oil, identified by comparison 
with compound 2.11b spectra. δH (400 MHz, CDCl3) 7.18 (1H, s, NH), 6.14 (1H, t, J 
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= 6.5 Hz, C=CH), 2.36 – 2.28 (2H, m, cy), 2.24 (2H, q, J = 7.5 Hz, COCH2CH3), 2.14 
– 2.08 (2H, m, cy), 1.75 – 1.69 (2H, m, cy), 1.62 – 1.56 (2H, m, cy), 1.54 – 1.47 (2H, 
m, cy), 1.15 (3H, t, J = 7.5 Hz, COCH2CH3). 
N-(Cyclohept-1-en-1-yl)isobutyramide (2.11f) 
 
The general procedure for the formation of alkenylacetamides (5.2.2) was used. 
Cycloheptanone oxime 2.10b (0.71g, 5.5mmol), copper iodide (0.10g, 0.55mol), 
sodium bisulfite (1.72g, 16.5mmol) and propionic anhydride (1.74g, 11.0mmol) were 
dissolved in 1,2-dichloroethane (20mL) under nitrogen and reacted together for a 
period of 24 hours at 120 °C. Yield 0.13g, 13%, brown oil, identified by comparison 
with compound 2.11c spectra. δH (300 MHz, CDCl3) 6.70 (1H, s, NH), 6.14 (1H, t, J 
= 7.0 Hz, C=CH), 2.42 – 2.31 (1H, m, COCH(CH3)2), 2.35 – 2.27 (2H, m, cy), 2.12 
(2H, dd, J = 11.0, 6.5 Hz, cy), 1.78 – 1.67 (2H, m, cy), 1.66 – 1.57 (2H, m, cy), 1.57 – 
1.46 (2H, m, cy), 1.16 (6H, d, J = 7.0 Hz, COCH(CH3)2). 
N-Cyclooctenylacetamide (2.11g) 
 
The general procedure for the formation of alkenylacetamides (5.2.2) was used. 
Cyclooctanone oxime 2.10c (1.50 g, 11mmol), copper iodide (0.21g, 1.1mmol), 
sodium bisulfite (3.43g, 33mmol) and acetic anhydride (2.24, 22mmol) were dissolved 
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in 1,2-dichloroethane (30mL) under nitrogen and reacted together for a period of 24 
hours at 120 °C. Yield 0.76g, 42%, brown oil, identified by comparison with 
compound 2.11a spectra. δH (400 MHz, CDCl3) 7.57 (1H, s, NH), 6.04 (1H, t, J = 8.5 
Hz, C=CH), 2.33 (2H, br s, cy), 2.11 (2H, br s, cy), 2.03 (3H, s, COCH3), 1.58 (2H, br 
s, cy), 1.50 (6H, br s, cy). 
N-(3-Methylbut-2-en-2-yl)acetamide (2.11h)69 
 
The general procedure for the formation of alkenylacetamides (5.2.2) was used. 3-
Methyl-2-butanone oxime 2.10d (5.0 g, 49.4mmol), copper iodide (0.94g, 4.94mmol), 
sodium bisulfite (15.4g, 148mmol) and acetic anhydride (10.1g, 98.8mmol) were 
dissolved in 1,2-dichloroethane (200mL) under nitrogen and reacted together for a 
period of 24 hours at 120 °C. Yield 2.46g, 39%, brown oil. δH (300 MHz, CDCl3) 8.08 
(1H, s, NH), 1.56 (3H, s, COCH3), 1.38 (3H, s, CH3), 1.23 (3H, s, CH3), 1.16 (3H, s, 
CH3).  
N-(3,4-Dihydronaphthalen-1-yl)acetamides (2.11i)84 
 
The general procedure for the formation of alkenylacetamides (5.2.2) was used. 
Tetralone oxime 2.10e (15.00 g, 94.0mmol), copper iodide (1.79g, 9.4mmol), sodium 
bisulfite (29.0g, 280mmol) and acetic anhydride (19.0g, 190mmol) were dissolved in 
1,2-dichloroethane (200mL) under nitrogen and reacted together for a period of 24 
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hours at 120 °C. Yield 6.66g, 38%, brown oil. δH (400 MHz, CDCl3) 7.45 (1H, s, NH), 
7.24 – 7.03 (4H, m, ArH), 6.29 (1H, t, J = 4.5 Hz, NC=CH), 2.71 (2H, t, J = 8.0 Hz, 
NC=CHCH2CH2) 2.35 – 2.26 (2H, m, NC=CHCH2CH2), 2.07 (3H, s, COCH3). 
 
N-(6,7-dimethoxy-3,4-dihydronaphthalen-1-yl)acetamide (2.11j) 
 
The general procedure for the formation of alkenylacetamides (5.2.2) was used. 6,7-
dimethoxy-3,4-dihydronaphthalen-1-one oxime 2.10f (1.69g, 7.64mmol), copper 
iodide (0.15g, 0.76mmol), sodium bisulfite (2.39g, 22.9mmol) and acetic anhydride 
(1.55g, 15.3mmol) were dissolved in 1,2-dichloroethane (50mL) under nitrogen and 
reacted together for a period of 24 hours at 120 °C. Yield 0.42g, 21%, brown oil 
identified by comparison to spectra for compound 2.11i. δH (300 MHz, CDCl3) 7.84 
(1H, s, NH), 6.70 (1H, s, ArH), 6.62 (1H, s, ArH), 6.09 (1H, t, J = 4.5 Hz, NC=CH), 
3.83 (3H, s, OCH3), 3.77 (3H, s, OCH3), 2.61 (2H, t, J = 8.0 Hz, NC=CHCH2CH2), 
2.31 – 2.19 (2H, m, NC=CHCH2CH2), 2.07 (3H, s, COCH3). 
 
 
 
 
 
133 
 
5.2.3 Alternative synthesis of acetamide 2.23 using iron powder69,84 
 
The general procedure for the synthesis of oximes was used: 2,2,6-
trimethylcyclohexanone (2.00g, 14.3mmol), hydroxylamine hydrochloride (1.09g, 
15.7mmol) and sodium acetate (1.29g, 15.7mmol) were dissolved in methanol (50mL), 
heated to reflux and stirred for 24 hours. An off-white solid was obtained (1.78g, 81%) 
and immediately used to synthesise the acetamide. 
 
A mixture of 2,2,6-trimethylcyclohexanone oxime (2.22) (2.00g, 12.9mmol, 1eq), 
acetic acid (2.32g, 38.6mmol, 3eq), acetic anhydride (3.94g, 38.6mmol, 3eq) and iron 
powder (1.44g, 25.8mmol, 2eq) in anhydrous toluene (100mL) was heated to reflux 
under nitrogen and left to react overnight. The mixture was then cooled, filtered 
through celite, diluted with dichloromethane and washed with brine (50mL) and 
sodium hydroxide (50mL), and then dried over magnesium sulphate. The solvent was 
removed under vacuum to yield a white solid. Yield 0.75g, 32%. δH (400 MHz, CDCl3) 
6.27 (1H, s, NH), 2.05 (3H, s, COCH3), 1.66 (3H, s, C=CCH3), 1.60 – 1.41 (6H, m, 
cy), 0.90 (3H, s, Me), 0.88 (3H, s, Me). 
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5.2.4 Synthesis of the aryl moieties 2.12 
Some benzyl bromides were available commercially and were used without further 
purification, but those that could not be obtained were synthesised as follows. 
2,6-Dibromobenzyl bromide84,188 
 
2,6-Dibromotoluene (1.00g, 4.00mmol, 1eq), N-bromosuccinimide (783mg, 
4.40mmol, 1.1eq), and benzoyl peroxide (65mg, 0.2mmol, 5 mol%) were dissolved in 
carbon tetrachloride (10mL) under nitrogen and reacted together for a period of 16 
hours at 80°C. The reaction mixture was then cooled to room temperature, diluted with 
dichloromethane (30mL), washed with water (3x50mL), dried with MgSO4 and the 
solvent removed under vacuum. The product was recrystallised with 10:1 hexane:ethyl 
acetate to yield an off-white crystalline solid. Yield 0.90g, 69%. δH (300 MHz, CDCl3) 
7.54 (1H, dd, J = 8.0, 1.0Hz, ArH), 7.41 (1H, dd, J = 7.5, 1.5Hz, ArH), 7.26 (1H, td, J 
= 7.5, 1.0 Hz, ArH), 7.12 (1H, td, J = 7.5, 1.5 Hz, ArH), 4.57 (2H, s, ArCH2Br). 
5-Bromo-4-(bromomethyl)benzo[1,3]dioxole  
 
5-Bromo-1,3-benzodioxole-4-carboxaldehyde (0.45g, 1.96mmol, 1eq) was reacted at 
room temperature for 2 hours with sodium borohydride (89mg, 2.35mmol, 1.2eq) in 
methanol (20mL). The reaction mixture was then quenched with HCl (20mL), 
extracted thrice with DCM (30mL), dried with MgSO4 and the solvent was removed 
under vacuum to furnish 0.40g (1.73mmol, 88%) of the alcohol. This was then reacted 
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with triphenylphosphine (0.49g, 1.90mmol, 1.1eq) and tetrabromomethane (0.63g, 
1.90mmol, 1.1eq) in diethyl ether (20mL) at room temperature for another hour, after 
which the reaction mixture was filtered and concentrated under vacuum. Purification 
by flash column chromatography with hexane as eluent produced 0.36g of the desired 
product (1.22mmol, 71%) as a yellow solid, identified by comparison with the starting 
material and with 2,6-dibromobenzylbromide. Overall yield 0.36g, 62%. δH (300 
MHz, CDCl3) 7.03 (1H, d, J = 8.5 Hz, ArH), 6.64 (1H, d, J = 8.5 Hz, ArH), 6.05 (2H, 
s, OCH2O), 4.55 (2H, s, CH2Br). 
 
5.2.5 General procedure for the synthesis of benzyl-N-alkenylacetamides  
N-Cycloalkenylacetamide (1eq), sodium hydride (5eq) and the aryl bromide (1.1eq) 
were dissolved in dry THF (20mL) under nitrogen and refluxed under nitrogen for 20 
hours. The reaction mixture was cooled to room temperature, poured into water, 
extracted thrice with EtOAc (50mL), dried with MgSO4 and concentrated under 
vacuum. The product was purified by flash column chromatography with 9:1 to 6:1 
pet ether:EtOAc. Compounds 2.8a-c, 2.8f-g, 2.8i and 2.8l have been synthesised by 
other groups, as referenced. All other syntheses are detailed below.  
N-Cyclohex-1-enyl-N-2-bromobenzylacetamide (2.8d) 
 
N-Cyclohexenylacetamide (2.11a) (0.40g, 2.85mmol), sodium hydride (0.36g, 
14.8mmol) and 2-bromobenzyl bromide (0.82, 3.28mmol) were reacted together as in 
the general protocol. Yield 0.31g, 35%; Yellow-brown oil;  Rf (6:1 pet ether:EtOAc) 
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0.54; νmax (film)/cm–1 2928 (C-H), 1647 (C=O); δH (CDCl3, 300 MHz)  7.44 (1H, d, J 
= 8.0 Hz, ArH), 7.34 (1H, d, J = 7.7 Hz, ArH), 7.20 (1H, t, J = 7.5 Hz, ArH), 7.04 (1H, 
t, J = 7.6 Hz, ArH), 5.38 (1H, br s, NC=CH), 4.73 (2H, s, NCH2), 2.05 (3H, s, COCH3), 
2.03 – 1.90 (4H, m, cy), 1.68 – 1.56 (2H, m, cy), 1.54 – 1.42 (2H, m, cy); δC (101 
MHz, CDCl3) 170.2 (C=O), 138.7 (ArC quaternary), 137.1 (NC=CH), 132.5, 130.4, 
128.7, 128.2 (ArCH), 127.5 (NC=CH), 124.0 (ArCBr), 48.8 (NCH2), 28.0, 24.8, 22.7 
(cy), 21.5 (COCH3), 21.4 (cy); m/z (ESI) 308.07 ([M]
+H); [Found: ([M]+H) 308.0644, 
C15H19
79BrNO  requires 308.0645]. 
 
N-Cyclohex-1-enyl-N-2-iodobenzylacetamide (2.8e) 
 
N-Cyclohexenylacetamide (2.11a) (90mg, 0.61mmol), sodium hydride (74mg, 
3.07mmol) and 2-iodobenzyl bromide (0.20, 0.67mmol) were reacted together as in 
the general protocol. Yield 97mg, 45%. Yellow oil;  Rf (6:1 pet ether:EtOAc) 0.49; 
νmax (film)/cm–1 2928 (C-H), 1643 (C=O); δH (CDCl3, 300 MHz) 7.73 (1H, d, J = 7.9 
Hz, ArH), 7.32 (1H, d, J = 7.7 Hz, ArH), 7.23 (1H, t, J = 7.5 Hz, ArH), 6.87 (1H, t, J 
= 8.4 Hz, ArH), 5.38 (1H, br s, NC=CH), 4.68 (2H, s, NCH2), 2.05 (3H, s, COCH3), 
1.99 (4H, s, cy), 1.68 – 1.58 (2H, m, cy), 1.50 (2H, qd, J = 11.0, 7.4 Hz, cy); δC (101 
MHz, CDCl3) 170.3 (C=O), 140.4 (ArC quaternary), 139.3(ArCH), 138.7 (NC=CH), 
129.8, 128.9 (ArCH), 128.5 (NC=CH), 99.7 (ArCI), 53.6 (NCH2), 28.2, 24.9, 22.8 
(cy), 21.6 (COCH3), 21.4 (cy); m/z (ESI) 356.05 ([M]
+H); [Found: ([M]+H) 356.0516, 
C15H19INO  requires 356.0506]. 
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N-Cyclohex-1-enyl-N-2,6-dibromobenzylacetamide (2.8h) 
 
N-Cyclohexenylacetamide (2.11a) (0.20g, 1.38mmol), sodium hydride (0.28g, 
6.90mmol) and 2,6-dibromobenzyl bromide (0.50, 1.52mmol) were reacted together 
as in the general protocol. Yield 0.14g, 26%. Yellow-brown oil;  Rf (6:1 pet 
ether:EtOAc) 0.47; νmax (film)/cm–1 2926 (C-H), 1648 (C=O); δH (CDCl3, 300 MHz)  
7.48 (2H, d, J = 8.0 Hz, ArH), 6.95 (1H, t, J = 8.0 Hz, ArH), 5.34 (1H, br s, NC=CH), 
5.06 (2H, s, NCH2), 2.02 (3H, s, COCH3), 1.87 (4H, d, J = 5.6 Hz, cy), 1.50 (4H, dd, 
J = 11.3, 5.6 Hz, cy), 1.38 (2H, d, J = 4.4 Hz, cy); δC (101 MHz, CDCl3) 169.9 (C=O), 
137.3 (ArC quaternary), 135.7 (NC=CH), 132.5, 130.2 (ArCH), 129.5 (NC=CH), 
127.1(ArCBr), 48.8 (NCH2), 28.7, 24.9, 22.8 (cy), 21.4 (COCH3), 21.3 (cy); m/z (ESI) 
385.98 ([M]+H); [Found: ([M]+H) 385.9747, C15H18
79Br2NO  requires 385.9750]. 
 
N-(2-Bromobenzyl)-N-(cyclohex-1-en-1-yl)propionamide (2.8j) 
 
N-(Cyclohex-1-en-1-yl)propionamide (2.11b) (0.20g, 1.30mmol), sodium hydride 
(0.16g, 6.50mmol) and 2-bromobenzyl bromide (0.35, 1.41mmol) were reacted 
together as in the general protocol. Yield 0.16g, 38%. Brown oil; νmax (film)/cm–1 2931 
(C-H), 1649 (C=O); δH (400 MHz, CDCl3) 7.49 (1H, d, J = 8.0 Hz, ArH), 7.37 (1H, d, 
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J = 7.5 Hz, ArH), 7.25 (1H, t, J = 7.5 Hz, ArH), 7.09 (1H, t, J = 7.0 Hz, ArH), 5.41 
(1H, br s, NC=CH), 4.78 (2H, s, NCH2), 2.37 (2H, q, J = 7.5 Hz, COCH2CH3), 2.09 – 
1.92 (4H, m, cy), 1.73 – 1.59 (2H, m, cy), 1.59 – 1.41 (2H, m, cy), 1.16 (3H, t, J = 7.5 
Hz, COCH2CH3); δC (101 MHz, CDCl3) 173.7 (C=O), 138.2 (ArC quaternary), 137.4 
(NC=CH) 132.5, 130.5, 128.7 (ArCH), 128.2 (NC=CH), 127.5 (ArCH), 124.1 
(ArCBr), 48.9 (NCH2), 28.2 (COCH2), 26.8, 24.9, 22.8, 21.4 (cy), 10.2 (COCH2CH3); 
m/z (ESI) 344.06 ([M]+Na); [Found: ([M]+Na) 344.0620, C16H20
79BrNNaO  requires 
344.0620]. 
 
N-(Cyclohex-1-en-1-yl)-N-(2,6-dibromobenzyl)propionamide (2.8k):  
 
N-(Cyclohex-1-en-1-yl)propionamide (2.11b) (0.22g, 1.40mmol), sodium hydride 
(0.16g, 7.0mmol) and 2,6-dibromobenzyl bromide (0.49, 1.50mmol) were reacted 
together as in the general protocol. Yield 0.14g, 25%; Brown oil; νmax (film)/cm–1 2940 
(C-H), 1646 (C=O);  δH (400 MHz, CDCl3) 7.52 (2H, d, J = 8.0 Hz, ArH), 6.98 (1H, 
t, J = 8.0 Hz, ArH), 5.35 (1H, t, J = 3.5 Hz, NC=CH), 5.11 (2H, s, NCH2), 2.37 – 2.23 
(2H, m, COCH2CH3), 1.95 – 1.84 (4H, m, cy), 1.60 – 1.52 (2H, m, cy), 1.48 – 1.40 
(2H, m, cy), 1.16 (3H, t, J = 7.5 Hz, COCH2CH3); δC (101 MHz, CDCl3)  173.0 (C=O), 
136.8 (ArC quaternary), 135.9 (NC=CH), 132.4 (NC=CH), 130.0, 129.3 (ArCH), 
127.0 (ArCBr), 48.7 (NCH2), 28.8, 26.7, 24.9, 22.8 (cy), 21.3 (COCH2CH3), 10.2 
(COCH2CH3); m/z (ESI) 421.97 ([M]
+Na); [Found: ([M]+Na) 421.9728, 
C16H19
79Br2NNaO  requires 421.9726]. 
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N-(2-Bromobenzyl)-N-cyclohexenylisobutyramide (2.8m) 
 
N-(Cyclohex-1-en-1-yl)isobutyramide (2.11c) (0.30g, 1.79mmol), sodium hydride 
(0.21g, 8.95mmol) and 2-bromobenzyl bromide (0.49, 1.97mmol) were reacted 
together as in the general protocol. Yield 0.24g, 40%. Yellow oil;  νmax (film)/cm–1 
2930 (C-H), 1656 (C=O); δH (400 MHz, CDCl3) 7.50 (1H, d, J = 8.0 Hz, ArH), 7.36 
(1H, d, J = 7.0 Hz, ArH), 7.25 (1H, dd, app t, J = 7.5 Hz, ArH), 7.09 (1H, dd, app t, J 
= 7.5 Hz, ArH), 5.41 (1H, s, C=CH), 4.77 (2H, s, NCH2), 2.84 (1H, hept, J = 6.5 Hz, 
COCH), 2.08 – 1.92 (4H, m, cy), 1.77 – 1.60 (2H, m, cy), 1.60 – 1.45 (2H, m, cy), 1.14 
(6H, d, J = 6.5 Hz, COCH(CH3)2); δC (101 MHz, CDCl3) 177.2 (C=O), 138.4 (ArC 
quaternary), 137.7 (NC=CH), 132.6, 130.5, 128.7, 127.8 (ArCH), 127.6 (NC=CH), 
124.2 (ArCBr), 49.0 (NCH2), 31.4 (COCH(CH3)2), 28.8, 24.9, 22.9, 21.5 (cy), 20.4 
(COCH(CH3)2);  m/z (ESI) 358.08 ([M]
+Na); [Found: ([M]+Na) 358.0776, 
C17H22
79BrNNaO  requires 358.0777]. 
 
N-(Cyclohex-1-en-1-yl)-N-(2,6-dibromobenzyl)isobutyramide (2.8n) 
 
N-(Cyclohex-1-en-1-yl)isobutyramide (2.11c) (0.31g, 1.82mmol), sodium hydride 
(0.21g, 9.10mmol) and 2,6-dibromobenzyl bromide (0.66, 2.01mmol) were reacted 
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together as in the general protocol. Yield 36mg, 6%; Yellow oil;  νmax (film)/cm–1 2929 
(C-H), 1649 (C=O); δH (300 MHz, CDCl3) 7.53 (2H, d, J = 8.0 Hz, ArH), 6.98 (1H, t, 
J = 8.0 Hz, ArH), 5.33 (1H, br s, NCHaCHb), 5.31 (1H, s, C=CH), 4.89 (1H, s, 
NCHaCHb), 2.76 (1H, hept, J = 7.0 Hz, COCH(CH3)2), 1.93 (4H, m, cy), 1.57 (2H, m, 
cy), 1.47 (2H, m, cy), 1.14 (6H, d, J = 7.0 Hz, COCH(CH3)2).; δC (126 MHz, CDCl3) 
176.6 (C=O), 136.9 (ArC quaternary), 136.3 (NC=CH), 132.5, 130.1 (ArCH), 129.1 
(NC=CH), 127.2 (ArCBr), 48.7 (NCH2), 31.8 (COCH(CH3)2), 29.4, 25.0, 22.9, 21.4 
(cy), 19.9 (COCH(CH3)2); m/z (ESI) 437.99 ([M]
+Na); [Found: 437.9866 ([M]+Na), 
C17H21
79Br2NNaO  requires 437.9862]. 
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N-Cyclohept-1-enyl-N-2-bromobenzylacetamide (2.8o):  
 
N-Cycloheptenylacetamide (2.11d) (0.60g, 3.9mmol), sodium hydride (0.52g, 
19.5mmol) and 2-bromobenzyl bromide (1.07g, 4.30mmol) were reacted together as 
in the general protocol. Yield 0.31g, 24%. Orange oil;  Rf (6:1 pet ether:EtOAc) 0.50; 
νmax (film)/cm–1 2920 (C-H), 1643 (C=O); δH (CDCl3, 300 MHz) 7.36 (1H, d, J = 8.0 
Hz, ArH), 7.22 (1H, d, J = 7.7 Hz, ArH), 7.12 (1H, dd, app t, J = 7.5 Hz, ArH), 6.96 
(1H, dd, app t, J = 7.6 Hz, ArH), 5.47 (1H, t, J = 6.4 Hz, NC=CH), 4.66 (2H, s, NCH2), 
2.13 – 2.05 (2H, m, cy), 1.99 (3H, s, COCH3), 1.94 – 1.84 (4H, m, cy), 1.58 – 1.47 
(2H, m, cy), 1.36 (2H, dd, J = 6.9, 4.1 Hz, cy); δC (101 MHz, CDCl3) 170.1 (C=O), 
143.6 (ArC quaternary), 136.9 (NC=CH), 132.6, 132.3, 130.7, 128.7 (ArCH), 127.4 
(NC=CH), 124.0 (ArCBr), 49.4 (NCH2), 34.0, 31.1, 27.0, 26.2, 25.9 (cy), 22.0 
(COCH3); m/z (ESI) 322.08 ([M]
+H); [Found: ([M]+H) 322.0805, C16H21
79BrNO  
requires 322.0801]. 
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N-Cyclohept-1-enyl-N-2,6-dibromobenzylacetamide (2.8p)  
 
N-Cycloheptenylacetamide (2.11d) (0.30g, 1.95mmol), sodium hydride (0.23g, 
9.8mmol) and 2,6-dibromobenzyl bromide (0.71g, 2.15mmol) were reacted together 
as in the general protocol. Yield 86mg, 11%. Yellow oil;  Rf (6:1 pet ether:EtOAc) 
0.45; νmax (film)/cm–1  2921 (C-H), 1647 (C=O); δH (400 MHz, CDCl3) 7.49 (2H, d, J 
= 8.0 Hz, ArH), 6.97 (1H, t, J = 8.0 Hz, ArH), 5.72 (1H, t, J = 6.2 Hz, NC=CH), 5.06 
(2H, d, J = 46.6 Hz, NCH2), 2.03 (3H, s, COCH3), 1.95 (4H, m, cy), 1.50 (2H, d, J = 
5.2 Hz, cy), 1.34 (2H, m, cy), 0.86 (2H, dd, J = 24.0, 17.6 Hz, cy); δC (101 MHz, 
CDCl3) 169.7 (C=O), 142.3 (ArC quaternary), 135.6 (NC=CH), 133.4, 132.6 (ArCH), 
130.3 (NC=CH), 127.2 (ArCBr), 49.7 (NCH2), 34.6, 30.8, 27.0, 26.2, 25.4 (cy), 21.9 
(COCH3); m/z (ESI) 399.99 ([M]
+H); [Found: ([M]+H) 399.9909, C16H20
79Br2NO  
requires 399.9906]. 
 
N-(2-Bromobenzyl)-N-(cyclohept-1-en-1-yl)propionamide (2.8q)  
 
N-(Cyclohex-1-en-1-yl)propionamide  (2.11e) (0.10g, 0.60mmol), sodium hydride 
(0.72g, 5.0mmol) and 2-bromobenzyl bromide (0.17g, 0.70mmol) were reacted 
together as in the general protocol. Yield 54mg, 27%. Yellow oil; νmax (film)/cm–1 2922 
(C-H), 1646 (C=O); δH (400 MHz, CDCl3) 7.50 (1H, d, J = 7.5 Hz, ArH), 7.35 (1H, 
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dd, J = 7.5, 1.0 Hz, ArH), 7.25 (1H, d, J = 7.5 Hz, ArH), 7.09 (1H, dd, J = 8.0, 1.5 Hz, 
ArH), 5.58 (1H, t, J = 6.5 Hz, NC=CH), 4.79 (2H, s, NCH2), 2.39 (2H, q, J = 7.5 Hz, 
COCH2), 2.28 – 2.12 (2H, m, cy), 2.03 (2H, dd, J = 11.0, 6.5 Hz, cy), 1.75 – 1.58 (2H, 
m, cy), 1.51 (4H, dd, J = 6.5, 4.5 Hz, cy), 1.16 (3H, t, J = 7.5 Hz, COCH2CH3); δC 
(101 MHz, CDCl3) 173.6 (C=O), 143.2 (ArC quaternary), 137.3 (NC=CH), 132.7 
(ArCH), 132.3 (NC=CH), 130.9, 128.8, 127.5 (ArCH), 124.1 (ArCBr), 49.6 (NCH2), 
34.3, 31.2 (cy), 27.1 (COCH2), 26.3, 26.0 (cy), 10.1 (COCH2CH3); m/z (ESI) 358.08 
([M]+Na); [Found: ([M]+Na) 358.0778, C17H22
79BrNNaO  requires 358.0777]. 
 
N-(2-Bromobenzyl)-N-cycloheptenylisobutyramide (2.8r):  
 
N-(Cyclohex-1-en-1-yl)isobutyramide  (2.11f) (0.20g, 1.1mmol), sodium hydride 
(1.32g, 5.5mmol) and 2-bromobenzyl bromide (0.30g, 1.2mmol) were reacted together 
as in the general protocol. Yield 0.13g, 33%. Yellow oil;  νmax (film)/cm–1 2923, 1646; 
δH (400 MHz, CDCl3) 7.50 (1H, d, J = 8.0 Hz, ArH), 7.33 (1H, d, J = 8.0 Hz, ArH), 
7.25 (1H, dd, app t, J = 7.5 Hz, ArH), 7.09 (1H, dd, app t, J = 7.5 Hz, ArH), 5.57 (1H, 
t, J = 6.5 Hz, NCCH), 4.77 (2H, br d, NCH2), 3.04 – 2.84 (1H, m, COCH), 2.21 (2H, 
s, cy), 2.03 (2H, d, J = 4.0 Hz, cy), 1.66 (2H, m, cy), 1.50 (4H, s, cy), 1.14 (6H, d, J = 
6.5 Hz, COCH(CH3)2); δC (101 MHz, CDCl3) 176.9 (C=O), 143.2 (ArC quaternary), 
137.2 (NC=CH), 132.6, 131.9, 130.8, 128.7 (ArCH), 127.5 (NC=CH), 124.1 (ArCBr), 
49.5 (NCH2), 34.7 (cy), 31.4 (COCH(CH3)2), 31.1, 26.9, 26.2, 25.8 (cy), 20.1 
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(COCH(CH3)2); m/z (ESI) 372.09 ([M]
+Na); [Found: 372.0932 ([M]+Na), 
C18H24
79BrNNaO  requires 372.0933]. 
 
N-(Cyclohept-1-en-1-yl)-N-(2,6-dibromobenzyl)isobutyramide (2.8s) 
 
N-(Cyclohex-1-en-1-yl)isobutyramide  (2.11f) (0.20g, 1.1mmol), sodium hydride 
(1.32g, 5.5mmol) and 2,6-dibromobenzyl bromide (0.40g, 1.2mmol) were reacted 
together as in the general protocol. Yield 0.31g, 66%. Off-white solid;  νmax (film)/cm–
1 2929 1648; δH (300 MHz, CDCl3) 7.53 (2H, d, J = 8.0 Hz, ArH), 6.98 (1H, t, J = 8.0 
Hz, ArH), 5.33 (1H, br s, NCHaCHb), 5.31 (1H, s, C=CH), 4.89 (1H, s, NCHaCHb), 
2.76 (1H, hept, J = 7.0 Hz, COCH(CH3)2), 1.93 (4H, m, cy), 1.57 (2H, m, cy), 1.47 
(2H, m, cy), 1.14 (6H, d, J = 7.0 Hz, COCH(CH3)2).; δC (126 MHz, CDCl3) 176.6 
(C=O), 136.9 (ArC quaternary), 136.3 (NC=CH), 132.5, 130.1 (ArCH), 129.1 
(NC=CH), 127.2 (ArCBr), 48.7 (NCH2), 31.8 (COCH(CH3)2), 29.4, 25.0, 22.9, 21.4 
(cy), 19.9 (COCH(CH3)2); m/z (ESI) 452.00 ([M]
+Na); [Found: 452.0017 ([M]+Na), 
C18H23
79Br2NNaO  requires 452.0019]. 
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N-Cyclooct-1-enyl-N-2-bromobenzylacetamide (2.8t) 
 
N-Cyclooctenylacetamide (2.11g) (0.40g, 2.4mmol), sodium hydride (0.28g, 
12.0mmol) and 2-bromobenzyl bromide (0.65g, 2.6mmol) were reacted together as in 
the general protocol. Yield 0.34g, 42%. Yellow oil; νmax (film)/cm–1 2926 (C-H), 1630 
(C=O); δH (CDCl3, 400 MHz) 7.49 (1H, d, J = 8.0 Hz, ArH), 7.26 (2H, m, ArH), 7.08 
(1H, dd, app t, J = 8.0 Hz, ArH), 5.51 (1H, t, J = 8.5 Hz, NC=CH), 4.81 (2H, s, NCH2), 
2.31 (2H, d, J = 5.5 Hz, cy), 2.19 (3H, s, COCH3), 2.15 – 2.02 (2H, m, cy), 1.60 – 1.32 
(8H, m, cy); δC (101 MHz, CDCl3) 170.7 (C=O), 141.5 (ArC quaternary), 136.6 
(NC=CH), 132.5 (ArCH), 129.8 (NC=CH), 129.0, 128.4, 127.3 (ArCH), 123.1 
(ArCBr), 50.3 (NCH2), 30.6, 28.9, 28.8, 26.2, 25.9 (cy), 22.1 (COCH3); m/z (ESI) 
336.10 ([M]+H); [Found: ([M]+H) 336.0955, C17H23
79BrNO  requires 336.0958]. 
 
N-Cyclooct-1-enyl-N-2,6-dibromobenzylacetamide (2.8u) 
 
N-Cyclooctenylacetamide (2.11g) (0.20g, 1.2mmol), sodium hydride (0.14g, 
6.0mmol) and 2,6-dibromobenzyl bromide (0.43g, 1.3mmol) were reacted together as 
in the general protocol. Yield 0.10g, 20%. Brown oil; νmax (film)/cm–1  2929 (C-H), 
1648 (C=O); δH (500 MHz, CDCl3) 7.51 (2H, d, J = 8.0 Hz, ArH), 6.97 (1H, t, J = 8.0 
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Hz, ArH), 5.53 (1H, t, J = 8.5 Hz, NC=CH), 5.16 (2H, s, NCH2), 2.22 (2H, m, cy), 
2.13 (3H, s, COCH3), 1.99 (2H, dd, J = 13.0, 8.0 Hz, cy), 1.53 – 1.44 (2H, m, cy), 1.46 
– 1.29 (6H, m, cy); δC (126 MHz, CDCl3) 170.2 (C=O), 140.2 (ArC quaternary), 135.9 
(NC=CH), 132.7, 132.6 (ArCH), 131.2 (NC=CH), 130.2 (ArCH), 127.2, 127.1 
(ArCBr), 49.3 (NCH2), 31.9, 28.2, 28.1, 26.2, 25.7, 25.5 (cy), 22.2 (COCH3); m/z (ESI) 
435.99 ([M]+Na); [Found: ([M]+Na) 435.9879, C17H21
79Br2NNaO  requires 435.9882]. 
 
N-((3-Bromonaphthalen-2-yl)methyl)-N-(cyclohex-1-en-1-yl)acetamide (2.9)  
 
N-Cyclohexenylacetamide (2.11a) (0.42g, 3.0mmol), sodium hydride (0.36g, 
15.0mmol) and 1-bromo-2-bromomethylnaphthalene (1.0g, 3.3mmol) were reacted 
together as in the general protocol. Yield 0.31g, 29%. Yellow oil;  νmax (film)/cm–1 
2927 (C-H), 1649 (C=O); δH (400 MHz, CDCl3) 8.30 (1H, d, J = 8.5 Hz, ArH), 7.76 
(2H, dd, J = 8.5, 8.0 Hz, ArH), 7.62 – 7.43 (3H, m, ArH), 5.34 (1H, s, NC=CH), 5.06 
(2H, s, NCH2), 2.12 (3H, s, COCH3), 2.04 (2H, d, J = 6.5 Hz, cy), 1.91 (2H, dd, J = 
5.5, 2.5 Hz, cy), 1.64 (2H, dd, J = 7.5, 4.0 Hz, cy), 1.48 (2H, dd, J = 7.5, 4.0 Hz, cy); 
δC (101 MHz, CDCl3) 170.4 (C=O), 138.5, 135.5, 133.8 (ArC quaternary), 132.2 
(NC=CH), 128.3, 128.1, 127.8, 127.5, 127.4 (ArCH), 126.4 (NC=CH), 124.0 (ArCBr), 
49.4 (NCH2), 28.0, 24.8, 22.8 (cy), 21.6 (COCH3), 21.4 (cy); m/z (ESI) 380.06 
([M]+Na); [Found: 380.0620 ([M]+Na), C19H20B
79BrNNaO  requires 380.0620]. 
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N-(2-Bromobenzyl)-N-(3-methylbut-2-en-2-yl)acetamide (2.16b) 
 
N-(3-Methylbut-2-en-2-yl)acetamide (2.11h) (1.0g, 7.86mmol), sodium hydride 
(0.94g, 39.3mmol) and 2-bromobenzyl bromide (2.16g, 8.65mmol) were reacted 
together as in the general protocol. Yield 0.66g, 28%. Yellow oil; νmax (film)/cm–1 2919 
(C-H), 1642 (C=O);  δH (250 MHz, CDCl3) 7.52 (1H, dd, J = 7.5, 1.5 Hz, ArH), 7.47 
(1H, dd, J = 8.0, 1.0 Hz, ArH), 7.23 (1H, td, J = 7.5, 1.0 Hz, ArH), 7.08 (1H, td, J = 
7.5, 1.5 Hz, ArH), 4.78 (2H, s, NCH2), 1.97 (3H, s, COCH3), 1.70 (3H, br s, CH3), 
1.63 (3H, br s, CH3), 1.31 (3H, br s, CH3); δC (75 MHz, CDCl3) 170.8 (C=O), 137.2 
(ArC quaternary), 132.7, 132.1 (ArCH), 131.7 (NC=CH), 129.5 (NC=CH), 129.1, 
127.7 (ArCH), 124.5 (ArCBr), 48.3 (NCH2), 21.3, 19.9, 19.5, 17.8 (Me); m/z (ESI) 
318.05 ([M]+Na); [Found: 318.0466 ([M]+Na), C14H18B
79BrNNaO  requires 
318.0464]. 
 
N-(2,6-Dibromobenzyl)-N-(3-methylbut-2-en-2-yl)acetamide (2.16c) 
 
N-(3-Methylbut-2-en-2-yl)acetamide (2.11h) (1.0g, 7.86mmol), sodium hydride 
(0.94g, 39.3mmol) and 2,6-dibromobenzyl bromide (2.83g, 8.65mmol) were reacted 
together as in the general protocol. Yield 0.59g, 20%. Brown oil; νmax (film)/cm–1 2914 
148 
 
(C-H), 1651 (C=O); δH (300 MHz, CDCl3) 7.52 (2H, d, J = 8.0 Hz, ArH), 6.99 (1H, t, 
J = 8.0 Hz, ArH), 5.21 (1H, d, J = 14.0 Hz, NCHaCHb), 4.92 (1H, d, J = 14.0 Hz, 
NCHaCHb), 1.97 (3H, s, COCH3), 1.60 (3H, s, NCCH3), 1.48 (3H, s, NC=CCH3CH3), 
1.46 (3H, s, NC=CCH3CH3); δC (75 MHz, CDCl3) 170.1 (C=O), 135.6 (ArC 
quaternary), 133.3 (NC=C), 132.6, 130.3 (ArCH), 128.5 (NC=C), 127.5 (ArCBr), 48.4 
(NCH2), 21.3, 20.0, 19.6, 18.4 (Me); m/z (ESI) 395.96 ([M]
+Na); [Found: 395.9567 
([M]+Na), C14H17
79Br2NNaO  requires 395.9569]. 
 
N-(2-Bromobenzyl)-N-(2,6,6-trimethylcyclohex-1-en-1-yl)acetamide (2.21b)  
 
N-(2,6,6-Trimethylcyclohex-1-en-1-yl)acetamide (2.23) (0.5g, 2.8mmol), sodium 
hydride (0.33g, 14.0mmol) and 2-bromobenzyl bromide (0.77g, 3.1mmol) were 
reacted together as in the general protocol. Yield 0.23g, 24%. Off-white solid; νmax 
(film)/cm–1 2948 (C-H), 1657 (C=O); δH (400 MHz, CDCl3) 7.53 (1H, d, J = 8.0 Hz, 
ArH), 7.48 (1H, d, J = 8.0 Hz, ArH), 7.27 (1H, dd, app t, J = 7.5 Hz, ArH), 7.07 (1H, 
dd, app t, J = 7.6 Hz, ArH), 4.88 (1H, d, J = 15.5 Hz, NCHaCHb), 4.53 (1H, d, J = 15.5 
Hz, NCHaCHb), 2.06 (3H, s, COCH3), 1.80 – 1.49 (4H, m, cy), 1.37 (3H, s, 
NC=CCH3), 1.30 – 1.18 (2H, m, cy), 1.09 (3H, s, CCH3CH3), 0.98 (3H, s, CCH3CH3); 
δC (75 MHz, CDCl3) 173.3 (C=O), 141.5 (ArC quaternary), 137.3 (NC=CCH3), 133.6 
(NC=CCH3), 132.7, 132.5, 130.7, 130.6, 128.7, 128.3, 127.5, 127.4 (ArCH, maj and 
min rotamers), 123.1 (ArCBr), 53.5 (NCH2), 40.6, 38.6, 36.3, 34.6, 32.1 (cy, major 
and minor rotamers), 28.6, 28.0, 27.9 (methyl groups), 24.8 (quaternary alkyl carbon), 
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22.6, 22.0 (COCH3, major and minor rotamers); m/z (ESI) 372.09 ([M]
+Na); [Found: 
372.0934 ([M]+Na), C18H24
79BrNNaO  requires 372.0933]. 
 
N-(2-Bromobenzyl)-N-(3,4-dihydronaphthalen-1-yl)acetamide (2.27)  
 
N-(3,4-Dihydronaphthalen-1-yl)acetamide (2.11i) (0.25g, 1.34mmol), sodium hydride 
(0.16g, 6.7mmol) and 2-bromobenzyl bromide (0.73g, 2.9mmol) were reacted together 
as in the general protocol. Yield 0.23g, 24%; Orange solid;  νmax (film)/cm–1 2973 (C-
H), 1664 (C=O); δH (400 MHz, CDCl3) 7.46 (1H, d, J = 8.0 Hz, ArH), 7.41 (1H, d, J 
= 7.5 Hz, ArH), 7.27 – 7.13 (4H, m, ArH), 7.12 – 6.99 (2H, m, ArH), 5.69 (1H, t, J = 
4.5 Hz, C=CH), 5.51 (1H, d, J = 15.0 Hz, NCHaCHb), 4.26 (1H, d, J = 15.0 Hz, 
NCHaCHb), 2.78 – 2.68 (2H, m, cy), 2.39 – 2.13 (2H, m, cy), 2.05 (3H, s, COCH3); δC 
(101 MHz, CDCl3) 171.3 (C=O), 138.3, 136.9, 136.9 (ArC quaternary), 132.6 (ArCH), 
131.4 (NC=CH), 130.8, 128.9, 128.3, 128.2, 128.0, 127.5, 126.9 (ArCH), 124.3 
(ArCBr), 121.8 (NC=CH), 49.7 (NCH2), 27.0, 22.8 (cy), 21.6 (COCH3); m/z (ESI) 
378.05 ([M]+Na); [Found: ([M]+Na) 378.0461, C19H18
79BrNNaO  requires 378.0464]. 
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N-((6-Bromobenzo[1,3]dioxol-5-yl)methyl)-N-(cyclohex-1-en-1-yl)acetamide 
(2.28)  
 
N-Cyclohexenylacetamide (2.11a) (0.43g, 3.10mmol), sodium hydride (0.37g, 
15.5mmol) and 5-bromo-6-(bromomethyl)benzo[1,3]dioxole (1.0g, 3.4mmol) were 
reacted together as in the general protocol. Yield 0.25g, 23%. Yellow oil;  νmax 
(film)/cm–1 2972 (C-H), 1631 (C=O); δH (400 MHz, CDCl3) 6.86 (2H, s, ArH), 5.88 
(2H, s, O-CH2-O), 5.32 (1H, s, NCCH), 4.61 (2H, s, NCH2), 2.00 (3H, s, COCH3), 
1.96 (4H, m, cy), 1.61 (2H, m, cy), 1.48 (2H, m, cy); δC (101 MHz, CDCl3) 170.2 
(C=O), 147.6, 138.5, 130.6 (ArC quaternary), 128.3 (NC=CH), 114.4 (NC=CH), 
112.2, 110.0 (ArCH), 101.7 (ArCBr), 48.3 (NCH2), 28.0, 24.8, 22.8 (cy), 21.5 
(COCH3), 21.4 (cy); m/z (ESI) 374.04 ([M]
+Na); [Found: 374.0366 ([M]+Na), 
C16H18
79BrNNaO3  requires 374.0362]. 
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N-((5-Bromobenzo[1,3]dioxol-4-yl)methyl)-N-(6,7-dimethoxy-3,4-
dihydronaphthalen-1-yl)acetamide (2.29) 
 
N-(6,7-Dimethoxy-3,4-dihydronaphthalen-1-yl)acetamide (2.11j) (0.10g, 0.40mmol), 
sodium hydride (50mg, 2.0mmol) and 5-bromo-4-(bromomethyl)benzo[1,3]dioxole 
(0.13g, 0.44mmol) were reacted together as in the general protocol. Yield 0.18g, 99%. 
Brown oil; νmax (film)/cm–1 2936 (C-H), 1655 (C=O); δH (400 MHz, CDCl3) 6.94 (1H, 
d, J = 8.5 Hz, ArH), 6.65 (1H, s, ArH), 6.56 (1H, s, ArH), 6.54 (1H, d, J = 8.5 Hz, 
ArH), 5.82 (1H, d, J = 1.0 Hz, OCHaHbO), 5.73 (1H, dd, J = 5.5, 4.0 Hz, NC=CH), 
5.70 (1H, d, J = 1.0 Hz, OCHaHbO), 5.18 (1H, d, J = 14.0 Hz, NCHaHb), 4.78 (1H, d, 
J = 14.0 Hz, NCHaHb), 3.86 (3H, s, OCH3), 3.82 (3H, s, OCH3), 2.68 – 2.45 (2H, m, 
cy), 2.36 – 2.12 (2H, m, cy), 2.03 (3H, s, COCH3); δC (101 MHz, CDCl3) 170.8 (C=O), 
148.4, 148.1, 147.5, 146.6 (ArCO), 137.4 (ArC quaternary), 129.3 (NC=CH), 126.1 
(NC=CH), 125.2 (ArCH), 124.8, 118.4 (ArC quaternary), 116.6 (ArCBr), 111.3, 
108.9, 106.2 (ArCH), 101.6 (OCH2O), 56.3, 56.0 (OCH3), 44.0 (NCH2), 27.0, 23.0 
(cy), 21.8 (COCH3); m/z (ESI) 482.06 ([M]
+Na); [Found: ([M]+Na) 482.0570, 
C22H22
79BrNNaO5  requires 482.0574]. 
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5.3 Tin Cyclisations discussed in Chapter 3 
General Procedure: 
The enamide (1 eq) was heated to reflux in toluene (0.02M), to which Bu3SnH (1.5 eq) 
and ABCN (0.2 eq) were added over the course of two hours via syringe pump, and 
the reaction mixture heated at reflux overnight. The solvent was then removed in 
vacuo, and the product taken up in acetonitrile and washed with hexane. The 
acetonitrile phase was concentrated in vacuo to give the crude product. Products were 
purified by column chromatography. 
Cyclisation of N-cyclohex-1-enyl-N-2-bromobenzylacetamide (2.8d) 
To a solution of N-cyclohex-1-enyl-N-2-bromobenzylacetamide 2.8d (90mg, 
0.29mmol) in toluene (10mL) at reflux was added a mixture of Bu3SnH (0.12mL, 
0.44mmol) and ABCN (14.3mg, 5.84x10-2mmol) in toluene (4.5mL). After standard 
work-up, the crude product was obtained as a yellow oil (0.12g). The mixture was 
purified by column chromatography (14:1 to 6:1 pet ether/EtOAc) to obtain products 
3.18acis, 3.18atrans, 3.19a, and the reduced starting material 2.8a, which were present 
in a 48:27:18:6 ratio in the crude mixture. 
 
Cis-1- (1,2,3,4,4a,10b-Hexahydrophenanthridin-5(6H)-yl)ethanone (3.18acis) 
(1:0.83 mixture of rotamers) : Yield 17mg, 25%. νmax (film)/cm–1 2930 (C-H), 1686 
(C=O). δH (CDCl3, 300 MHz) 6.93-7.96 (4H maj + 4H min, m, ArH), 5.04 (1H maj, d, 
J = 18.0Hz, NCHaHb), 4.76-4.89 (1H min, m, NCH), 4.66 (1H min, d, J = 16.5Hz, 
NCHaHb), 4.55 (1H min, d, J = 16.5Hz, NCHaHb), 4.35 (1H maj, d, J = 18.0Hz, 
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NCHaHb), 3.88-4.04 (1H maj, m, NCH), 3.24 (1H maj, br s, NCHCH), 3.13 (1H min, 
br s, NCHCH), 2.35-2.72 (1H maj +1H min, m, cy), 2.21 (1H maj, s, COCH3), 2.18 
(1H min, s, COCH3), 1.07-1.86 (7H maj + 7H min, m, cy) ; δC (100 MHz, CDCl3) 
169.4 (C=O maj), 169.3 (C=O min), 135.9, 134.4, 133.2, 132.5 (ArC, quaternary), 
127.2, 126.8, 126.7, 126.4, 126.2, 126.1, 126.0, 125.9 (ArCH), 55.7 (NCH maj), 49.9 
(NCH min), 45.9 (NCH2 min), 42.6 (NCH2 maj), 37.2 (NCHCH maj), 36.4 (NCHCH 
min), 27.6, 27.3, 27.2, 25.7, 25.6, 25.4 (cy), 22.4, 21.7 (COCH3), 19.8, 19.5 (cy); m/z 
(ESI) 252.14 ([M]+Na); [Found: ([M]+Na) 252.1357, C15H19NONa  requires 
252.1359]. 
Trans-1-(1,2,3,4,4a,10b-Hexahydrophenanthridin-5(6H)-yl)ethanone (3.18atrans) 
(1:0.54 mixture of rotamers) : Yield 4mg, 6%. νmax (film)/cm–1 2927 (C-H), 1686 
(C=O). δH (CDCl3, 300 MHz) 7.03-7.46 (4H maj + 4H min, m, ArH), 5.57 (1H min, d, 
J = 14.1Hz, NCHaHb), 4.46 (1H maj, d, J = 14.8Hz, NCHaHb), 4.30 (1H maj, d, J = 
14.7Hz, NCHaHb), 3.76 (1H min, d, J = 14.5Hz, NCHaHb), 3.38 (1H maj, t, J = 10.5Hz, 
NCH), 3.10 (1H min, m, NCH), 2.37-2.69 (2H maj + 2H min, m, cy), 2.15 (3H maj, s, 
COCH3), 2.05 (3H min, s, COCH3), 1.15-2.08 (6H maj + 6H min, m, cy) ; δC (100 
MHz, CDCl3) 170.6 (C=O min), 169.8 (C=O maj), 139.9, 139.2, 137.7, 136.3 (ArC 
quaternary), 127.9, 127.5, 126.3, 126.2, 125.6, 124.4, 123.1, 122.6 (ArCH), 60.2, 58.3 
(NCH min), 53.8 (NCH maj), 47.1 (NCH min), 43.2 (NCH2 maj), 42.1 (NCH2 maj), 
41.8 (NCHCH), 33.9, 31.0, 27.8, 26.0, 25.8, 25.3, 25.2 (cy), 22.9 (CH3), 22.5, 22.4 
(cy), 21.8 (CH3); m/z (ESI) 252.14 ([M]
+Na); [Found: ([M]+Na) 252.1351, 
C15H19NONa  requires 252.1359]. 
 
1-(Spiro[cyclohexane-1,1'-isoindoline]-2'-yl)ethanone (3.19a): Yield 9mg, 13%. 
νmax (film)/cm–1 2927 (C-H), 1626 (C=O). δH (CDCl3, 300 MHz) 7.68 (1H, m, ArH), 
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7.20-7.29 (3H, m, ArH), 4.78 (2H, s, NCH2), 3.10 (2H, td, J = 12.9, 5.6, ortho-cy), 
2.16 (3H, s, COCH3), 1.70-1.88 (4H, m, cy), 1.46-1.70 (4H, m, cy); δC (100 MHz, 
CDCl3) 169.4 (C=O), 147.0, 134.0 (ArC), 127.3, 127.2, 124.0, 122.4 (ArCH), 70.7 
(NC quaternary), 53.8 (NCH2), 32.1, 27.8 (cy), 25.3 (CH3), 24.3, 22.4 (cy); m/z (ESI) 
252.14 ([M]+Na); [Found: ([M]+Na) 252.1372, C15H19NONa  requires 252.1359]. 
 
Cyclisation of N-cyclohex-1-enyl-N-2,6-dibromobenzylacetamide (2.8h) 
To a solution of N-cyclohex-1-enyl-N-2,6-dibromobenzylacetamide 2.8h (100mg, 
2.58x10-4mol) in toluene (10mL) at reflux was added a mixture of Bu3SnH (0.10mL, 
3.87x10-4mol) and ABCN (12.6mg, 5.16x10-5mol) in toluene (3mL). After standard 
work-up, the crude product was obtained as a yellow oil with tin residue (0.20g).The 
mixture was purified by column chromatography (14:1 to 1:1 pet ether/EtOAc) which 
led to the isolation of 3.18hcis, 3.18htrans and 3.19h, as well as the non-brominated 
products 3.18acis, 3.18atrans and 3.19a. Products 3.18acis, 3.18atrans, 3.19a, 3.18hcis, 
3.18htrans and 3.19h were present in the crude product in the approximate ratio 
11:2:10:21:17:39. 
 
Cis-1-(7-Bromo-1,2,3,4,4a,10b-hexahydrophenanthridin-5(6H)-yl)ethanone 
(3.18hcis) (1:0.71 mixture of rotamers): Yield 10mg, 12%. νmax (film)/cm–1 2929 (C-
H), 1632 (C=O). δH (CDCl3, 700 MHz ) 7.45 (1H maj, d, J = 7.9Hz, ArH) 7.44 (1H 
min, d, J = 7.8 Hz, ArH), 7.37 (1H min, d, J = 7.8Hz, ArH), 7.32 (1H maj, d, J = 7.9Hz, 
ArH), 7.16 (1H maj, dd, app t, J = 7.9Hz, ArH), 7.12 (1H min, dd, app t, J = 7.9Hz, 
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ArH), 5.17 (1H min, d, J = 18.8 Hz, NCHaHb), 4.87 (1H maj, dt, J = 12.5, 4.5 Hz, 
NCH), 4.62 (1H maj, d, J = 17.3 Hz, NCHaHb), 4.45 (1H maj, d, J = 17.3 Hz, NCHaHb), 
4.14 (1H min, d, J = 18.8Hz, NCHaHb), 3.95 (1H min, dt, J = 12.1, 4.4 Hz, NCH), 3.23 
(1H min, br s, NCHCH), 3.12 (1H maj, br s, NCHCH), 2.59 – 2.40 (2H maj + 2H min, 
m, cy), 2.22 (1H min, s, COCH3), 2.21 (1H maj, s, COCH3), 2.18 – 2.10 (1H maj + 1H 
min, m, cy), 2.10 – 1.00 (5H maj + 5H min, m, cy); δC (176 MHz, CDCl3) 169.4 (C=O 
maj), 169.2 (C=O min), 138.7, 137.1, 132.6, 131.7 (ArC quaternary), 130.6, 130.2, 
128.5, 128.0, 125.7, 125.2 (ArCH), 123.0, 122.5 (ArCBr), 55.1 (NCH maj), 48.9 (NCH 
min), 46.9 (NCH2 min), 43.5 (NCH2 maj), 37.6(NCHCH maj), 36.6 (NCHCH min), 
28.0, 27.8, 27.6, 26.6, 25.5, 25.3 (cy), 22.4 (COCH3 maj), 21.7 (COCH3 min), 19.8, 
19.5(cy); m/z (ESI) 330.05 ([M]+Na); [Found: ([M]+Na) 330.0458, C15H18BrNONa  
requires 330.0464]. 
Trans-1-(7-Bromo-1,2,3,4,4a,10b-hexahydrophenanthridin-5(6H)-yl)ethanone 
(3.18htrans) (one rotamer only): Yield 5mg, 6%. νmax (film)/cm–1 2926 (C-H), 1630 
(C=O). δH (CDCl3, 300 MHz ) 7.40-7.46 (1H, m, ArH), 7.11-7.21 (2H, m, ArH), 5.08 
(1H, d, J = 15.2Hz, NCHaHb), 4.13 (1H, d, J = 15.0Hz, NCHaHb), 3.35 (1H, t, J = 
10.2Hz, NCH), 2.34-2.57 (3H, m, cy), 2.23 (3H, s, COCH3), 1.20-2.05 (6H, m, cy); δC 
(151 MHz, CDCl3) 170.3 (C=O), 142.5, 136.3 (ArC quaternary), 129.9, 129.0, 122.3 
(ArCH), 119.9 (ArCBr), 58.0 (NCH), 45.7 (NCH2), 42.5 (NCHCH), 32.1, 30.9, 25.9, 
25.0 (cy), 22.9 (COCH3); m/z (ESI) 330.05 ([M]
+Na); [Found: ([M]+Na) 330.0457, 
C15H18BrNONa  requires 330.0464]. 
1-(4'-Bromospiro[cyclohexane-1,1'-isoindoline]-2'-yl)ethanone (3.19h): Yield 
40mg, 50%. νmax (film)/cm–1 2922 (C-H), 1629 (C=O). δH (CDCl3, 400 MHz) 7.61 (1H, 
d, J = 7.8 Hz, ArH), 7.44 (1H, d, J = 7.9 Hz, ArH), 7.16 (1H, dd, app t, J = 7.9 Hz, 
ArH), 4.71 (2H, s, NCH2), 3.18 – 2.98 (2H, m, cy), 2.17 (3H, s, COCH3), 1.89 – 1.70 
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(5H, m, cy), 1.70 – 1.44 (3H, m, cy); δC (101 MHz, CDCl3) 169.5 (C=O), 148.8, 134.8 
(ArC), 130.4, 129.2, 122.9 (ArCH), 117.5 (ArCBr), 72.1 (NC quaternary), 55.2 
(NCH2), 32.2(cy), 25.4(CH3), 24.2, 22.3 (cy); m/z (ESI) 330.05 ([M]
+Na); [Found: 
([M]+Na) 330.0459, C15H18BrNONa  requires 330.0464]. 
 
Cyclisation of N-cyclohept-1-enyl-N-2-bromobenzylacetamide (2.8o) 
To a solution of N-cyclohept-1-enyl-N-2-bromobenzylacetamide 2.8o (150mg, 
4.80x10-1mmol) in toluene (20mL) at reflux was added a mixture of Bu3SnH (0.19mL, 
7.22x10-1mmol) and ABCN (6.3mg, 2.58x10-2mmol) in toluene (4mL). After standard 
work-up, the crude product was obtained as a yellow oil. The mixture was purified by 
column chromatography (6:1 to 1:1 pet ether/EtOAc) which led to the isolation of 
products 3.18ocis and 3.19o (combined yield 25mg, 21%, as the products were 
inseparable by column chromatography), present in the crude product in the 
approximate ratio 86:14. 
 
Cis-1-(7,8,9,10,11,11a-Hexahydro-5H-cyclohepta[c]isoquinolin-6(6aH)-
yl)ethanone (3.18ocis) (1:0.95 mixture of rotamers): Approx. yield 22mg, 19%. νmax 
(film)/cm–1 2927 (C-H), 1693 (C=O). δH (CDCl3, 250 MHz ) 7.36 – 7.03 (4H maj + 
4H min, m, ArH), 5.19 (1H maj, d, J = 17.5 Hz, NCHaHb), 4.99 (1H min, dd, J = 11.6, 
6.5 Hz, NCH), 4.57 (1H min, d, J = 16.4 Hz, NCHaHb), 4.49 (1H min, d, J = 16.5 Hz, 
NCHaHb), 4.16 (1H maj, d, J = 17.4 Hz, NCHaHb), 4.11 – 4.04 (1H maj, m, NCH), 
3.27 (1H maj + 1H min, dt, J = 14.3, 6.5 Hz, cy), 2.19 (3H min, s, COCH3), 2.12 (3H 
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maj, s, COCH3), 1.95 – 1.43 (8H maj + 8H min, m, cy), 1.42 – 1.14 (2H maj + 2H min, 
m, cy); δC (151 MHz, CDCl3) 168.8, 168.7 (C=O), 141.3, 139.4, 132.2, 131.5 (ArC), 
130.2, 129.8, 128.4, 127.8, 126.7, 126.0 (ArCH), 122.6, 121.8 (ArCBr), 57.7, 51.5 
(NCH), 45.9, 42.0 (NCH2), 39.9, 39.1 (NCHCH), 30.8, 30.4, 30.0, 29.5, 29.2, 29.1, 
26.8, 26.5, 23.2, 22.7 (cy), 22.1, 21.7 (COCH3); m/z (ESI) 266.15 ([M]
+Na); [Found: 
([M]+Na) 266.1512, C16H21NONa  requires 266.1515]. 
1-(Spiro[cycloheptane-1,1'-isoindoline]-2'-yl)ethanone (3.19o): Approx 3mg, 2%. 
νmax (film)/cm–1 2926 (C-H), 1686 (C=O). δH (CDCl3, 250 MHz ) 7.37-7.45 (1H, m, 
ArH), 7.03-7.35 (3H, m, ArH), 4.71 (2H, s, NCH2), 2.57-2.78 (2H, m, cy), 2.03 (3H, 
s, COCH3), 1.12-1.97 (12H, m, cy); δC (151 MHz, CDCl3) 169.9 (C=O), 153.9, 142.1 
(ArC quaternary), 133.6, 129.2, 126.7, 126.0 (ArCH), 72.1 (NC quaternary), 39.2 
(NCH2), 31.1, 30.3, 28.4 (cy), 27.8 (COCH3), 25.2, 24.8, 22.1 (cy); m/z (ESI) 266.15 
([M]+Na); [Found: ([M]+Na) 266.1512, C16H21NONa  requires 266.1515].  
 
Cyclisation of N-cyclohept-1-enyl-N-2,6-dibromobenzylacetamide (2.8p) 
To a solution of N-cyclohept-1-enyl-N-2-bromobenzylacetamide 2.8p (128mg, 
3.19x10-1mmol) in toluene (12mL) at reflux was added a mixture of Bu3SnH (0.13mL, 
4.79x10-1mmol) and ABCN (16mg, 6.38x10-2mmol) in toluene (4mL). After standard 
work-up, the crude product was obtained as a yellow oil (0.33g). The mixture was 
purified by column chromatography (6:1 to 1:1 pet ether/EtOAc) which led to the 
isolation of compounds 3.18pcis and 3.19p, as well as the non-brominated products 
3.18ocis and 3.19o. Products 3.18ocis, 3.19o, 3.18pcis, 3.19p were present in the crude 
product in the approximate ratio 22:55:tr:23. Unfortunately no carbon data could be 
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obtained for compounds 3.18pcis and 3.19p due to inseparability and weakness of the 
samples (combined yield 0.01g, organotin residue still present). 
 
Cis-1-(4-Bromo-7,8,9,10,11,11a-hexahydro-5H-cyclohepta[c]isoquinolin-6(6aH)-
yl)ethanone (3.18pcis) (1:0.63 mixture of rotamers): νmax (film)/cm–1 2924 (C-H), 
1624 (C=O). δH (CDCl3, 300 MHz ) 7.06-7.57 (3H, m, ArH), 5.36 (1H min, d, J = 18.5 
Hz, NCHaHb), 5.01 (1H maj, m, NCH), 4.69 (1H maj, d, J = 17.5 Hz, NCHaHb), 4.33 
(1H maj, d, J = 17.5Hz, NCHaHb), 4.03-4.14 (1H min, m, NCH), 3.96 (1H min, d, J = 
18.5Hz, NCHaHb), 3.21-3.38 (1H maj + 1H min, m, cy), 2.23-2.50 (2H maj + 2H min, 
m, cy), 2.21 (3H min, s, COCH3), 2.18 (3H maj, s, COCH3), 1.10-1.94 (8H maj + 8H 
min, m, cy); m/z (ESI) 344.06 ([M]+Na); [Found: ([M]+Na) 344.0612, C16H20BrNONa  
requires 344.0620]. 
1-(4'-Bromospiro[cycloheptane-1,1'-isoindoline]-2'-yl)ethanone (3.19p): νmax 
(film)/cm–1 2923 (C-H), 1635 (C=O); δH (CDCl3, 300 MHz ) 7.07-7.59 (3H, m, ArH), 
4.67 (2H, s, NCH2), 2.70 (2H, dd, J = 13.6, 8.6Hz, cy), 2.17 (3H, s, COCH3), 1.05-
1.87 (10H, m, cy); m/z (ESI) 344.06 ([M]+Na); [Found: ([M]+Na) 344.0616, 
C16H20BrNONa  requires 344.0620].  
Cyclisation of N-cyclooct-1-enyl-N-2-bromobenzylacetamide (2.8t) 
To a solution of N-cyclooct-1-enyl-N-2-bromobenzylacetamide 2.8t (200mg, 5.90x10-
1mmol) in toluene (26mL) at reflux was added a mixture of Bu3SnH (0.24mL, 8.90x10
-
1mmol) and ABCN (30mg, 1.2x10-1mmol) in toluene (4mL). After standard work-up, 
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the crude product was obtained as a yellow oil. The mixture was purified by column 
chromatography (6:1 to 1:1 pet ether/EtOAc) which led to the isolation of products 
3.18tcis and 3.19t present in the crude product in the approximate ratio 50:11, with 
13% of reduced product and 27% of starting material. 
 
Cis-1-((6aS,12aS)-6a,7,8,9,10,11,12,12a-Octahydrocycloocta[c]isoquinolin-
6(5H)-yl)ethan-1-one (3.18tcis) (1:0.78 mixture of rotamers): Yield 17mg, 11%. νmax 
(film)/cm–1 2920 (C-H), 1640 (C=O); δH (CDCl3, 400 MHz ) 7.41 – 7.03 (4Hmaj + 4H 
min, m, ArH), 5.23 (1H min, d, J = 5.0 Hz, NCH), 4.99 (1H maj, d, J = 18.0 Hz, 
NCHaHb), 4.62 (1H min, d, J = 16.0 Hz, NCHaHb), 4.54 (1H min, d, J = 16.0 Hz, 
NCHaHb), 4.41 (1H min, m, NCH), 4.37 (1H maj, d, J = 18.0 Hz, NCHaHb), 3.13 – 
3.03 (1H maj, m, NCHCH), 3.03 – 2.93 (1H min, m, NCHCH), 2.51 – 2.29 (1H maj + 
1H min, m, cy), 2.25 (3H maj, s, COCH3), 2.16 (3H min, s, COCH3), 1.90 – 1.17 (11H 
maj + 11H min, m, cy + organotin residue); δC (75 MHz, CDCl3) 178.1 (C=O), 127.2, 
126.8 (ArC quaternary), 126.4, 126.3, 125.7(ArCH), 53.2, 46.2 (NCH2), 43.5, 43.0 
(NCH), 41.9 (NCHCH), 40.9, 29.8, 26.9, 26.0 (cy), 25.2, 24.0 (CH3);  m/z (ESI) 280.17 
([M]+Na); [Found: ([M]+Na) 280.1680, C17H23NONa  requires 280.1677]. 
1-(Spiro[cyclooctane-1,1'-isoindolin]-2'-yl)ethan-1-one (3.19t): Yield 5mg, 3%. 
νmax (film)/cm–1 2921 (C-H), 1634 (C=O); δH (CDCl3, 300 MHz)  7.44 (1H, br s, ArH), 
7.40 – 7.03 (3H, m, ArH), 4.74 (2H, s, NCH2), 2.91 – 2.77 (2H, m, cy), 2.33 (2H, br s, 
cy), 2.15 (3H, s, COCH3), 1.92 – 1.42 (11H, m, cy); m/z (ESI) 280.17 ([M]+Na); 
160 
 
[Found: ([M]+Na) 280.1676, C17H23NONa  requires 280.1677]. Sample was too weak 
to obtain carbon NMR. 
 
Cyclisation of N-cyclooct-1-enyl-N-2,6-dibromobenzylacetamide (2.8u) 
To a solution of N-cyclooct-1-enyl-N-2,6-dibromobenzylacetamide 2.8u (300mg, 
7.2x10-1mmol) in toluene (30mL) at reflux was added a mixture of Bu3SnH (0.31mL, 
1.08 mmol) and ABCN (35mg, 1.44 x10-1mmol) in toluene (6mL). After standard 
work-up, the crude product was obtained as a yellow oil. The mixture was purified by 
column chromatography (6:1 to 1:1 pet ether/EtOAc) which led to the identification 
of products 3.18ucis and 3.19u present in the crude product in the approximate ratio 
68:23, with 9% of starting material. 
 
Cis-1-((6aS,12aS)-4-Bromo-6a,7,8,9,10,11,12,12a-
octahydrocycloocta[c]isoquinolin-6(5H)-yl)ethan-1-one (3.18ucis) (1:0.80 mixture 
of rotamers): νmax (film)/cm–1 2919 (C-H), 1624 (C=O); δH (CDCl3, 400 MHz ) 7.65 
(1Hmaj, d, J = 7.5 Hz, ArH), 7.58 – 7.42 (3H maj/min, m, ArH), 7.20 – 7.07 (2H 
maj/min, m, ArH), 5.13 (1H min, d, J = 19.0 Hz, NCHaHb), 4.76 – 4.70 (1H min, m, 
NCH), 4.60 (1H maj, d, J = 17.5 Hz, NCHaHb), 4.49 (1H maj, d, J = 17.5 Hz, NCHaHb), 
4.42 – 4.35 (1H maj, m, NCH), 4.20 (1H min, d, J = 18.5 Hz, NCHaHb), 3.11 – 3.04 
(1H min, m, NCHCH), 2.99 (1H maj, m, NCHCH), 2.25 (3H min, s, COCH3), 2.20 
(3H maj, s, COCH3), 1.95 – 1.34 (12H maj + 12H min, m, cy); δC (126 MHz, CDCl3) 
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171.8, 169.0 (C=O), 144.5, 143.0, 140.7, 139.0 (ArC quaternary), 131.2, 130.3, 128.6, 
128.1, 126.0, 125.1 (ArCH), 117.3, 117.2 (ArCBr), 55.5, 55.0 (NCH), 47.0, 46.9 
(NCH2), 41.1, 41.0 (NCHCH), 29.5, 29.3, 28.7, 28.4, 27.9, 27.6, 27.4, 26.2, 25.9, 25.7, 
25.2, 25.0 (cy), 13.8, 13.5 (COCH3); m/z (ESI) 358.08 ([M]
+Na); [Found: ([M]+Na) 
358.0778, C17H22BrNONa  requires 358.0777]. 
1-(4'-Bromospiro[cyclooctane-1,1'-isoindolin]-2'-yl)ethan-1-one (3.19u): νmax 
(film)/cm–1 2920 (C-H), 1622 (C=O); δH (CDCl3, 500 MHz ) 7.45 (1H, d, J = 8.0 Hz, 
ArH), 7.41 – 7.32 (1H, m, ArH), 7.11 (1H, dd, app t, J = 8.0 Hz, ArH), 4.61 (2H, s, 
NCH2), 2.82 – 2.68 (2H, m, cy), 2.11 (3H, s, COCH3), 1.96 – 1.43 (12H, m, cy); δC 
(126 MHz, CDCl3) 169.4 (C=O), 135.15 (ArC quaternary), 134.3, 130.3, 122.6 
(ArCH), 120.8 (ArC quaternary), 117.2 (ArCBr), 70.4 (NC quaternary), 55.0 (NCH2), 
35.7, 35.1, 29.1, 28.9, 25.0, 23.7, 23.4 (cy), 13.8 (COCH3); m/z (ESI) 358.08 ([M]
+Na); 
[Found: ([M]+Na) 358.0777, C17H22BrNONa  requires 358.0777]. 
 
Cyclisation of N-(2-bromobenzyl)-N-(cyclohex-1-en-1-yl)propionamide (2.8j) 
To a solution of N-(2-bromobenzyl)-N-(cyclohex-1-en-1-yl)propionamide 2.8j (50mg, 
1.6x10-1mmol) in toluene (6mL) at reflux was added a mixture of Bu3SnH (6.5x10
-2 
mL, 2.4x10-1 mmol) and ABCN (8mg, 3.2x10-2 mmol) in toluene (2mL). After 
standard work-up, the crude product was obtained as a yellow oil with tin residue 
(0.104g). The mixture was purified by column chromatography (8:1 to 1:1 pet 
ether/EtOAc) which led to the identification of products 3.18jcis and 3.19j present in 
the crude product in the approximate ratio 41:30 (17 mg combined isolated yield, 
44%), with 29% of starting material. 
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Cis-1-(2,3,4,4a,6,10b-Hexahydrophenanthridin-5(1H)-yl)propan-1-one (3.18jcis) 
(1:0.75 mixture of rotamers): Yield 10 mg, 25%. νmax (film)/cm–1 2938 (C-H), 1680 
(C=O); δH (CDCl3, 400 MHz ) 7.39, (1H min, d, J = 8.0Hz, ArH), 7.34 (1H maj, d, J = 
7.5 Hz, ArH), 7.23 – 7.06 (3H maj + 3H min, m, ArH), 5.09 (1H maj, d, J = 18.0 Hz, 
NCHaHb), 4.88 – 4.81 (1H min, m, NCH), 4.67 (1H min, d, J = 16.5 Hz, NCHaHb), 
4.53 (1H min, d, J = 16.5 Hz, NCHaHb), 4.33 (1H maj, d, J = 18.0 Hz, NCHaHb), 4.00 
(1H maj, m, NCH), 3.25 – 3.20 (1H min, m, NCHCH), 3.16 – 3.10 (1H maj, m, 
NCHCH), 2.67 – 2.29 (2H maj + 2H min + 2H maj + 2H min, m, COCH2 + cy), 1.77 
– 1.50 (2H maj + 2H min, m, cy), 1.45 – 1.11 (4H maj + 4H min, m, cy + organotin 
residue), 0.92 (3H, t, J = 7.5 Hz, COCH2CH3); δC (101 MHz, CDCl3) 168.6 (C=O maj), 
168.0 (C=O min), 136.8, 135.3, 133.2, 131.9 (ArC, quaternary), 127.1, 126.8, 126.7, 
126.5, 126.2, 126.1, 125.9, 125.8 (ArCH), 56.0 (NCH maj), 50.1 (NCH min), 45.8 
(NCH2 min), 43.5 (NCH2 maj), 37.7 (NCHCH maj), 37.3 (NCHCH min), 28.7, 28.4, 
26.2, 26.0, 25.4, 25.3, 25.1, 24.9 (cy), 19.4, 19.2 (COCH2CH3), 18.6, 18.5 
(COCH2CH3); m/z (ESI) 266.15 ([M]
+Na); [Found: ([M]+Na) 266.1523, C16H21NONa  
requires 266.1521]. 
1-(spiro[cyclohexane-1,1'-isoindolin]-2'-yl)propan-1-one (3.19j): Yield 7mg, 19%. 
νmax (film)/cm–1 2932 (C-H), 1675 (C=O ); δH (CDCl3, 400 MHz ) 7.43 – 7.08 (4H, m, 
ArH), 4.76 (2H, s, NCH2), 3.13 (2H, td, J = 13.0, 5.1 Hz, cy), 2.38 (2H, q, J = 7.5 Hz, 
COCH2CH3), 1.70 – 1.52 (4H, m, cy), 1.41 – 1.21 (6H, m, cy), 1.17 (3H, t, J = 7.5 Hz, 
COCH2CH3); δc (101 MHz, CDCl3) 167.5 (C=O), 129.6, 128.2 (ArC quaternary), 
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127.4, 127.3, 124.1, 122.5 (ArCH), 73.9 (NC quaternary), 52.8 (NCH2), 32.3, 29.8, 
28.4, 22.6 (cy), 17.44 (COCH2CH3), 13.7 (COCH2CH3); m/z (ESI) 266.15 ([M]
+Na); 
[Found: ([M]+Na) 266.1522, C16H21NONa requires 266.1521]. 
Cyclisation of N-(cyclohex-1-en-1-yl)-N-(2,6-dibromobenzyl)propionamide (2.8k) 
To a solution of N-(cyclohex-1-en-1-yl)-N-(2,6-dibromobenzyl)propionamide 2.8k 
(104mg, 2.0x10-1mmol) in toluene (10mL) at reflux was added a mixture of Bu3SnH 
(0.103 mL, 3.9x10-1 mmol) and ABCN (15mg, 5.2x10-2 mmol) in toluene (3mL). After 
standard work-up, the crude product was obtained as a yellow oil. The mixture was 
purified by column chromatography (9:1 to 6:1 pet ether/EtOAc) which led to the 
identification of products 3.18kcis and 3.19k present in the crude product in the 
approximate ratio 17:29 (combined yield 22mg, 35%), with 40% of starting material 
and 14% of another unidentified compound. 
 
Cis-1-((4aS,10bS)-7-Bromo-2,3,4,4a,6,10b-hexahydrophenanthridin-5(1H)-
yl)propan-1-one (3.18kcis) (1:0.77 mixture of rotamers): Yield 8mg, 12%. νmax 
(film)/cm–1 2930 (C-H), 1624 (C=O);  δH (CDCl3, 300 MHz ) 7.45 (1H maj + 1H min, 
d, J = 8.0 Hz, ArH), 7.34 (1H min + 1H maj, m, ArH), 7.14 (1H maj + 1H min, m, 
ArH), 5.22 (1H min, d, J = 19.0 Hz, NCHaHb), 4.96 – 4.83 (1H maj, m, NCH), 4.66 
(1H maj, d, J = 17.5 Hz, NCHaHb), 4.41 (1H maj, d, J = 17.5 Hz, NCHaHb), 4.13 (1H 
min, d, J = 19.0 Hz, NCHaHb), 4.05 – 3.94 (1H min, m, NCH), 3.22 (1H min, br s, 
NCHCH), 3.13 (1H maj, br s, NCHCH), 2.48 (2H maj + 2H min, q, J = 7.5 Hz, 
COCH2CH3), 1.91 – 1.38 (8H maj + 8H min, m, cy), 1.21 (3H maj + 3H min, t, J = 
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7.5 Hz, COCH2CH3); δC (75 MHz, CDCl3) 170.6, 170.1 (C=O), 132.7, 132.6, 131.1, 
131.0 (ArC quaternary), 130.6, 130.3, 128.5, 128.0, 125.8, 125.2 (ArCH), 123.0, 122.2 
(ArCBr), 54.1, 49.2 (NCH), 46.1, 43.6 (NCH2), 37.6, 36.7 (NCHCH), 28.2, 27.7, 27.0, 
26.8, 25.7, 25.4, 23.9, 23.4 (cy), 19.9, 19.6 (COCH2CH3), 17.8, 17.4 (COCH2CH3); 
m/z (ESI) 344.06 ([M]+Na); [Found: ([M]+Na) 344.0627, C16H20NONaBr  requires 
344.0626]. 
1-(4'-Bromospiro[cyclohexane-1,1'-isoindolin]-2'-yl)propan-1-one (3.19k): Yield 
13mg, 20%. νmax (film)/cm–1 2925 (C-H), 1620 (C=O); δH (CDCl3, 300 MHz ) 7.62 
(1H, d, J = 8.0 Hz, ArH), 7.44 (1H, d, J = 7.5 Hz, ArH), 7.17 (1H, dd, app t, J = 8.0 
Hz, ArH), 4.70 (2H, s, NCH2), 3.12 (2H, m, cy), 2.41 (2H, q, J = 7.5 Hz, COCH2CH3), 
1.85 – 1.68 (4H, m, cy), 1.65 – 1.46 (4H, m, cy), 1.18 (3H, t, J = 7.5 Hz, COCH2CH3); 
δC (75 MHz, CDCl3) 169.3 (C=O), 132.6, 130.5 (ArC quaternary), 128.4, 127.6, 124.8 
(ArCH), 119.2 (ArCBr), 70.5 (NC quaternary), 50.4 (NCH2), 29.8, 28.7, 27.7, 23.5 
(cy), 19.8 (COCH2CH3), 12.6 (COCH2CH3)m/z (ESI) 344.06 ([M]
+Na); [Found: 
([M]+Na) 344.0626, C16H20NONaBr  requires 344.0626]. 
 
Cyclisation of N-(2-bromobenzyl)-N-cyclohexenylisobutyramide (2.8m) 
To a solution of N-(2-bromobenzyl)-N-cyclohexenylisobutyramide (2.8m) (100mg, 
2.9x10-1mmol) in toluene (10mL) at reflux was added a mixture of Bu3SnH (0.13mL, 
4.4x10-1mmol) and ABCN (14mg, 5.7x10-2mmol) in toluene (4.5mL). After standard 
work-up, the crude product was obtained as a yellow oil. Purification of the mixture 
was attempted by column chromatography (14:1 to 1:1 pet ether/EtOAc) which led to 
the identification of compounds 3.18mcis, 3.18mtrans, 3.19m and reduced product 2.8l, 
present in the crude product in the approximate ratio 71:trace:20:10. The products were 
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inseparable by column chromatography and no carbon NMR spectrum could be 
obtained from the mixture. Combined yield 23mg, 31%. 
 
Cis-1-((4aS,10bS)-2,3,4,4a,6,10b-Hexahydrophenanthridin-5(1H)-yl)-2-
methylpropan-1-one (3.18mcis) (1:0.80 mixture of rotamers): νmax (film)/cm–1 2922 
(C-H), 1654 (C=O); δH (300 MHz, CDCl3) 7.49 – 7.07 (4H, m, ArH), 5.10 (1H maj, 
d, J = 18.0 Hz, NCHaHb), 4.93 – 4.81 (1H min, m, NCH), 4.77 (1H min, d, J = 16.5 
Hz, NCHaHb), 4.59 (1H min, d, J = 16.0, NCHaHb), 4.31 (1H maj, d, J = 18.0 Hz, 
NCHaHb), 4.15 – 3.97 (1H maj, m, NCH), 3.24 (1H maj, br s, NCHCH), 3.13 (1H min, 
br s, NCHCH), 2.90 (1H maj +1H min, m, COCH), 2.04 – 1.01 (14H maj + 14H min, 
m, alkyl protons); m/z (ESI) 280.17 ([M]+Na); [Found: ([M]+Na) 280.1677, 
C17H23NONa requires 280.1677]. 
2-Methyl-1-(spiro[cyclohexane-1,1'-isoindolin]-2'-yl)propan-1-one (3.19m): νmax 
(film)/cm–1 2922 (C-H), 1654 (C=O); δH (300 MHz, CDCl3) 7.45 – 7.04 (4H, m, ArH), 
4.84 (2H, s, NCH2), 3.10 (2H, td, J = 13.0, 6.0 Hz, meta-cy), 2.75 (1H, dq, J = 29.0, 
6.5 Hz, COCH), 1.96 – 1.32 (8H, m, cy), 1.14 (3H, d, J = 6.5 Hz, COCH(CH3)a(CH3)b), 
1.10 (3H, d, J = 6.5 Hz, COCH(CH3)a(CH3)b); m/z (ESI) 280.17 ([M]
+Na); [Found: 
([M]+Na) 280.1678, C17H23NONa  requires 280.1677]. 
 
 
166 
 
Cyclisation of N-(cyclohex-1-en-1-yl)-N-(2,6-dibromobenzyl)isobutyramide 
(2.8n) 
To a solution of N-(cyclohex-1-en-1-yl)-N-(2,6-dibromobenzyl)isobutyramide (2.8n) 
(80mg, 1.9x10-1mmol) in toluene (5mL) at reflux was added a mixture of Bu3SnH 
(0.078mL, 2.9x10-1mmol) and ABCN (10mg, 3.8x10-2mmol) in toluene (4.5mL). 
After standard work-up, the crude product was obtained as a yellow oil containing the 
products 3.18ncis, 3.18ntrans, 3.19n and the reduced product 2.8l in the ratio 
32:14:32:22. Combined yield 35mg, 53%. 
 
Cis-1-(7-Bromo-2,3,4,4a,6,10b-hexahydrophenanthridin-5(1H)-yl)-2-
methylpropan-1-one (3.18ncis) (1:0.88 mixture of rotamers): Yield 11mg, 17%. νmax 
(film)/cm–1 2941 (C-H), 1628 (C=O); δH (400 MHz, CDCl3) 7.45 (1H maj + 1H min, 
d, J = 8.0 Hz, ArH), 7.37 (1H min, d, J = 8.0 Hz, ArH), 7.32 (1H maj, d, J = 8.0 Hz, 
ArH), 7.23 – 7.08 (1H maj + 1H min, m, ArH), 5.26 (1H min, d, J = 19.0 Hz, NCHaHb), 
4.91 (1H min, dt, J = 12.0, 4.5 Hz, NCH), 4.77 (1H maj, d, J = 17.5 Hz, NCHaHb), 
4.44 (1H maj, d, J = 17.5 Hz, NCHaHb), 4.11 (1H min, d, J = 19.0 Hz, NCHaHb), 4.11 
– 4.03 (1H maj, m, NCH), 3.24 (1H min, br s, NCHCH), 3.13 (1H maj, br s, NCHCH), 
2.92 (1H maj + 1H min, sept, J = 7.0 Hz, COCH), 2.55 (1H min, d, J = 14.5 Hz, cy), 
2.47 (1H maj, d, J = 14.5 Hz, cy), 1.59 – 1.51 (3H maj + 3H min, m, cy), 1.45 (4H maj 
+ 4H min, m, cy), 1.18 (3H min, d, J = 7.0 Hz, COCH(CH3)(CH3)), 1.14 (3H maj, d, 
J = 7.0 Hz, COCH(CH3)(CH3)); δC (101 MHz, CDCl3) 168.7, 168.0 (C=O), 137.7, 
135.3, 134.9, 134.3 (ArC quaternary), 130.3, 130.2, 129.7, 128.4, 122.2, 121.8 
167 
 
(ArCH), 118.1, 117.6 (ArCBr), 55.7, 54.5 (NCH), 53.2, 52.9 (NCH2), 52.8, 52.0 
(NCHCH), 32.5, 30.9, 30.6, 29.9, 25.04, 24.3, 23.9, 22.5 (cy), 19.7, 19.4 
(COCH(CH3)2), 18.5, 18.3 COCH(CH3)2; m/z (ESI) 358.08 ([M]
+Na); [Found: 
([M]+Na) 358.0776, C17H22BrNONa  requires 358.0777]. 
Trans-1-(7-Bromo-2,3,4,4a,6,10b-hexahydrophenanthridin-5(1H)-yl)-2-
methylpropan-1-one (3.18ntrans): Yield 6mg, 9%. νmax (film)/cm–1 2936 (C-H), 1620 
(C=O); δH (400 MHz, CDCl3)  7.44 – 7.40 (1H, m, ArH), 7.19 – 7.13 (2H, m, ArH), 
5.21 (1H, d, J = 15.0 Hz, NCHaHb), 4.12 (1H, d, J = 13.0 Hz, NCHaHb), 3.48 – 3.29 
(1H, m, NCH), 2.99 (1H, m, COCH), 2.58 - 2.36 (2H, m, NCHCH), 2.07 – 1.78 (8H, 
m, cy), 1.20 (3H, d, J = 7.0 Hz, COCH(CH3)(CH3)), 1.08 (3H, d, J = 6.0 Hz, 
COCH(CH3)(CH3)); m/z (ESI) 336.10 ([M]
+H); [Found: ([M]+Na) 336.0944, 
C17H23BrNO requires 336.0958]. Insufficient material for carbon NMR. 
1-(4'-Bromospiro[cyclohexane-1,1'-isoindolin]-2'-yl)-2-methylpropan-1-one 
(3.19n): Yield 10mg, 16%. νmax (film)/cm–1 2929 (C-H), 1620 (C=O); δH (400 MHz, 
CDCl3) 7.62 (1H, d, J = 8.0 Hz, ArH), 7.44 (1H, d, J = 8.0 Hz, ArH), 7.17 (1H, dd, 
app t, J = 8.0 Hz, ArH), 4.80 (2H, s, NCH2), 3.18 – 3.04 (2H, m, cy), 2.77 (1H, dt, J = 
13.5, 6.5 Hz, COCH), 1.90 – 1.84 (2H, m, cy), 1.83 – 1.71 (2H, m, cy), 1.64 – 1.51 
(4H, m, cy), 1.18 (6H, d, J = 6.5 Hz, COCH(CH3)2). δC (101 MHz, CDCl3) 169.1 
(C=O), 136.5, 134.3 (ArC quaternary), 130.3, 129.4, 122.6 (ArCH), 117.2 (ArCBr), 
62.3 (NC quaternary), 54.0 (NCH2), 32.2, 31.1, 24.3, 23.2, 22.5 (cy), 19.3, 19.3 
(COCH(CH3)2), 18.5 (COCH(CH3)2; m/z (ESI) 358.08 ([M]
+Na); [Found: ([M]+Na) 
358.0783, C17H22BrNONa requires 358.0777]. 
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Cyclisation of N-(2-bromobenzyl)-N-(cyclohex-1-en-1-yl)propionamide (2.8q) 
To a solution of N-(2-bromobenzyl)-N-(cyclohex-1-en-1-yl)propionamide 2.8q 
(204mg, 6.1x10-1mmol) in toluene (30mL) at reflux was added a mixture of Bu3SnH 
(0.247mL, 9.2x10-1 mmol) and ABCN (30mg, 1.2x10-1 mmol) in toluene (5.5mL). 
After standard work-up, the crude product was obtained as a yellow oil. The mixture 
was purified by column chromatography (8:1 to 1:1 pet ether/EtOAc) which led to the 
identification of products 3.18qcis and 3.19q present in the crude product in the 
approximate ratio 40:21, with 10% reduced product and 29% of starting material. 
Combined yield 84mg, 57%. 
 
Cis-1-(5,6a,7,8,9,10,11,11a-Octahydro-6H-cyclohepta[c]isoquinolin-6-yl)propan-
1-one (3.18qcis) (1:0.91 mixture of rotamers): Yield 47mg, 32% νmax (film)/cm–1 
2918 (C-H), 1664 (C=O); δH (300 MHz, CDCl3)  7.38 – 7.02 (4H maj + 4H min, m, 
ArH), 5.24 (1H min, d, J = 17.5 Hz, NCHaHb), 5.00 (1H min, br s, NCH), 4.61 (1H 
maj, d, J = 16.0 Hz, NCHaHb), 4.47 (1H maj, d, J = 16.5 Hz, NCHaHb), 4.23 – 4.06 
(1H maj + 1H min, m, NCH + NCHaHb), 3.28 (1H maj + 1H min, dt, J = 8.0, 7.0 Hz, 
NCHCH), 2.39 (1H maj + 1H min, m, COCH), 2.29 (2H maj + 2H min, m, cy), 1.76 
(4H maj + 4H min, m, cy), 1.60 (4H maj + 4H min, m, cy), 1.21 (3H maj + 3H min, d, 
J = 5.5 Hz, COCH(CH3)(CH3)), 1.17 (3H maj + 3H min, d, J = 5.5 Hz, 
COCH(CH3)(CH3)); δC (75 MHz, CDCl3) 169.2, 167.6 (C=O), 136.8, 135.0, 134.4, 
134.2 (ArC quaternary), 127.4, 127.2, 126.8, 126.6, 126.3, 126.0, 125.7, 125.5 
(ArCH), 57.2, 56.0 (NCH), 44.2, 41.1 (NCH2), 39.9, 38.9 (NCHCH), 30.8, 30.4, 29.7, 
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29.2, 27.1, 26.8, 25.2, 24.7, 23.3, 22.9 (cy), 18.5, 18.4 (COCH2CH3), 17.1, 16.8 
(COCH2CH3); m/z (ESI) 280.18 ([M]
+Na); [Found: ([M]+Na) 280.1678, C17H23NONa  
requires 280.1677]. 
1-(Spiro[cycloheptane-1,1'-isoindolin]-2'-yl)propan-1-one (3.19q): Yield 25mg, 
17%. νmax (film)/cm–1 2926 (C-H), 1667 (C=O); δH (300 MHz, CDCl3)  7.43 – 7.24 
(4H, m, ArH), 4.71 (2H, s, NCH2), 3.24 (2H, m, cy), 1.82 – 1.47 (4H, m, cy), 1.44 – 
1.05 (6H, m, cy), 0.91 (2H, q, J = 7.5 Hz, COCH2CH3), 0.87 (3H, t, J = 7.5 Hz, 
COCH2CH3); δC (75 MHz, CDCl3) 170.6 (C=O), 132.4, 130.5 (ArC quaternary), 
128.8, 127.1, 123.2, 122.5 (ArCH), 65.6 (NC quaternary), 51.3 (NCH2), 29.4, 27.4, 
26.8, 26.4, 24.8, 23.7 (cy), 17.3 (COCH2CH3), 13.7 (COCH2CH3); m/z (ESI) 280.18 
([M]+Na); [Found: ([M]+Na) 280.1684, C17H23NONa  requires 280.1677]. 
 
Cyclisation of N-(2-bromobenzyl)-N-cycloheptenylisobutyramide (2.8r) 
To a solution of N-(2-bromobenzyl)-N-cycloheptenylisobutyramide (2.8r) (240mg, 
7.1x10-1mmol) in toluene (30mL) at reflux was added a mixture of Bu3SnH (0.28mL, 
1.1 mmol) and ABCN (35mg, 1.42x10-1mmol) in toluene (6mL). After standard work-
up, the crude product was obtained as a yellow oil. The mixture was purified by column 
chromatography (14:1 to 1:1 pet ether/EtOAc) which led to the isolation of compounds 
3.18rcis and 3.19r, present in the crude product in the approximate ratio 80:20. 
Combined yield 153mg, 80%. 
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Cis-2-Methyl-1-((6aS,11aS)-5,6a,7,8,9,10,11,11a-octahydro-6H-
cyclohepta[c]isoquinolin-6-yl)propan-1-one (3.18rcis) (1:0.87 mixture of 
rotamers): Yield 122mg, 64%. νmax (film)/cm–1 2925 (C-H), 1677 (C=O); δH (300 
MHz, CDCl3) 7.45 – 6.92 (4H maj + 4H min, m, ArH), 5.21 (1H min, d, J = 17.5 Hz, 
NCHaHb), 4.97 (1H min, m, NCH), 4.62 (1H maj, d, J = 16.5 Hz, NCHaHb), 4.43 (1H 
maj, d, J = 16.5 Hz, NCHaHb), 4.20 – 4.11 (1H maj, m, NCH), 4.06 (1H min, d, J = 
17.5 Hz, NCHaHb), 3.32 – 3.07 (1H maj + 1H min, m, NCHCH), 2.81 (1H maj + 1H 
min, ddt, J = 20.0, 13.5, 6.5 Hz, COCH), 2.33 – 2.18 (1H maj + 1H min, m, cy), 1.89 
– 1.20 (9H maj + 9H min, m, cy), 1.12 (3H maj, d, J = 6.5 Hz, COCH(CH3)a(CH3)b), 
1.00 (3H min, d, J = 6.5 Hz, COCH(CH3)a(CH3)b); δ (126 MHz, CDCl3) 175.3, 175.2 
(C=O), 138.9, 137.0, 133.2, 132.5 (ArC quaternary), 127.6, 127.3, 126.9, 126.8, 126.4, 
126.1, 125.8, 125.6 (ArCH), 57.0, 52.3 (NCH), 44.2, 41.1 (NCH2), 40.1, 38.9 
(NCHCH), 31.0, 30.7, 30.6, 29.9, 29.6, 29.4, 27.0, 26.9, 23.5, 23.0 (cy), 19.9, 19.7 
(COCH), 19.5, 19.3 (COCH(CH3)2); m/z (ESI) 294.18 ([M]
+Na); [Found: ([M]+Na) 
294.1830, C18H25NONa  requires 294.1834]. 
2-Methyl-1-(spiro[cycloheptane-1,1'-isoindolin]-2'-yl)propan-1-one (3.19r): 
Yield 31mg, 16%. νmax (film)/cm–1 2928 (C-H), 1666 (C=O);  δH (CDCl3, 300 MHz ) 
7.47 – 7.10 (4H, m, ArH), 4.78 (2H, s, NCH2), 2.76 – 2.56 (1H, m, COCH), 2.17 – 
2.04 (2H, m, meta-cy), 1.91 – 1.44 (8H, m, cy), 1.15 (6H, d, J = 6.5 Hz, COCH(CH3)2); 
δC (126 MHz, CDCl3) 167.8 (C=O), 134.5, 133.0 (ArC quaternary), 128.4, 127.3, 
124.3, 122.2 (ArCH), 72.5 (NC quaternary), 52.2 (NCH2), 31.7, 31.1, 25.1, 25.1, 24.9, 
23.2 (cy), 19.2 (COCH(CH3)2), 19.2, 19.1 (COCH(CH3)2); m/z (ESI) 294.18 ([M]
+Na); 
[Found: ([M]+Na) 294.1830, C18H25NONa  requires 294.1834]. 
 
171 
 
Cyclisation of N-(cyclohept-1-en-1-yl)-N-(2,6-dibromobenzyl)isobutyramide 
(2.8s) 
To a solution of N-(cyclohept-1-en-1-yl)-N-(2,6-dibromobenzyl)isobutyramide (2.8s) 
(124mg, 2.9x10-1mmol) in toluene (10mL) at reflux was added a mixture of Bu3SnH 
(0.12mL, 4.4x10-1mmol) and ABCN (14mg, 5.7x10-2mmol) in toluene (4.5mL). After 
standard work-up, the crude product was obtained as a yellow oil. Purification of the 
mixture was attempted by column chromatography (14:1 to 1:1 pet ether/EtOAc), 
however the products 3.18scis and 3.19s obtained were impure. Key peaks are listed. 
 
Cis- 1-((6aS,11aS)-4-Bromo-5,6a,7,8,9,10,11,11a-octahydro-6H-
cyclohepta[c]isoquinolin-6-yl)-2-methylpropan-1-one (3.18scis) (1:0.83 mixture of 
rotamers): νmax (film)/cm–1 2923 (C-H), 1625 (C=O); δH (CDCl3, 400 MHz ) 7.42 (1H 
maj+ 1H min, d, J = 8.0 Hz, ArH), 7.26 (1H maj + 1H min, t, J = 12.0 Hz, ArH), 7.11 
(1H maj + 1H min, m, ArH), 5.44 (1H min, d, J = 18.5 Hz, NCHaHb), 5.04 (1H maj, 
m, NCH), 4.83 (1H maj, d, J = 17.5 Hz, NCHaHb), 4.31 (1H maj, d, J = 17.5 Hz, 
NCHaHb), 4.22 (1H min, m, NCH), 3.93 (1H min, d, J = 18.5 Hz, NCHaHb), 3.38 – 
3.19 (1H maj + 1H min, m, NCHCH), 2.87 (1H maj + 1H min, dt, J = 13.5, 7.0 Hz, 
COCH), 2.35 (1H maj + 1H min, m, cy), 1.94 – 0.77 (16H, m, alkyl + organotin 
residues); m/z (ESI) 372.09 ([M]+Na); [Found: ([M]+Na) 372.0932, C18H24NBrONa  
requires 372.0939]. Impure and insufficient material to obtain carbon NMR. 
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1-(4'-Bromospiro[cycloheptane-1,1'-isoindolin]-2'-yl)-2-methylpropan-1-one 
(3.19s): νmax (film)/cm–1 2920 (C-H), 1621 (C=O); δH (CDCl3, 400 MHz ) 7.51 – 7.00 
(3H, m, ArH), 4.67 (2H, s, NCH2), 2.72 – 2.48 (2H, m, COCH + 2H, m, meta-cy), 2.13 
– 0.60 (16H, m, alkyl + organo tin residues); m/z (ESI) 372.09 ([M]+Na); [Found: 
([M]+Na) 372.0935, C18H24NBrONa  requires 372.0939]. Impure and insufficient 
material to obtain carbon NMR. 
 
Cyclisation of N-((3-bromonaphthalen-2-yl)methyl)-N-(cyclohex-1-en-1-
yl)acetamide (2.9) 
To a solution of N-((3-bromonaphthalen-2-yl)methyl)-N-(cyclohex-1-en-1-
yl)acetamide (2.9) (100mg, 2.8x10-1mmol) in toluene (10mL) at reflux was added a 
mixture of Bu3SnH (0.12mL, 4.26x10
-1mmol) and ABCN (14mg, 5.6x10-2mmol) in 
toluene (4mL). After standard work-up, the crude product was obtained as a yellow oil 
with tin residue (0.15g). Purification of the mixture was attempted by column 
chromatography (14:1 to 1:1 pet ether/EtOAc), resulting in the isolation of one 
unidentified product, which was not seen upon subsequent attempts. Subsequent 
attempts showed the crude reaction mixture as a 95:5 mixture of starting material to 
the presumed reduced product, which however could not be separated for full analysis. 
 
Cyclisation of N-(2-bromobenzyl)-N-(3-methylbut-2-en-2-yl)acetamide (2.16b) 
To a solution of N-(2-bromobenzyl)-N-(3-methylbut-2-en-2-yl)acetamide (2.16b) 
(100mg, 3.4x10-1mmol) in toluene (12mL) at reflux was added a mixture of Bu3SnH 
(0.14mL, 5.1x10-1mmol) and ABCN (17mg, 6.8x10-2mmol) in toluene (5mL). After 
standard work-up, the crude product was obtained as a yellow oil with tin residue 
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(0.12g). No cyclisation products were observed in the crude mixture, only 13% of the 
reduced starting material, identified by comparison to data obtained in a paper by 
Clark.69 
 
Cyclisation of N-(2-bromobenzyl)-N-(2,6,6-trimethylcyclohex-1-en-1-
yl)acetamide (2.21b) 
To a solution of N-(2-bromobenzyl)-N-(2,6,6-trimethylcyclohex-1-en-1-yl)acetamide 
(2.21b) (100mg, 2.9x10-1mmol) in toluene (10mL) at reflux was added a mixture of 
Bu3SnH (0.115mL, 4.28x10
-1mmol) and ABCN (14mg, 5.7x10-2mmol) in toluene 
(4.25mL). After standard work-up, the crude product was obtained as a yellow oil. The 
mixture was purified by column chromatography (14:1 to 1:1 pet ether/EtOAc) which 
led to the isolation of compounds 3.37cis, 3.38 and the reduced product 3.39, present 
in the crude mixture in the approximate ratio 31/37/32. Combined yield 70mg, 89%. 
 
Cis-1-((4aS,10bS)-4,4,10b-Trimethyl-2,3,4,4a,6,10b-hexahydrophenanthridin-
5(1H)-yl)ethan-1-one (3.37cis) (1:1 mixture of rotamers): Yield 20mg, 25%. νmax 
(film)/cm–1 2920 (C-H), 1684 (C=O); δH (CDCl3, 300 MHz )  7.30 (1H maj+min, d, J 
= 8.0 Hz, ArH), 7.21 (1H maj+min, dd, app t, J = 8.5 Hz, ArH), 7.14 (1H maj+min, 
m, ArH), 7.07 (1H maj+min, dd, app t, J = 8.0 Hz, ArH), 5.17 (1H min, d, J = 18.5 
Hz, NCHaHb), 4.78 (1H maj, d, J = 16.5 Hz, NCHaHb), 4.70 (1H maj, d, J = 16.5 Hz, 
NCHaHb), 4.53 (1H min, s, NCH), 4.48 (1H min, d, J = 18.5 Hz, NCHaHb), 3.52 (1H 
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maj, s, NCH), 2.57 (1H maj+min, m, cy), 2.28 (3H maj + 3H min, s, COCH3), 1.62 – 
1.19 (5H maj + 5H min, m, cy), 1.10 (3H min, s, C(CH3)(CH3)), 1.05 (3H maj, s, 
C(CH3)(CH3)), 0.98 (3H min, s, C(CH3)(CH3)), 0.90 (3H maj, s, C(CH3)(CH3)), 0.35 
(3H maj, s, CCH3), 0.25 (3H min, s, CCH3); δC (75 MHz, CDCl3) 171.9 (C=O), 140.9, 
139.4, 133.7, 132.6 (ArC quaternary), 127.3, 126.8, 126.5, 126.4, 126.2, 126.0, 123.6, 
123.3 (ArCH), 68.6, 62.1 (NCH), 48.7, 46.2 (NCH2), 42.5, 41.7 (cy), 39.4, 38.5, 38.3, 
37.8 (quaternary C), 36.9, 36.3 (cy), 32.7, 32.1, 32.0, 31.9 (C(CH3)2), 23.0, 22.7, 22.7, 
22.2 (COCH3 and CCH3), 18.7, 18.6 (cy); m/z (ESI) 294.18 ([M]
+Na); [Found: 
([M]+Na) 294.1827, C18H25NNaO requires 294.1828]. 
1-(2,2,6-Trimethylspiro[cyclohexane-1,1'-isoindolin]-2'-yl)ethan-1-one (3.38) : 
Yield 26mg, 33%. νmax (film)/cm–1 2918 (C-H), 1678 (C=O); δH (CDCl3, 300 MHz )  
7.34 (1H, d, J = 7.0 Hz, ArH), 7.30 – 7.20 (2H, m, ArH), 7.21 – 7.10 (1H, m, ArH), 
4.67 (2H, s, NCH2), 2.70 – 2.52 (1H, m, NCH), 2.50 – 2.31 (2H, m, cy), 2.22 (3H, s, 
COCH3), 1.77 – 1.49 (4H, m, cy), 0.94 (3H, s, Me), 0.92 (3H, s, Me), 0.69 (3H, s, Me); 
δC (75 MHz, CDCl3) 172.2 (C=O), 139.5, 136.4 (ArC quaternary), 127.4, 126.4, 125.7, 
121.2 (ArCH), 57.3 (NCH2), 37.6 (NC quaternary), 36.7 (NCCH), 36.0 (NCC 
quaternary), 30.5 (cy), 27.7 (Me), 27.4 (Me), 26.1 (Me), 21.1 (cy), 17.4 (cy), 17.3 
(Me); m/z (ESI) 294.18 ([M]+Na); [Found: ([M]+Na) 294.1828, C18H25NNaO requires 
294.1828]. 
5-Acetyl-4,4,10b-trimethyl-1,3,4,4a,5,10b-hexahydrophenanthridin-6(2H)-one 
(3.40cis): 3.37cis decomposes in air to give 3.40cis over a period of weeks.  
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Yield 20 mg, 95%. νmax (film)/cm–1 2924 (C-H), 1690 (C=O); δH (CDCl3, 600 MHz )  
8.15 (1H, d, J = 8.0 Hz, ArH), 7.55 (1H, dd, app t, J = 7.5 Hz, ArH), 7.38 (1H, dd, app 
t, J = 7.5 Hz, ArH), 7.31 (1H, d, J = 8.0 Hz, ArH), 4.66 (1H, s, NCH), 2.71 (3H, s, 
COCH3), 2.52 (1H, dd, J = 14.0, 3.0 Hz, cy), 1.58 – 1.52 (2H, m, cy), 1.50 – 1.43 (2H, 
m, cy), 1.42 – 1.36 (2H, m, cy), 1.18 (3H, s, Me), 0.84 (3H, s, Me), 0.23 (3H, s, Me); 
δC (151 MHz, CDCl3) 174.2, 166.6 (C=O), 145.9 (ArC quaternary), 134.0 (ArCH), 
130.0 (ArC quaternary), 129.7, 127.0, 123.2 (ArCH), 65.6 (NCH), 41.0 (cy), 38.2, 37.5 
(quaternary C), 35.7 (cy), 33.1, 31.4, 27.7, 23.3 (Me), 18.6 (cy); m/z (ESI) 302.16 
([M]+Na); [Found: ([M]+Na) 308.1617, C18H23NNaO2 requires 308.1621]. 
 
Cyclisation of N-(2-bromobenzyl)-N-(3,4-dihydronaphthalen-1-yl)acetamide 
(2.27) 
To a solution of N-(2-bromobenzyl)-N-(3,4-dihydronaphthalen-1-yl)acetamide (2.27) 
(100mg, 2.8x10-1mmol) in toluene (10mL) at reflux was added a mixture of Bu3SnH 
(0.12mL, 4.26x10-1mmol) and ABCN (14mg, 5.6x10-2mmol) in toluene (4mL). After 
standard work-up, the crude product was obtained as a yellow oil. The mixture was 
purified by column chromatography (pet ether, then 10:1 to 1:1 pet ether/EtOAc) 
which led to the isolation of compounds 3.42cis, 3.42trans and 3.43, present in the crude 
product in the approximate ratio 22:58:20. Combined yield 54mg, 69%. 
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Cis-1-((4bR,10bS)-6,10b,11,12-Tetrahydrobenzo[c]phenanthridin-5(4bH)-
yl)ethan-1-one (3.42cis) (1:0.89): Yield 8mg, 10%. νmax (film)/cm–1 2935 (C-H), 1682 
(C=O); δH (CDCl3, 500 MHz) 7.53 – 6.88 (8H maj + 8H min, m, ArH), 6.28 (1H maj, 
d, J = 6.0 Hz, NCH), 5.37 (1H min, d, J = 17.5 Hz, NCHaHb), 5.30 (1H min, d, J = 6.0 
Hz, NCH), 4.57 (1H maj, d, J = 16.5 Hz, NCHaHb), 4.27 (1H maj, d, J = 16.5 Hz, 
NCHaHb), 3.84 (1H min d, J = 17.4 Hz, NCHaHb), 3.58 (1H min, br s, NCHCH), 3.52 
(1H maj, br s, NCHCH), 2.50-2.78 (4H maj + 4H min, m, cy), 2.34 (3H min, s, 
COCH3), 2.31 (3H maj, s, COCH3); δC (126 MHz, CDCl3) 170.1 (C=O), 137.8, 137.3, 
135.2, 133.8, 133.5, 133.4, 133.4, 132.8 (ArC quaternary), 129.3, 129.0, 127.5, 127.3, 
127.2, 126.8, 126.8, 126.7, 126.6, 126.6, 126.5, 126.4, 126.3, 126.1, 126.1, 125.8 
(ArCH), 55.9, 49.9 (NCH), 44.7, 40.5 (NCH2), 35.7, 34.4 (NCHCH), 25.3, 25.2, 24.3, 
24.2 (cy), 22.1, 21.5 (COCH3); m/z (ESI) 300.14 ([M]
+Na); [Found: ([M]+H) 
300.1359, C19H19NNaO  requires 300.1359]. 
Trans-1-((4bR,10bS)-6,10b,11,12-Tetrahydrobenzo[c]phenanthridin-5(4bH)-
yl)ethan-1-one (3.42trans) (1:0.89 mixture of rotamers): Yield 40mg, 51%. νmax 
(film)/cm–1 2933 (C-H), 1680 (C=O); δH (CDCl3, 500 MHz) 7.39 – 7.32 (2H maj + 2H 
min, m, ArH), 7.30 – 7.24 (4H maj + 4H min, m, ArH), 7.21 – 7.10 (2H maj + 2H min, 
m, ArH), 5.71 (1H min, d, J = 14.5 Hz, NCHaHb), 4.80 (1H min, d, J = 10.5 Hz, NCH), 
4.63 (1H maj, d, J = 15.0 Hz, NCHaHb), 4.34 (1H maj, d, J = 10.5 Hz, NCH), 4.25 (1H 
maj, d, J = 14.0 Hz, NCHaHb), 3.67 (1H min, d, J = 14.5 Hz, NCHaHb), 3.22 – 3.09 
(2H maj + 2H min, m, cy), 2.80 (1H min, br s, NCHCH), 2.78 – 2.58 (2H maj + 2H 
min, m, cy + 1H maj, br s, NCHCH), 2.31 (3H maj, s, COCH3), 2.00 (3H min, s, 
COCH3); δC (126 MHz, CDCl3) 171.8, 171.7 (C=O), 139.4, 139.0, 138.3, 138.2, 137.1, 
136.6, 136.0 (ArC quaternary), 129.2, 128.9, 128.3, 127.8, 127.6, 127.1, 126.8, 126.6, 
126.1, 126.0, 125.8, 125.2, 124.6, 124.1, 123.8, 123.3 (ArCH), 59.9, 58.3 (NCH), 47.6, 
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42.0 (NCH2), 40.6, 39.6 (NCHCH), 26.7, 22.9 (cy), 22.3 (COCH3); m/z (ESI) 300.14 
([M]+Na); [Found: ([M]+H) 300.1358, C19H19NNaO  requires 300.1359]. 
N-(2-(1-Oxo-1,2,3,4-tetrahydronaphthalen-2-yl)benzyl)acetamide (3.43): Yield 
6mg, 8%. δH (CDCl3, 500 MHz) 8.03 (1H, dd, J = 8.0, 1.0 Hz, ArH), 7.53 (1H, ddd, J 
= 7.5, 1.5 Hz, ArH), 7.36 – 7.26 (5H, m, ArH), 7.18 (1H, dd, J = 7.5, 1.5 Hz, ArH), 
6.11 (1H, s, NH), 4.41 (2H, ddd, J = 42.5, 14.0, 5.0 Hz, NCH2), 4.01 (1H, dd, J = 13.0, 
4.5 Hz, H1), 3.22 (1H, ddd, J = 17.0, 12.5, 4.5 Hz, H3), 3.09 (1H, dt, J = 16.5, 3.5 Hz, 
H3), 2.54 (1H, qd, J = 13.0, 4.0 Hz, H2), 2.41 – 2.32 (1H, m, H2), 1.90 (3H, s, COCH3); 
δC (126 MHz, CDCl3) 199.4 (C=O), 169.7 (NHC=O), 144.3, 139.1, 136.5 (ArC 
quaternary), 133.9 (ArCH), 132.5 (ArC quaternary), 130.5, 128.9, 128.6, 128.1, 127.8, 
127.6, 126.9 (ArCH), 51.2 (C1), 42.7 (NCH2), 30.8 (C
2), 29.8 (C3), 23.12 (COCH3); 
m/z (ESI) 316.13 ([M]+); [Found: ([M]+H) 316.1307, C19H19NNaO2  requires 
316.1308]. 
 
Cyclisation of N-((6-bromobenzo[1,3]dioxol-5-yl)methyl)-N-(cyclohex-1-en-1-
yl)acetamide (2.28) 
To a solution of N-((6-bromobenzo[1,3]dioxol-5-yl)methyl)-N-(cyclohex-1-en-1-
yl)acetamide (2.28) (100mg, 2.84x10-1mmol) in toluene (10mL) at reflux was added a 
mixture of Bu3SnH (0.12mL, 4.26x10
-1mmol) and ABCN (14mg, 5.68x10-2mmol) in 
toluene (4mL). After standard work-up, the crude product was obtained as a yellow 
oil. The mixture was purified by column chromatography (pet ether, then 10:1 to 1:1 
pet ether/EtOAc) which led to the isolation of compounds 3.47cis, 3.47trans and 3.48, 
present in the crude product in the approximate ratio 45:36:19. Combined yield 40mg, 
51%. 
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Cis-1-((4aS,11bS)-2,3,4,4a,6,11b-Hexahydro-[1,3]dioxolo[4,5-j]phenanthridin-
5(1H)-yl)ethan-1-one (3.47cis) (1:0.70 mixture of rotamers): Yield 20mg, 25%. νmax 
(film)/cm–1 2928 (C-H), 1665 (C=O);νmax (film)/cm–1. δH (CDCl3, 500 MHz ) 6.76 
(1Hmaj +1H min, d, J = 19.5 Hz, ArH), 6.52 (1H maj +1H min, d, J = 21.5 Hz, ArH), 
5.94 – 5.79 (2H maj + 2H min, m, O-CH2-O), 4.86 (1H maj, d, J = 17.5 Hz, NCHaCHb), 
4.70 (1H min, dt, J = 12.0, 4.5 Hz, NCH), 4.46 (1H min, d, J = 16.0 Hz, NCHaCHb), 
4.37 (1H min, d, J = 16.0 Hz, NCHaCHb), 4.16 (1H maj, d, J = 17.5 Hz, NCHaCHb), 
3.83 (1H maj, dt, J = 12.0, 4.5 Hz, NCH), 3.06 (1H maj, br s, NCHCH), 2.94 (1H min, 
br s, NCHCH), 2.41 – 2.33 (1H maj, m, cy), 2.33 – 2.27 (1H min, m, cy), 2.12 (3H 
maj, s, COCH3), 2.08 (3H min, s, COCH3), 1.78 – 1.01 (7H maj + 7H min, m, cy); δC 
(126 MHz, CDCl3) 169.3, 169.2 (C=O), 147.2, 146.9, 146.0, 145.9 (ArC quaternary), 
129.3, 127.6, 126.3, 125.3 (ArC-O), 106.6, 106.4, 106.0, 106.0 (ArCH), 101.0, 100.9 
(OCH2O), 55.6, 49.8 (NCH), 45.9, 42.6 (NCH2), 37.1, 36.2 (NCHCH), 28.0, 27.7, 
27.0, 25.5, 25.3 (cy), 22.4, 21.7 (COCH3), 19.8, 19.5 (cy); m/z (ESI) 296.13 ([M]
+Na); 
[Found: ([M]+Na) 296.1259, C16H19NO3Na  requires 296.1257]. 
Trans-1-((4aR,11bS)-2,3,4,4a,6,11b-Hexahydro-[1,3]dioxolo[4,5-
j]phenanthridin-5(1H)-yl)ethan-1-one (3.47trans): Yield 10mg, 13%. νmax (film)/cm–
1 2924(C-H), 1662 (C=O); δH (CDCl3, 500 MHz ) 6.77 – 6.53 (2H maj + 2H min, m, 
ArH), 5.86 (2H maj + 2H min, d, J = 3.5 Hz, OCH2O), 5.39 (1H min, d, J = 14.0 Hz, 
NCHaCHb), 4.28 (1H maj, d, J = 14.5 Hz, NCHaCHb), 4.12 (1H maj, d, J = 14.5 Hz, 
NCHaCHb), 3.57 (1H min, d, J = 14.0 Hz, NCHaCHb), 3.23 (1H maj, t, J = 10.0 Hz, 
NCH), 2.94 (1H min, m, NCH), 2.34 (2H maj + 2H min, m, NCHCH + ortho-cy), 2.07 
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(3H maj + 3H min, s, COCH3), 2.00 – 1.13 (7H maj + 7H min, m, cy); δC (126 MHz, 
CDCl3); m/z (ESI) 274.14 ([M]
+H); [Found: ([M]+H) 274.1438, C16H20NO3  requires 
274.1438]. Insufficient material for carbon NMR. 
1-(Spiro[cyclohexane-1,5'-[1,3]dioxolo[4,5-f]isoindol]-6'(7'H)-yl)ethan-1-one 
(3.48): Yield 10mg, 13%. νmax (film)/cm–1 2930 (C-H), 1670 (C=O); δH (CDCl3, 500 
MHz ) 7.08 (1H, s, ArH), 6.58 (1H, s, ArH), 5.90 (2H, s, OCH2O), 4.60 (2H, s, NCH2), 
3.08 – 2.93 (2H, m, cy), 2.05 (3H, s, COCH3), 1.76 – 1.41 (8H, m, cy); m/z (ESI) 
296.13 ([M]+Na); [Found: ([M]+Na) 296.1260, C16H19NO3Na  requires 296.1257]. 
Insufficient material for carbon NMR. 
 
Cyclisation of N-((5-bromobenzo[1,3]dioxol-4-yl)methyl)-N-(6,7-dimethoxy-3,4-
dihydronaphthalen-1-yl)acetamide (2.29) 
To a solution of N-((5-bromobenzo[1,3]dioxol-4-yl)methyl)-N-(6,7-dimethoxy-3,4-
dihydronaphthalen-1-yl)acetamide (2.29) (50mg, 1.1x10-1mmol) in toluene (4mL) at 
reflux was added a mixture of Bu3SnH (4.5x10
-2 mL, 1.6x10-1mmol) and ABCN (5mg, 
2.2x10-2mmol) in toluene (1.5mL). After standard work-up, the crude product was 
obtained as a yellow oil containing tin residue (150mg). No cyclisation products were 
observed in the crude mixture, only 5% of the presumed reduced starting material, 
which could not be isolated for further analysis.  
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5.4 Reactions relevant to Chapter Four 
5.4.1 Samarium iodide reactions 
Attempted cyclisation of 2.8d using SmI2 
To a solution of N-cyclohex-1-enyl-N-2-bromobenzylacetamide (2.8d) (100mg, 3.2 
x10-1 mmol, 1eq) in THF was added SmI2 in THF (3.5mL, 0.1M, 3.5 x10
-1 mmol, 
1.1eq), dropwise over several minutes. This solution was stirred at room temperature 
under nitrogen for 24hrs, after which the SmI2 was seen to have fully oxidised (colour 
change from dark blue to yellow). The reaction mixture was washed with NH4Cl and 
brine, extracted into EtOAc and dried with MgSO4. The NMR of the crude reaction 
mixture showed no reaction: only starting material was recovered (96mg, 96%).  
Subsequent attempts were made using the same conditions and an additive: 1,3-
dimethyl-2-imidazolidinone (0.28mL, 2.56mmol, 8eq), dimethylsulfoxide (0.3mL, 
2.56mmol, 8eq) and hexamethylphosphoramide (0.45mL, 2.56mmol, 8eq) were all 
equally unsuccessful in promoting the reaction under these conditions.  
 
Successful cyclisation of 2.8d using SmI2 
To a solution of N-cyclohex-1-enyl-N-2-bromobenzylacetamide (2.8d) (50mg, 1.5 x 
10-1 mmol, 1eq) in THF was added HMPA (0.29mL, 1.6 mmol, 10eq) and SmI2 in 
THF (8.0mL, 0.1M, 8.0 x10-1 mmol, 5eq), dropwise over several minutes. This 
solution was stirred at room temperature under nitrogen for 24hrs, after which the SmI2 
was seen to have fully oxidised (colour change from dark blue to yellow). The solvent 
was removed in vacuo and the crude reaction mixture analysed by NMR to show the 
products 3.18acis, 3.18atrans, 3.19a and the starting material 2.8d in the approximate 
ratio 14:39:14:33. Combined yield 23mg, 67%. 
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5.4.2 Iron-mediated reactions 
To a solution of N-cyclohex-1-enyl-N-2-bromobenzylacetamide (2.8d) (100mg, 3.2 
x10-1 mmol, 1eq), Fe(acac)3 (1.2mg, 3.2 x10
-3 mmol, 0.01eq), TMEDA (5µL, 3.2 x 10-
2 mmol, 0.1eq) in THF (1mL) was added EtMgCl (1.9mL, 0.2M, 3.8 x 10-1 mmol, 
1.2eq). The solution was heated at reflux until it turned black and then for a further 4 
hours. It was then cooled to room temperature, quenched with potassium chloride 
buffer solution (pH = 2) and extracted with EtOAc. The crude reaction mixture (70mg) 
was shown by NMR to contain mostly reduced product 2.8a, with trace amounts of 
3.18acis that was not recoverable by column chromatography.  
 
5.4.3 Indium-mediated reactions 
A solution of N-cyclohex-1-enyl-N-2-bromobenzylacetamide (2.8d) (100mg, 3.2 x10-
1 mmol, 1eq), InCl3 (3mg, 1.5 x 10
-2 mmol, 0.05eq) and NaOAc (25mg, 3.2 x10-1 
mmol, 1eq) in DMF was stirred at 140 oC for 24 hours. The reaction mixture was then 
washed with water and extracted with EtOAc, and the solvent was removed under 
vacuum. The NMR of the crude reaction material showed only starting material. 
 
5.4.4 Cobalt-mediated reactions 
A solution of N-cyclohex-1-enyl-N-2-bromobenzylacetamide (2.8d) (150mg, 5.0 x10-
1 mmol, 1eq), CoBr2 (55mg, 2.5 x 10
-1 mmol, 0.5eq) and MeMgBr (0.33mL, 3.0M 
solution in diethyl ether, 1.0 mmol, 2eq) in THF was stirred at room temperature for 
24 hours. The mixture was then quenched by careful addition of concentrated HCl, 
and the solvent was removed under vacuum. The residue was taken up in petroleum 
ether, washed with sodium bicarbonate solution and dried with MgSO4. The solvent 
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was again removed under vacuum to give the crude product mixture, which was shown 
by NMR to contain mostly starting material.  
 
5.4.5 Palladium-mediated reactions 
5.4.5.1 Preliminary Reactions 
Cyclisation of N-cyclohex-1-enyl-N-2-iodobenzylacetamide (2.8e) using a 
palladium reagent 
A solution of N-cyclohex-1-enyl-N-2-iodobenzylacetamide 2.8e (100mg, 2.81x10-
1mmol, 1eq), Pd2(dba)3 (25mg, 2.81x10
-2mmol, 0.1eq), (t-Bu)3P (13.7μL, 5.64x10-
2mmol, 0.2eq) and triethylamine (43μL, 3.1x10-1mmol, 1.1eq) in toluene was stirred 
at room temperature for 24 hours. The reaction mixture was then poured into saturated 
LiCl solution and washed with ether. The ether layer was then concentrated under 
vacuum to give a brown oil. The crude product was purified by column 
chromatography (9:1 to 2:1 pet ether:EtOAc) to obtain  the desired 5-exo cyclised 
product 4.13a as a yellow oil (30mg, 47%). 
 
1-(Spiro[cyclohexane-1,1'-isoindolin]-3-en-2'-yl)ethan-1-one (4.13a):  νmax 
(film)/cm–1 2919 (C-H), 1632 (C=O); δH (CDCl3, 500 MHz ) 7.39 (1H, d, J = 7.5 Hz, 
ArH), 7.35 – 7.18 (3H, m, ArH), 5.92 – 5.76 (2H, m, HC=CH), 4.82 (1H, d, J = 14.0 
Hz, NCHaCHb), 4.78 (1H, d, J = 14.0 Hz, NCHaCHb), 3.94 – 3.76 (1H, m, cy), 3.20 – 
3.04 (1H, m, cy), 2.29 (2H, m, cy), 2.17 (3H, s, COCH3), 2.05 (1H, m, cy), 1.50 (1H, 
m, cy); δC (126 MHz, CDCl3) 169.5 (C=O), 146.5 (ArC quaternary), 133.6 (ArC 
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quaternary), 127.9, 127.6 (ArCH), 126.3, 126.2 (HC=CH), 123.1, 122.0 (ArCH), 68.6 
(NC quaternary), 53.7 (NCH2), 33.3, 28.3 (cy), 25.0 (COCH3), 23.4 (cy); m/z (ESI) 
250.12 ([M]+Na); [Found: ([M]+Na) 250.1200, C15H17NONa  requires 250.1202]. 
 
Cyclisation of N-cyclohex-1-enyl-N-2-bromobenzylacetamide (2.8d) using a 
palladium reagent 
General procedure: 
A solution of N-cyclohex-1-enyl-N-2-bromobenzylacetamide 2.8d (1eq), palladium 
precatalyst (0.1eq), phosphine ligand (0.2eq) and base (1.1eq) in 5mL of solvent was 
stirred at room temperature or reflux for 24-48 hours. The reaction mixture was then 
poured into saturated LiCl solution and washed with ether. The ether layer was then 
concentrated under vacuum to give a brown oil. The crude product was purified by 
column chromatography (9:1 to 2:1 pet ether:EtOAc) to obtain  the desired 5-exo 
cyclised products 4.13a and 4.13b as yellow oils.  
 
1-(Spiro[cyclohex[2]ene-1,1'-isoindoline]-2'-yl)ethanone (4.13b) (1:0.68 mixture 
of rotamers): νmax (film)/cm–1 2927 (C-H), 1629 (C=O). δH (CDCl3, 500 MHz ) 7.36-
7.16 (4H, m, ArH), 6.06 (1H maj, ddd, J = 10.0, 5.0, 2.0 Hz, NCCH=CH), 5.93 (1H 
min, ddd, J = 10.0, 5.0, 2.5 Hz, NCCH=CH), 5.74 – 5.65 (1H maj, m, NCCH=CH), 
5.64 – 5.56 (1H min, m, NCCH=CH), 4.96 (1H maj, d, J = 16.5 Hz, NCHaCHb), 4.86 
– 4.77 (2H min, m, NCH2), 4.74 (1H maj, d, J = 16.5 Hz, NCHaCHb), 2.76 (1H min, 
td, J = 13.5, 4.0 Hz, NCCHaCHb), 2.26 (3H maj, s, COCH3), 2.15 (3H min, s, COCH3), 
2.14 – 1.76 (6H maj + 5H min, m, cy); δC (126 MHz, CDCl3) 170.1, 168.7 (C=O), 
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145.7, 145.1 (ArC quaternary), 134.6, 134.3 (ArC quaternary), 131.3, 130.9, 129.5, 
128.0, 127.7, 127.5, 127.2, 127.0, 124.1, 123.9, 122.7, 122.3 (ArCH), 68.9, 67.9 (NC 
quaternary), 53.1, 52.0 (NCH2), 35.5, 32.0 (NCCH2), 24.2 (COCH3), 23.7, 23.6 
(NCCH2CH2), 22.5 (COCH3), 19.6, 19.3 (NCCH=CHCH2); m/z (ESI) 250.12 
([M]+Na); [Found: ([M]+Na) 250.1202, C15H17NONa  requires 250.1202]. 
Compound 4.13b was then observed to decay in air to compound 4.13c. 
 
2'-Acetylspiro[cyclohexane-1,1'-isoindolin]-2-en-3'-one (4.13c): δH (CDCl3, 500 
MHz ) 7.90 (1H, d, J = 7.5 Hz, ArH), 7.65 (1H, dd, J = 7.5, 1.2 Hz, ArH), 7.55 – 7.47 
(2H, m, ArH), 6.07 (1H, ddd, J = 10.0, 5.0, 2.5 Hz, NCCH=CH), 5.40 – 5.34 (1H, m, 
NCCH=CH), 2.82 (1H, m, NCCHaCHb), 2.67 (3H, s, COCH3), 2.48 – 1.84 (5H, m, 
cy); δC (126 MHz, CDCl3) 170.7, 168.4 (C=O), 151.3 (ArC quaternary, NCH2C), 134.0 
(ArCH), 130.1 (NCCH=CH), 128.7 (ArCH), 128.7 (ArC quaternary), 127.7 
(NCCH=CH), 125.0, 123.6 (ArCH), 63.6 (NC quaternary), 31.7 (cy), 27.0 (COCH3), 
23.4, 20.0 (cy); m/z (ESI) 264.10 ([M]+Na); [Found: ([M]+Na) 264.0990, 
C15H15NO2Na  requires 264.0995]. 
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5.4.5.2 Palladium screening 
All reactions were conducted under nitrogen in a 2-neck 25mL round-bottom flask. A 
solution of N-cyclohex-1-enyl-N-2-bromobenzylacetamide 2.8d (1eq), catalyst 
(0.1eq), ligand (0.2eq) and base (1.1eq) in toluene was stirred at the given temperature 
for 24-48 hours. All conditions tested and results thereof are summarised in the 
following tables. 
Entry Catalyst Ligand Base Solvent Additive Temp Time 
1 Pd2(dba)3 P(t-Bu)3 NEt3 Toluene / Reflux 24 
2 Pd2(dba)3 PPh3 NEt3 Toluene / Reflux 24 
3 Pd2(dba)3 P(o-Tol)3 NEt3 Toluene / Reflux 24 
4 Pd(OAc)2 P(t-Bu)3 NEt3 Toluene / Reflux 24 
5 Pd(OAc)2 PPh3 NEt3 Toluene / Reflux 24 
6 Pd(OAc)2 P(o-Tol)3 NEt3 Toluene / Reflux 24 
7 Pd(PPh3)4 P(t-Bu)3 NEt3 Toluene / Reflux 24 
8 Pd(PPh3)4 PPh3 NEt3 Toluene / Reflux 24 
9 Pd(PPh3)4 P(o-Tol)3 NEt3 Toluene / Reflux 24 
10 Pd(dba)2 P(t-Bu)3 NEt3 Toluene / Reflux 24 
11 Pd(dba)2 PPh3 NEt3 Toluene / Reflux 24 
12 Pd(dba)2 P(o-Tol)3 NEt3 Toluene / Reflux 24 
13 Pd2(dba)3 P(t-Bu)3 NEt3 Toluene / RT 48 
14 Pd2(dba)3 P(t-Bu)3 NEt3 THF / RT 48 
15 Pd2(dba)3 P(t-Bu)3 NEt3 DMF / RT 48 
16 Pd2(dba)3 P(t-Bu)3 NEt3 DMF / 140 48 
17 Pd2(dba)3 P(t-Bu)3 NEt3 CH3CN / RT 48 
18 Pd2(dba)3 P(t-Bu)3 NEt3 DCE / RT 48 
19 Pd2(dba)3 P(t-Bu)3 NEt3 Dioxane / RT 48 
20 Pd2(dba)3 P(t-Bu)3 NEt3 DMF AgNO3
a 140 48 
21 Pd(PPh3)4 P(t-Bu)3 NEt3 DMF / 140 48 
22 Pd(PPh3)4 P(t-Bu)3 NEt3 DMF AgNO3
a 140 48 
23 Pd(PPh3)4 P(t-Bu)3 DABCO DMF / 140 48 
24 Pd(PPh3)4 P(t-Bu)3 Ag2CO3 DMF / 140 48 
25 Pd(PPh3)4 P(t-Bu)3 NEt3 DMF NBu4Br
a 140 48 
26 Pd(PPh3)4 P(t-Bu)3 NEt3 THF / Reflux 48 
27 Pd(PPh3)4 P(t-Bu)3 NEt3 CH3CN / Reflux 48 
28 Pd(PPh3)4 P(t-Bu)3 NEt3 DMF NBu4Br
b 140 48 
29 Pd(PPh3)4 P(t-Bu)3 NEt3 DMF NBu4Br
b 140 48 
30 Pd(PPh3)4 P(t-Bu)3 NEt3 DMF NBu4Br
c 140 48 
31 Pd(PPh3)4 PPh3 NEt3 DMF / 140 48 
a1.1eq; b3 eq; c10eq 
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Entry Results (%) 
4.13a 4.13b 2.8d Other 
1 22.6 8.4 69.1 
 
2 2.2 1.9 76.9 19.0 
3 17.0 9.4 73.6 
 
4 9.6 6.6 83.8 
 
5 3.8 6.5 89.7 
 
6 2.6 2.4 95.0 
 
7 29.1 45.3 25.6 
 
8 1.0 29.6 69.4 
 
9 0.0 9.0 75.2 15.8 
10 2.9 0.0 97.1 
 
11 2.0 0.0 98.0 
 
12 8.9 6.6 84.5 
 
13 0.0 0.0 99.0 1.0 
14 0.0 0.0 69.4 30.5 
15 11.9 0.0 88.1 
 
16 28.9 0.0 66.2 4.9 
17 0.0 0.0 100 
 
18 0.0 0.0 100 
 
19 0.0 0.0 100 
 
20 0.0 0.0 100 
 
21 20.6 79.3 0 
 
22 6.3 13.4 80.3 
 
23 15.2 72.5 12.3 
 
24 20.4 62.8 16.8 
 
25 45.5 41.8 12.7 
 
26 0.0 0.0 100 
 
27 0.7 10.1 89.2 
 
28 41.7 52.9 5.4 
 
29 42.7 52.1 5.1 
 
30 38.0 56.3 5.7 
 
31 4.0 84.5 11.5 
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5.4.5.3 Palladium reactions of other compounds 
The compounds below were cyclised using the optimised method detailed in entry 31 
of the reaction conditions screening table to give the products below. Key diagnostic 
peaks are listed below for each cyclisation. 
 
Compound 4.13b (%) 4.13a (%) SM (%) 4.13c (%) 
2.8h 55 20 25  
2.8j 25 tr 69  
2.8k 56 13 31  
2.8m 7 tr 93  
2.8n 64 14 22  
2.8o 100 tr tr  
2.8t tr 83 0 17 
2.9 100 tr tr  
2.16b No reaction 
2.21b No reaction 
2.27 28 tr 72  
2.28 89 tr 11  
2.29 No reaction 
 
Cyclisation of 2.8h, Diagnostic peaks: δH (300 MHz, CDCl3) 6.14 – 6.03 (1H maj, 
m, NCCH=CH, 4.13b), 6.01 – 5.90 (1H min, m, NCCH=CH, 4.13b), 5.88 – 5.74 (2H, 
m, HC=CH, 4.13a), 5.69 (1H maj, d, J = 11.5 Hz, NCCH=CH, 4.13b), 5.60 (1H min, 
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d, J = 10.0 Hz, NCCH=CH, 4.13b), 4.98 (1H maj, d, J = 5.0 Hz, NCHaCHb, 4.13b), 
4.92 (2H min, m, NCH2, 4.13b), 4.81 (1H, m, NCHaCHb, 4.13a), 4.76 (1H, m, 
NCHaCHb, 4.13a), 4.68 (1H maj, d, J = 17.0 Hz, NCHaCHb, 4.13b), 3.87 (1H, m, cy, 
4.13a), 3.81 (1H, m, cy, 4.13a), 3.19 – 3.05 (1H, m, cy, 4.13a), 2.81 – 2.70 (1H min, 
m, NCCHaCHb, 4.13b). 
Cyclisation of 2.8j, Diagnostic peaks: δH (300 MHz, CDCl3) 6.03 – 5.93 (1H maj, m, 
NCCH=CH, 4.13b), 5.88 (1H min, dd, J = 8.5, 5.5 Hz, NCCH=CH, 4.13b), 5.64 (1H 
maj, m, NCCH=CH, 4.13b), 5.53 (1H min, m, NCCH=CH, 4.13b), 4.93 (2H, d, J = 
8.0 Hz, NCH2). 
Cyclisation of 2.8k, Diagnostic peaks: δH (300 MHz, CDCl3) 5.99 (1H min, ddd, J = 
7.0, 4.5, 2.0 Hz, NCCH=CH, 4.13b), 5.93 – 5.84 (1H maj, m, NCCH=CH, 4.13b), 5.73 
(2H, m, HC=CH, 4.13a), 5.63 (1H min, d, J = 9.5 Hz, NCCH=CH, 4.13b), 5.52 (1H 
maj, d, J = 9.5 Hz, NCCH=CH, 4.13b), 4.96 (1H maj, d, J = 10.0 Hz, NCHaCHb, 
4.13b), 4.90 (1H, d, J = 6.5 Hz, NCHaCHb, 4.13a), 4.85 (1H, d, J = 6.5 Hz, NCHaCHb, 
4.13a), 4.72 (2H min, s, NCH2, 4.13b), 4.59 (1H maj, d, J = 10.0 Hz, NCHaCHb, 4.13b), 
3.81 (1H, m, cy, 4.13a), 3.13 – 2.99 (1H, m, cy, 4.13a). 
Cyclisation of 2.8m, Diagnostic peaks (4.13b only): δH (300 MHz, CDCl3) 6.08 – 
5.97 (1H min, m, NCCH=CH), 5.93 (1H min + maj, m, NCCH=CH + NCCH=CH), 
5.75 (1H maj, d, J = 11.0 Hz, NCCH=CH), 5.60 (2H maj, d, J = 15.0 Hz, NCH2), 4.87 
(1H maj, d, J = 11.0 Hz, NCHaCHb), 4.63 (1H min, d, J = 11.0 Hz, NCHaCHb). 
Cyclisation of 2.8n, Diagnostic peaks: δH (300 MHz, CDCl3) 6.02 – 5.92 (1H min, 
m, NCCH=CH, 4.13b), 5.92 – 5.81 (1H maj, m, NCCH=CH, 4.13b), 5.70 (2H, br s, 
HC=CH, 4.13a), 5.67 (1H min, d, J = 10.0 Hz, NCCH=CH, 4.13b), 5.52 (1H maj, d, J 
= 9.0 Hz, NCCH=CH, 4.13b), 4.90 (1H maj, d, J = 10.5 Hz, NCHaCHb, 4.13b), 4.76 
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(1H maj, d, J = 10.5 Hz, NCHaCHb, 4.13b), 4.70, (2H min, m, NCH2, 4.13b), 4.64 (2H, 
m, NCH2, 4.13a), 3.77 (1H, d, J = 16.5 Hz, cy, 4.13a). 
Cyclisation of 2.8o, Diagnostic peaks (4.13b only): δH (400 MHz, CDCl3) 5.87 – 
5.77 (1H maj + 1H min, m, NCH=CH), 5.71 (1H maj + 1H min, d, J = 13.0 Hz, 
NCH=CH), 4.93 (1H min, d, J = 16.5 Hz, NCHaCHb), 4.78 (2H maj, s, NCH2), 4.69 
(1H min, d, J = 16.5 Hz, NCHaCHb). 
 
Cyclisation of 2.9, Diagnostic peaks (4.18b only): δH (300 MHz, CDCl3) 6.32 – 6.23 
(1H min, m, NCCH=CH), 6.19 – 6.08 (1H maj, m, NCCH=CH), 5.97 (1H min, d, J = 
10.5 Hz, NCCH=CH), 5.73 (1H maj, d, J = 10.0 Hz, NCCH=CH), 5.08 (1H min, d, J 
= 16.5 Hz, NCHaCHb), 4.87 (2H maj, s, NCH2), 4.75 (1H min, d, J = 16.5 Hz, 
NCHaCHb), 2.87 (s, 21H), 2.80 (s, 22H). 
 
Cyclisation of 2.28, Diagnostic peaks (4.19b only): δH (400 MHz, CDCl3) 6.08 – 
6.00 (1H maj, m, NCCH=CH), 5.94 – 5.88 (1H min, m, NCCH=CH), 5.65 (1H min, 
d, J = 10.0 Hz, NCCH=CH), 5.56 (1H maj, d, J = 10.2 Hz, NCCH=CH), 4.84 (1H min, 
d, J = 16.0 Hz, NCHaCHb), 4.70 (2H maj, s, NCH2), 4.63 (1H min, d, J = 16.0 Hz, 
NCHaCHb). 
190 
 
 
Cyclisation of 2.27, Diagnostic peaks (4.20 only): δH (300 MHz, CDCl3) 6.22 – 6.12 
(1H maj + min, m, NCCH=CH), 5.94 (1H maj + min, m, NCCH=CH), 5.16 (1H min, 
d, J = 16.0 Hz, NCHaCHb), 5.06 (2H maj, d, J = 11.0 Hz, NCH2), 4.96 (1H min, d, J = 
16.0 Hz, NCHaCHb). 
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